Citation Report
List of articles citing

# Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

DOI: 10.1016/j.ccr.2009.12.020
Cancer Cell, 2010, 17, 98-110.

**Source:** https://exaly.com/paper-pdf/48068941/citation-report.pdf
**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|---|---|---|---|
| 2227 | Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. **2009**, 4, e7752 | | 390 |
| 2226 | Protein residues that control the reaction trajectory in S-adenosylmethionine radical enzymes: mutagenesis of asparagine 153 and aspartate 155 in Escherichia coli biotin synthase. **2009**, 48, 2448-58 | | 20 |
| 2225 | Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. **2010**, 69, 729-36 | | 66 |
| 2224 | Taking a systems approach to the identification of novel therapeutic targets and biomarkers. **2010**, 11, 721-34 | | 7 |
| 2223 | Glioma diagnosis: immunohistochemistry and beyond. **2010**, 17, 187-201 | | 46 |
| 2222 | Low- and High-Grade Glioma. **2010**, 7-23 | | |
| 2221 | Personalized medicine: marking a new epoch in cancer patient management. **2010**, 8, 1175-87 | | 125 |
| 2220 | Malignant gliomas: new translational therapies. **2010**, 77, 655-66 | | 16 |
| 2219 | Molecular diagnostics of gliomas: state of the art. **2010**, 120, 567-84 | | 208 |
| 2218 | Targeted therapies on the horizon for malignant glioma. **2010**, 5, 157-60 | | |
| 2217 | Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives. **2010**, 5, 183-91 | | 21 |
| 2216 | DNA methylation in glioblastoma: impact on gene expression and clinical outcome. **2010**, 11, 701 | | 140 |
| 2215 | Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. **2010**, 60, 166-93 | | 950 |
| 2214 | PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2. **2010**, 10, 550 | | 15 |
| 2213 | GliomaPredict: a clinically useful tool for assigning glioma patients to specific molecular subtypes. **2010**, 10, 38 | | 10 |
| 2212 | Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell*, **2010**, 17, 510-22 | 24.3 | 1754 |
| 2211 | To infinium, and beyond!. *Cancer Cell*, **2010**, 17, 419-20 | 24.3 | 10 |

| | | | |
|---|---|---|---|
| 2210 | Non-stem cell origin for oligodendroglioma. *Cancer Cell*, **2010**, 18, 669-82 | 24.3 | 183 |
| 2209 | Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. *Cancer Cell*, **2010**, 18, 619-29 | 24.3 | 183 |
| 2208 | Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma. **2010**, 74, 4-5 | | 15 |
| 2207 | Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. **2010**, 116, 4632-7 | | 57 |
| 2206 | Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective. **2010**, 4, 904-14 | | 32 |
| 2205 | Cancer-associated IDH mutations: biomarker and therapeutic opportunities. **2010**, 29, 6409-17 | | 221 |
| 2204 | Glioblastoma stem-like cells give rise to tumour endothelium. **2010**, 468, 829-33 | | 940 |
| 2203 | Navigating genomic maps of cancer cells. **2010**, 28, 241-2 | | 3 |
| 2202 | Genomics boosts brain-cancer work. **2010**, 463, 278 | | 9 |
| 2201 | Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. **2010**, 10, 319-31 | | 578 |
| 2200 | [Epithelial mesenchymal transition during development in fibrosis and in the progression of carcinoma]. **2010**, 97, 1285-95 | | 22 |
| 2199 | Allelic selection of amplicons in glioblastoma revealed by combining somatic and germline analysis. **2010**, 6, e1001086 | | 21 |
| 2198 | Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. **2010**, 5, e10767 | | 51 |
| 2197 | Using effective subnetworks to predict selected properties of gene networks. **2010**, 5, e13080 | | 4 |
| 2196 | Standardization of Gene Expression Quantification by Absolute Real-Time qRT-PCR System Using a Single Standard for Marker and Reference Genes. **2010**, 5, 79-85 | | 13 |
| 2195 | The future role of personalized medicine in the treatment of glioblastoma multiforme. **2010**, 3, 111-27 | | 12 |
| 2194 | Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. **2010** , 1, 822-35 | | 74 |
| 2193 | PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. **2010**, 24, 2205-18 | | 152 |

| | | |
|---|---|---|
| 2192 | A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. **2010**, 70, 6128-38 | 92 |
| 2191 | The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. **2010**, 16, 6060-70 | 128 |
| 2190 | Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H. **2010**, 20, 1188-200 | 90 |
| 2189 | Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?. **2010**, 30, 15337-57 | 172 |
| 2188 | Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables. **2010**, 5, 153-68 | 18 |
| 2187 | Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. **2010**, 24, 2194-204 | 63 |
| 2186 | Glioblastoma-specific protein interaction network identifies PP1A and CSK21 as connecting molecules between cell cycle-associated genes. **2010**, 70, 6437-47 | 19 |
| 2185 | The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme. **2010**, 9, 2618-26 | 32 |
| 2184 | Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. **2010**, 19, 1409-22 | 95 |
| 2183 | Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. **2010**, 16, 4864-75 | 194 |
| 2182 | Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. **2010**, 9, 1849-65 | 92 |
| 2181 | [Genetic and molecular abnormalities of glioblastomas (GBM)]. **2010**, 97, 1389-407 | 4 |
| 2180 | Neuro-oncology: unmasking the multiforme in glioblastoma. **2010**, 6, 304-5 | 7 |
| 2179 | Diagnostic and prognostic molecular markers in common adult gliomas. **2010**, 10, 637-49 | 1 |
| 2178 | Best use of experimental data in cancer informatics. **2010**, 6, 1551-62 | 3 |
| 2177 | PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. **2010**, 70, 5457-64 | 189 |
| 2176 | Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. **2010**, 6, 1407-14 | 20 |
| 2175 | An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. **2010**, 9, 234 | 34 |

| | | |
|---|---|---|
| 2174 | Cellular and vaccine therapeutic approaches for gliomas. **2010**, 8, 100 | 20 |
| 2173 | Molecular tools: biology, prognosis, and therapeutic triage. **2010**, 20, 273-82 | 6 |
| 2172 | [Glioblastoma: clinical, radiological and biological prognostic factors]. **2010**, 56, 467-76 | 7 |
| 2171 | [Classification of glioblastoma and genome profiling]. **2010**, 56, 464-6 | |
| 2170 | Classification of adrenal cortical tumors: promise of the 'molecular' approach. **2010**, 24, 887-92 | 4 |
| 2169 | The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. **2010**, 21, 944-50 | 112 |
| 2168 | Molecularly Targeted Therapies for Astrocytomas. **2010**, 231-265 | 1 |
| 2167 | Molecularly Targeted Therapy for Childhood Cancer. **2010**, | 1 |
| 2166 | Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme. **2010**, 2, 65 | 133 |
| 2165 | An integrative approach for in silico glioma research. **2010**, 57, 2617-21 | 49 |
| 2164 | Heat shock protein-peptide complex in the treatment of glioblastoma. **2011**, 10, 721-31 | 21 |
| 2163 | Animal models for glioma drug discovery. **2011**, 6, 1271-83 | 12 |
| 2162 | Classifying six glioma subtypes from combined gene expression and CNVs data based on compressive sensing approach. **2011**, | |
| 2161 | Integrative, multimodal analysis of glioblastoma using TCGA molecular data, pathology images, and clinical outcomes. **2011**, 58, 3469-74 | 47 |
| 2160 | Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. **2011**, 13, 1288-95 | 14 |
| 2159 | Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays. **2011**, 13, 634-47 | 44 |
| 2158 | A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. **2011**, 13, 74-84 | 155 |
| 2157 | Network modeling of the transcriptional effects of copy number aberrations in glioblastoma. **2011**, 7, 486 | 67 |

| | | |
|---|---|---|
| 2156 | p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer. **2011**, 2, 431-42 | 43 |
| 2155 | Metabolism of glioma and IDH1/IDH2 mutations. **2011**, 167, 699-703 | 8 |
| 2154 | Biomarqueurs pronostiques et facteurs prédictifs de la réponse au traitement dans les gliomes de l'adulte. **2011**, 2, 64-70 | 1 |
| 2153 | Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. **2011**, 167, 683-90 | 22 |
| 2152 | The advent of personal genome sequencing. **2011**, 13, 188-90 | 52 |
| 2151 | LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. **2012**, 5, 575-9 | 29 |
| 2150 | Childhood brain tumors: epidemiology, current management and future directions. **2011**, 7, 495-506 | 94 |
| 2149 | Integrated genomic analyses of ovarian carcinoma. **2011**, 474, 609-15 | 5210 |
| 2148 | Prognostic implications of the DNA damage response pathway in glioblastoma. **2011**, 26, 423-30 | 7 |
| 2147 | Cancer epigenetics: linking basic biology to clinical medicine. **2011**, 21, 502-17 | 223 |
| 2146 | [OMICS and biomarkers of glial tumors]. **2011**, 167, 691-8 | 2 |
| 2145 | Personalized medicine: progress and promise. **2011**, 12, 217-44 | 183 |
| 2144 | Integration and analysis of genome-scale data from gliomas. **2011**, 7, 439-50 | 83 |
| 2143 | Targeting cancer metabolism: a therapeutic window opens. **2011**, 10, 671-84 | 1018 |
| 2142 | Targeted therapies for hepatocellular carcinoma. **2011**, 140, 1410-26 | 360 |
| 2141 | Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas. **2011**, 11, 799-806 | 20 |
| 2140 | Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. **2011**, 11, 1759-74 | 22 |
| 2139 | PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation. **2011**, 13, 492-503 | 45 |

| | | |
|---|---|---|
| 2138 | Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. **2011**, 178, 1395-402 | 102 |
| 2137 | NPAS3 demonstrates features of a tumor suppressive role in driving the progression of Astrocytomas. **2011**, 179, 462-76 | 20 |
| 2136 | Mosaic analysis with double markers reveals tumor cell of origin in glioma. **2011**, 146, 209-21 | 461 |
| 2135 | An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. **2011**, 147, 370-81 | 571 |
| 2134 | The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. **2011**, 25, 2594-609 | 274 |
| 2133 | Virchow 2011 or how to ID(H) human glioblastoma. **2011**, 29, 4473-4 | 18 |
| 2132 | Will kinase inhibitors make it as glioblastoma drugs?. **2012**, 355, 135-69 | 18 |
| 2131 | A combined preclinical therapy of cannabinoids and temozolomide against glioma. **2011**, 10, 90-103 | 185 |
| 2130 | Treatment of recurrent high-grade gliomas. **2011**, 8, 171-177 | |
| 2129 | Genetic architecture of cancer and other complex diseases: lessons learned and future directions. **2011**, 32, 945-54 | 76 |
| 2128 | Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. **2011**, 71, 7587-96 | 62 |
| 2127 | The Role of Isocitrate Dehydrogenase Mutations in Glioma Brain Tumors. **2011**, | 1 |
| 2126 | Integrative Network-based Association Studies: Leveraging cell regulatory models in the post-GWAS era. **2011**, | 4 |
| 2125 | Classification of Primary Brain Tumors: Molecular Aspects. **2011**, | |
| 2124 | Genetics and Biology of Glioblastoma Multiforme. **2011**, | 2 |
| 2123 | The Role of Sox Transcription Factors in Brain Tumourigenesis. **2011**, | 1 |
| 2122 | Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors. **2011**, 2011, 852970 | 21 |
| 2121 | Extracellular Matrix Microenvironment in Glioma Progression. **2011**, | 15 |

| | | |
|---|---|---|
| 2120 | Cryopreservation of cancer-initiating cells derived from glioblastoma. **2011**, 3, 698-708 | 7 |
| 2119 | The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science. **2011**, 31, 61-71 | 31 |
| 2118 | Overview and recent advances in neuropathology. Part 1: Central nervous system tumours. **2011**, 43, 88-92 | 12 |
| 2117 | Immunothérapie cellulaire et glioblastomes : un espoir de traitement ?. **2011**, 98, 457 | 5 |
| 2116 | Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. **2011**, 6, e14545 | 56 |
| 2115 | 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. **2011**, 6, e16812 | 92 |
| 2114 | A ten-microRNA expression signature predicts survival in glioblastoma. **2011**, 6, e17438 | 161 |
| 2113 | Unifying gene expression measures from multiple platforms using factor analysis. **2011**, 6, e17691 | 11 |
| 2112 | TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma. **2011**, 6, e18608 | 33 |
| 2111 | Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. **2011**, 6, e25451 | 204 |
| 2110 | The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression. **2011**, 6, e25631 | 44 |
| 2109 | Multigene sets for clinical application in glioma. **2011**, 9, 449-56; quiz 457 | 5 |
| 2108 | Glioma stem cell maintenance: the role of the microenvironment. **2011**, 17, 2386-401 | 67 |
| 2107 | Alteration in NFKBIA and EGFR in glioblastoma multiforme. **2011**, 68, N14-5 | 3 |
| 2106 | Collateral damage control in cancer therapy: defining the stem identity in gliomas. **2011**, 17, 2370-85 | 1 |
| 2105 | Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. **2011**, 70, 715-23 | 82 |
| 2104 | Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. **2011**, 70, 568-77 | 110 |
| 2103 | Ecatenin/Tcf-4 complex transcriptionally regulates AKT1 in glioma. **2011**, 39, 883-90 | 19 |

| | | |
|---|---|---|
| 2102 | Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. **2011**, 117, 2935-43 | 67 |
| 2101 | Advances in translational research in neuro-oncology. **2011**, 68, 303-8 | 4 |
| 2100 | Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study. **2011**, 31, 583-8 | 28 |
| 2099 | Cancer genomics: from discovery science to personalized medicine. **2011**, 17, 297-303 | 415 |
| 2098 | Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. **2011**, 30, 1341-50 | 32 |
| 2097 | NF-Β addiction and its role in cancer: 'one size does not fit all'. **2011**, 30, 1615-30 | 371 |
| 2096 | Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. **2011**, 104, 545-53 | 85 |
| 2095 | Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. **2011**, 91, 1068-78 | 38 |
| 2094 | Suppression of lung adenocarcinoma progression by Nkx2-1. **2011**, 473, 101-4 | 312 |
| 2093 | Integrative genomics viewer. **2011**, 29, 24-6 | 7463 |
| 2092 | Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. **2011**, 18, 959-73 | 64 |
| 2091 | The use of global profiling in biomarker development for gliomas. **2011**, 21, 88-95 | 17 |
| 2090 | Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies. **2011**, 21, 479-500 | 16 |
| 2089 | Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets. **2011**, 21, 619-32 | 33 |
| 2088 | Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. **2011**, 15, 2735-44 | 67 |
| 2087 | Genome-wide approaches for cancer gene discovery. **2011**, 29, 558-68 | 25 |
| 2086 | Analysis of cancer signaling networks by systems biology to develop therapies. **2011**, 21, 200-6 | 25 |
| 2085 | Neuro-oncology: continuing multidisciplinary progress. **2011**, 10, 18-20 | 6 |

| | | | |
|---|---|---|---|
| 2084 | Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. **2011**, 38, 173-85 | | 49 |
| 2083 | Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. **2011**, 38 Suppl 4, S2-10 | | 86 |
| 2082 | Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. **2011**, 38 Suppl 4, S21-33 | | 38 |
| 2081 | Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007. **2011**, 11, 325 | | 76 |
| 2080 | Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of □ketoglutarate-dependent dioxygenases. *Cancer Cell*, **2011**, 19, 17-30 | 24.3 | 1919 |
| 2079 | The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. *Cancer Cell*, **2011**, 19, 359-71 | 24.3 | 119 |
| 2078 | Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. *Cancer Cell*, **2011**, 19, 305-16 | 24.3 | 212 |
| 2077 | Monoallelic deletion of NFKBIA in glioblastoma: when less is more. *Cancer Cell*, **2011**, 19, 163-5 | 24.3 | 9 |
| 2076 | PARP inhibitors in cancer therapy: promise, progress, and puzzles. *Cancer Cell*, **2011**, 19, 165-7 | 24.3 | 47 |
| 2075 | Glioma models: new GEMMs add "class" with genomic and expression correlations. *Cancer Cell*, **2011**, 19, 295-7 | 24.3 | 5 |
| 2074 | Escaping Anoikis through ROS: ANGPTL4 controls integrin signaling through Nox1. *Cancer Cell*, **2011**, 19, 297-9 | 24.3 | 16 |
| 2073 | Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. *Cancer Cell*, **2011**, 20, 143-57 | 24.3 | 395 |
| 2072 | Many tumors in one: a daunting therapeutic prospect. *Cancer Cell*, **2011**, 20, 695-7 | 24.3 | 30 |
| 2071 | New strategies in the molecular targeting of glioblastoma: how do you hit a moving target?. **2011**, 17, 6-11 | | 17 |
| 2070 | Twisted tango: brain tumor neurovascular interactions. **2011**, 14, 1375-81 | | 59 |
| 2069 | The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. **2011**, 12, 495-508 | | 223 |
| 2068 | Predictive and prognostic factors for gliomas. **2011**, 11, 781-9 | | 49 |
| 2067 | Molecular Pathogenesis. **2011**, 27-44 | | 1 |

| | | |
|---|---|---|
| 2066 | Molecular pathogenesis of malignant glial tumors. **2011**, 39, 158-66 | 16 |
| 2065 | Molecular Subtypes of Gliomas. **2011**, 25-29 | |
| 2064 | Expression of genes belonging to the IGF-system in glial tumors. **2011**, 45, 303-317 | 3 |
| 2063 | CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. **2011**, 30, 4309-22 | 123 |
| 2062 | Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept. **2011**, 63, 558-67 | 36 |
| 2061 | PI3Kinase signaling in glioblastoma. **2011**, 103, 417-27 | 56 |
| 2060 | A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. **2011**, 105, 639-46 | 62 |
| 2059 | Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas. **2011**, 121, 529-43 | 14 |
| 2058 | Persistent roles of signal transduction of platelet-derived growth factor B in genesis, growth, and anaplastic transformation of gliomas in an in-vivo serial transplantation model. **2011**, 28, 33-42 | 4 |
| 2057 | Genetic profile of astrocytic and oligodendroglial gliomas. **2011**, 28, 177-83 | 124 |
| 2056 | Loss of heterozygosity analysis in malignant gliomas. **2011**, 28, 191-6 | 18 |
| 2055 | Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR. **2011**, 28, 291-6 | 24 |
| 2054 | New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status. **2011**, 28, 203-8 | 6 |
| 2053 | Neuropathological diagnosis of brain tumours. **2011**, 32 Suppl 2, S209-11 | 18 |
| 2052 | Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology?. **2011**, 7, 227-37 | 26 |
| 2051 | BTECH: a platform to integrate genomic, transcriptomic and epigenomic alterations in brain tumors. **2011**, 9, 59-67 | 5 |
| 2050 | MicroRNAs as regulators of neural stem cell-related pathways in glioblastoma multiforme. **2011**, 44, 235-49 | 39 |
| 2049 | Current state of our knowledge on brain tumor epidemiology. **2011**, 11, 329-35 | 70 |

| | | |
|---|---|---|
| 2048 | Genomic profiles of glioma. **2011**, 11, 291-7 | 34 |
| 2047 | Tumor profiling: development of prognostic and predictive factors to guide brain tumor treatment. **2011**, 13, 26-36 | 1 |
| 2046 | Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. **2011**, 13, 42-9 | 19 |
| 2045 | Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. **2011**, 10, 128 | 223 |
| 2044 | Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. **2011**, 4, 49 | 65 |
| 2043 | The PathOlogist: an automated tool for pathway-centric analysis. **2011**, 12, 133 | 28 |
| 2042 | Morphometic analysis of TCGA glioblastoma multiforme. **2011**, 12, 484 | 35 |
| 2041 | p53 directly represses Id2 to inhibit the proliferation of neural progenitor cells. **2011**, 29, 1090-101 | 33 |
| 2040 | Functional genomics of the brain: uncovering networks in the CNS using a systems approach. **2011**, 3, 628-48 | 10 |
| 2039 | Current concepts and management of glioblastoma. **2011**, 70, 9-21 | 319 |
| 2038 | A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target. **2011**, 59, 590-602 | 84 |
| 2037 | Genetic modeling of gliomas in mice: new tools to tackle old problems. **2011**, 59, 1155-68 | 79 |
| 2036 | The origins of glioma: E Pluribus Unum?. **2011**, 59, 1135-47 | 65 |
| 2035 | Drosophila melanogaster as a model system for human brain cancers. **2011**, 59, 1364-76 | 34 |
| 2034 | Molecular subclassification of diffuse gliomas: seeing order in the chaos. **2011**, 59, 1190-9 | 180 |
| 2033 | Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. **2011**, 117, 380-9 | 32 |
| 2032 | Molecular signatures classify astrocytic gliomas by IDH1 mutation status. **2011**, 128, 1095-103 | 64 |
| 2031 | Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. **2011**, 128, 1981-8 | 41 |

| | | |
|---|---|---|
| 2030 | A strategy for distinguishing optimal cancer subtypes. **2011**, 129, 931-7 | 19 |
| 2029 | Therapeutic potential of AZD1480 for the treatment of human glioblastoma. **2011**, 10, 2384-93 | 74 |
| 2028 | Antitumor effect of aspirin in glioblastoma cells by modulation of β-catenin/T-cell factor-mediated transcriptional activity. **2011**, 115, 780-8 | 18 |
| 2027 | Rethinking pediatric gliomas as developmental brain abnormalities. **2011**, 94, 283-308 | 4 |
| 2026 | Genomic alterations and the pathogenesis of glioblastoma. **2011**, 10, 1174-5 | 3 |
| 2025 | Preclinical drug development for childhood cancer. **2011**, 6, 49-64 | 7 |
| 2024 | Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. **2011**, 19, 1793-801 | 38 |
| 2023 | Epigenetics. **2011**, 8, 117; discussion 118 | |
| 2022 | Brain tumor pathway identification by integrating transcriptome and interactome data. **2011**, | |
| 2021 | Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. **2011**, 29, 4482-90 | 337 |
| 2020 | DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. **2011**, 103, 143-53 | 194 |
| 2019 | Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. **2011**, 8, 135-48 | 82 |
| 2018 | MORPHOLOGICAL SIGNATURES AND GENOMIC CORRELATES IN GLIOBLASTOMA. **2011**, 1624-1627 | 17 |
| 2017 | Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. **2011**, 10, 2437-48 | 40 |
| 2016 | Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRβ. **2011**, 10, 1407-18 | 39 |
| 2015 | MADM gives new insights into gliomagenesis. **2011**, 3, 273-5 | 2 |
| 2014 | High β-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression. **2011**, 13, 600-9 | 58 |
| 2013 | Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. **2011**, 71, 7198-206 | 23 |

| | | |
|---|---|---|
| 2012 | Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. **2011**, 208, 313-26 | 527 |
| 2011 | NFKBIA deletion in glioblastomas. **2011**, 364, 627-37 | 188 |
| 2010 | Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. **2011**, 13, 99-108 | 43 |
| 2009 | Making sense of cancer genomic data. **2011**, 25, 534-55 | 260 |
| 2008 | Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. **2011**, 17, 1603-15 | 315 |
| 2007 | NKX2.2 suppresses self-renewal of glioma-initiating cells. **2011**, 71, 1135-45 | 19 |
| 2006 | Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. **2011**, 13, 1178-91 | 64 |
| 2005 | Report from the fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop. **2011**, 13, 692-9 | 6 |
| 2004 | Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. **2011**, 208, 2657-73 | 50 |
| 2003 | Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. **2011**, 2011, 732413 | 93 |
| 2002 | Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. **2011**, 5, 265-314 | 27 |
| 2001 | Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. **2011**, 29, 1424-30 | 513 |
| 2000 | Genetics of glioblastoma: a window into its imaging and histopathologic variability. **2011**, 31, 1717-40 | 36 |
| 1999 | Neurooncology. **2011**, 39, 124-8 | 1 |
| 1998 | Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. **2011**, 13, 84-98 | 99 |
| 1997 | Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. **2011**, 71, 4550-61 | 122 |
| 1996 | Platelet-derived growth factor receptor alpha in glioma: a bad seed. **2011**, 30, 590-602 | 30 |
| 1995 | RAD51 can inhibit PDGF-B-induced gliomagenesis and genomic instability. **2011**, 13, 1277-87 | 9 |

| | | |
|---|---|---|
| 1994 | A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. **2011**, 208, 689-702 | 65 |
| 1993 | WITHDRAWN: Cytogenetic and molecular genetic study on glioblastoma arising in granular cell astrocytoma: a case report. **2011**, | 1 |
| 1992 | Targeting ErbB receptors in high-grade glioma. **2011**, 17, 2468-87 | 27 |
| 1991 | Gene regulation in glioblastoma: a combinatorial analysis of microRNAs and transcription factors. **2011**, 4, 111-26 | 3 |
| 1990 | Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. **2011**, 10, 33-8 | 62 |
| 1989 | Ecatenin and Gli1 are prognostic markers in glioblastoma. **2011**, 11, 753-61 | 94 |
| 1988 | Annexin A2 promotes glioma cell invasion and tumor progression. **2011**, 31, 14346-60 | 90 |
| 1987 | A novel function of the proneural factor Ascl1 in progenitor proliferation identified by genome-wide characterization of its targets. **2011**, 25, 930-45 | 284 |
| 1986 | Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. **2011**, 71, 3066-75 | 117 |
| 1985 | Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma. **2011**, 105, 1235-43 | 19 |
| 1984 | Advances in malignant glioma drug discovery. **2011**, 6, 739-53 | 15 |
| 1983 | Novel ways to target brain tumour metabolism. **2011**, 15, 1227-39 | 12 |
| 1982 | A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. **2011**, 17, 7148-55 | 93 |
| 1981 | A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. **2011**, 108, 1591-6 | 94 |
| 1980 | A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. **2011**, 71, 3387-99 | 154 |
| 1979 | How genetically engineered mouse tumor models provide insights into human cancers. **2011**, 29, 2273-81 | 97 |
| 1978 | Genetic alterations in glioma. **2011**, 3, 1129-40 | 19 |
| 1977 | Role of isocitrate dehydrogenase in glioma. **2011**, 11, 1399-409 | 12 |

| | | |
|---|---|---|
| 1976 | Proteomics of gliomas: initial biomarker discovery and evolution of technology. **2011**, 13, 926-42 | 62 |
| 1975 | Aberrant signaling pathways in glioma. **2011**, 3, 3242-78 | 125 |
| 1974 | A data model and database for high-resolution pathology analytical image informatics. **2011**, 2, 32 | 44 |
| 1973 | Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. **2012**, 33, 436-41 | 61 |
| 1972 | Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12. **2012**, 14, 160-74 | 20 |
| 1971 | Uncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma. **2012**, 8, e1002488 | 110 |
| 1970 | Bidirectional discrimination with application to data visualization. **2012**, 99, 851-864 | 9 |
| 1969 | The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas. **2012**, 2012, 454957 | 3 |
| 1968 | Oncogenic extracellular vesicles in brain tumor progression. **2012**, 3, 294 | 86 |
| 1967 | Concordance between local, institutional, and central pathology review in glioblastoma: implications for research and practice: a pilot study. **2012**, 60, 61-5 | 5 |
| 1966 | Integrins and p53 pathways in glioblastoma resistance to temozolomide. **2012**, 2, 157 | 22 |
| 1965 | MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. **2012**, 18, 3030-41 | 36 |
| 1964 | Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation. **2012**, 14, 426-39 | 44 |
| 1963 | Increased expression of microRNA-17 predicts poor prognosis in human glioma. **2012**, 2012, 970761 | 39 |
| 1962 | Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch. **2012**, 14, 1215-26 | 17 |
| 1961 | Expression of B-crystallin overrides the anti-apoptotic activity of XIAP. **2012**, 14, 1332-45 | 13 |
| 1960 | Key concepts in glioblastoma therapy. **2012**, 83, 753-60 | 59 |
| 1959 | Glioma-propagating cells as an in vitro screening platform: PLK1 as a case study. **2012**, 17, 1136-50 | 5 |

| | | |
|---|---|---|
| 1958 | Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. **2012**, 14, 326-32 | 53 |
| 1957 | Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells. **2012**, 109, E2998-3007 | 52 |
| 1956 | The putative tumor suppressor miR-524-5p directly targets Jagged-1 and Hes-1 in glioma. **2012**, 33, 2276-82 | 63 |
| 1955 | Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. **2012**, 18, 69-81 | 136 |
| 1954 | STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. **2012**, 11, 1289-99 | 129 |
| 1953 | 1H NMR metabolomics analysis of glioblastoma subtypes: correlation between metabolomics and gene expression characteristics. **2012**, 287, 20164-75 | 54 |
| 1952 | Management of malignant gliomas and primary CNS lymphoma: standard of care and future directions. **2012**, 18, 406-15 | 8 |
| 1951 | Individualized targeted therapy for glioblastoma: fact or fiction?. **2012**, 18, 40-4 | 57 |
| 1950 | A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. **2012**, 22, 2339-55 | 137 |
| 1949 | EFFECTIVE MODELS FOR GENE NETWORKS AND THEIR APPLICATIONS. **2012**, 07, 41-70 | 4 |
| 1948 | Exploiting the mutanome for tumor vaccination. **2012**, 72, 1081-91 | 556 |
| 1947 | Integrative functional genomics identifies RINT1 as a novel GBM oncogene. **2012**, 14, 1325-31 | 12 |
| 1946 | Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. **2012**, 21, 5406-16 | 85 |
| 1945 | FoxM1 and Wnt/Ecatenin signaling in glioma stem cells. **2012**, 72, 5658-62 | 124 |
| 1944 | Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. **2012**, 18, 2930-42 | 87 |
| 1943 | Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin 61 in glioblastoma. **2012**, 72, 1428-37 | 30 |
| 1942 | Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. **2012**, 26, 1926-44 | 275 |
| 1941 | Therapeutic Kinase Inhibitors. **2012**, | 1 |

| | | |
|---|---|---|
| 1940 | Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. **2012**, 109, 570-5 | 96 |
| 1939 | Les mutations des gènes IDH1 et 2 dans les gliomes conditionnent l'acquisition d'un phénotype « hyperméthylateur » au sein des tumeurs. **2012**, 99, 729 | 1 |
| 1938 | SSBP2 variants are associated with survival in glioblastoma patients. **2012**, 18, 3154-62 | 18 |
| 1937 | Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth. **2012**, 10, 156-66 | 31 |
| 1936 | Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?. **2012**, 1, 137-48 | 5 |
| 1935 | PDGF in gliomas: more than just a growth factor?. **2012**, 117, 92-8 | 17 |
| 1934 | Myc proteins in brain tumor development and maintenance. **2012**, 117, 122-31 | 28 |
| 1933 | Neural stem cells: brain building blocks and beyond. **2012**, 117, 132-42 | 45 |
| 1932 | PDGF and PDGF receptors in glioma. **2012**, 117, 99-112 | 120 |
| 1931 | Neuronal immunoexpression and a distinct subtype of adult primary supratentorial glioblastoma with a better prognosis. **2012**, 117, 476-85 | 7 |
| 1930 | Editorial: glioblastoma subtype. **2012**, 117, 474; discussion 475 | |
| 1929 | MET signaling regulates glioblastoma stem cells. **2012**, 72, 3828-38 | 130 |
| 1928 | Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. **2012**, 14 Suppl 4, iv100-8 | 120 |
| 1927 | VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling. **2012**, 14, 1026-36 | 85 |
| 1926 | Investigating survival prognosis of glioblastoma using evolutional properties of gene networks. **2012**, | 4 |
| 1925 | Molecular bases of morphometric composition in Glioblastoma multiforme. **2012**, | 4 |
| 1924 | Integrated morphologic analysis for the identification and characterization of disease subtypes. **2012**, 19, 317-23 | 66 |
| 1923 | UNCOVER CONTEXT-SPECIFIC GENE REGULATION BY TRANSCRIPTION FACTORS AND microRNAs USING BAYESIAN SPARSE NONNEGATIVE FACTOR REGRESSION. **2012**, 20, 377-402 | 1 |

| | | |
|---|---|---|
| 1922 | Cancer. Can one cell influence cancer heterogeneity?. **2012**, 338, 1035-6 | 2 |
| 1921 | Development of robust discriminant equations for assessing subtypes of glioblastoma biopsies. **2012**, 106, 1816-25 | 7 |
| 1920 | MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme. **2012**, 3, e398 | 101 |
| 1919 | HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation. **2012**, 31, 1299-310 | 20 |
| 1918 | Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. **2012**, 31, 1995-2006 | 37 |
| 1917 | Leveraging models of cell regulation and GWAS data in integrative network-based association studies. **2012**, 44, 841-7 | 198 |
| 1916 | Gene expression profiles of gliomas in formalin-fixed paraffin-embedded material. **2012**, 106, 538-45 | 13 |
| 1915 | Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. **2012**, 287, 43565-72 | 111 |
| 1914 | Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival. **2012**, 72, 2543-53 | 62 |
| 1913 | Discovery in context: leveraging multidimensional glioblastoma datasets to identify targetable regulatory networks. **2012**, 2, 676-8 | 1 |
| 1912 | Tyrosine phosphorylation of the p21 cyclin-dependent kinase inhibitor facilitates the development of proneural glioma. **2012**, 287, 38523-30 | 17 |
| 1911 | Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. **2012**, 109, 3041-6 | 381 |
| 1910 | Correlation of perfusion parameters with genes related to angiogenesis regulation in glioblastoma: a feasibility study. **2012**, 33, 1343-8 | 39 |
| 1909 | Stem Cells and Cancer Stem Cells, Volume 2. **2012**, | |
| 1908 | Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. **2012**, 14, 518-25 | 53 |
| 1907 | Can molecular markers help with decision making?. **2012**, 23 Suppl 10, x25-7 | 0 |
| 1906 | Regenerative Biology of the Spine and Spinal Cord. **2012**, | |
| 1905 | Progenitor-like traits contribute to patient survival and prognosis in oligodendroglial tumors. **2012**, 18, 4122-35 | 14 |

| | | |
|---|---|---|
| 1904 | Identification of genomic targets of transcription factor AEBP1 and its role in survival of glioma cells. **2012**, 10, 1039-51 | 31 |
| 1903 | Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. **2012**, 14, 1432-40 | 133 |
| 1902 | Moving toward molecular classification of diffuse gliomas in adults. **2012**, 79, 1917-26 | 54 |
| 1901 | On the origin of glioma. **2012**, 117, 113-21 | 51 |
| 1900 | Integrated Analysis Reveals hsa-miR-142 as a Representative of a Lymphocyte-Specific Gene Expression and Methylation Signature. **2012**, 11, 61-75 | 17 |
| 1899 | Disease biology in the coming decade(s). **2012**, 19, 149-50 | 1 |
| 1898 | Current trends in targeted therapies for glioblastoma multiforme. **2012**, 2012, 878425 | 102 |
| 1897 | Catenin Signalling in Glioblastoma Multiforme and Glioma-Initiating Cells. **2012**, 2012, 192362 | 57 |
| 1896 | Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. **2012**, 14, 1136-45 | 61 |
| 1895 | Nucleic acids in human glioma treatment: innovative approaches and recent results. **2012**, 2012, 735135 | 15 |
| 1894 | Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. **2012**, 26, 1247-62 | 75 |
| 1893 | Glioblastoma blood flow measured with stable xenon CT indicates tumor necrosis, vascularity, and brain invasion. **2012**, 14, 641-8 | 1 |
| 1892 | Studying a complex tumor: potential and pitfalls. **2012**, 18, 107-14 | 23 |
| 1891 | Targeted therapeutic strategies for relapsed disease. **2012**, 28-40 | |
| 1890 | Methods of resistance to epidermal growth factor receptor inhibition in glioblastoma multiforme. **2012**, 70, N13-4 | |
| 1889 | Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma. **2012**, 20, 994-1001 | 42 |
| 1888 | KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas. **2012**, 135, 1027-41 | 37 |
| 1887 | Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification. **2012**, 18, 5595-605 | 26 |

| | | |
|---|---|---|
| 1886 | Th□apies mol□ulaires cibl□s et antiangiog□iques dans le traitement des glioblastomes. **2012**, 9, 1-13 | |
| 1885 | Epidermal growth factor receptor: a re-emerging target in glioblastoma. **2012**, 25, 774-9 | 66 |
| 1884 | Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype. **2012**, 71, 83-9 | 37 |
| 1883 | Cancer immunoediting in malignant glioma. **2012**, 71, 201-22; discussion 222-3 | 62 |
| 1882 | Identification of prognostic biomarkers for glioblastomas using protein expression profiling. **2012**, 40, 1122-32 | 17 |
| 1881 | . | 1 |
| 1880 | Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. **2012**, 41, 1029-35 | 42 |
| 1879 | Glioma and Other Neuroepithelial Neoplasms. **2012**, 767-794 | |
| 1878 | Primary brain tumours in adults. **2012**, 379, 1984-96 | 447 |
| 1877 | Differential expression of 2',3'-cyclic-nucleotide 3'-phosphodiesterase and neural lineage markers correlate with glioblastoma xenograft infiltration and patient survival. **2012**, 18, 3628-36 | 34 |
| 1876 | Efficient methods for identifying mutated driver pathways in cancer. **2012**, 28, 2940-7 | 109 |
| 1875 | Transcriptional factors for epithelial-mesenchymal transition are associated with mesenchymal differentiation in gliosarcoma. **2012**, 22, 670-6 | 38 |
| 1874 | Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. **2012**, 18, 1835-40 | 521 |
| 1873 | Activation of canonical WNT/□catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. **2012**, 325, 42-53 | 160 |
| 1872 | microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-□signaling in glioblastoma. **2012**, 2, 736-49 | 90 |
| 1871 | Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. **2012**, 103, 1871-9 | 32 |
| 1870 | Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. **2012**, 11, 489-502 | 53 |
| 1869 | Prospective, high-throughput molecular profiling of human gliomas. **2012**, 110, 89-98 | 44 |

| | | | |
|---|---|---|---|
| 1868 | A-Disintegrin and Metalloprotease (ADAM) 10 and 17 promote self-renewal of brain tumor sphere forming cells. **2012**, 326, 79-87 | | 15 |
| 1867 | Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. **2012**, 72, 3350-9 | | 73 |
| 1866 | Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. **2012**, 124, 615-25 | | 295 |
| 1865 | Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1. **2012**, 31, 4698-708 | | 52 |
| 1864 | 53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma. **2012**, 72, 5250-60 | | 24 |
| 1863 | Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas. **2012**, 14, 1393-403 | | 31 |
| 1862 | Integrin 51 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. **2012**, 72, 3463-70 | | 87 |
| 1861 | IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. **2012**, 18, 5562-71 | | 254 |
| 1860 | Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma. **2012**, 72, 4856-68 | | 49 |
| 1859 | Synergistic effect of different levels of genomic data for cancer clinical outcome prediction. **2012**, 45, 1191-8 | | 73 |
| 1858 | Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. **2012**, 338, 1080-4 | | 391 |
| 1857 | Laminin alpha 2 enables glioblastoma stem cell growth. **2012**, 72, 766-78 | | 117 |
| 1856 | Multiple Response Regression for Gaussian Mixture Models with Known Labels. **2012**, 5, 493 | | 2 |
| 1855 | Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. **2012**, 90, 1161-1171 | | 70 |
| 1854 | Molecular markers of glioma: an update on recent progress and perspectives. **2012**, 138, 1971-81 | | 43 |
| 1853 | Molecular characteristics of glioblastoma with 1p/19q co-deletion. **2012**, 29, 148-53 | | 21 |
| 1852 | Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell*, **2012**, 22, 425-37 | 24.3 | 1243 |
| 1851 | Methylome alterations "mark" new therapeutic opportunities in glioblastoma. *Cancer Cell*, **2012**, 22, 417-8 | 24.3 | 8 |

| | | | |
|---|---|---|---|
| 1850 | The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. *Cancer Cell*, **2012**, 22, 765-80 | 24.3 | 153 |
| 1849 | Terapie molecolari mirate e antiangiogeniche nel trattamento dei glioblastomi. **2012**, 12, 1-14 | | |
| 1848 | IDH mutations in human glioma. **2012**, 23, 471-80 | | 42 |
| 1847 | Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. **2012**, 5, 56-65 | | 57 |
| 1846 | Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma. **2012**, 8, 605 | | 73 |
| 1845 | Recent developments on immunotherapy for brain cancer. **2012**, 17, 181-202 | | 50 |
| 1844 | Support vector machine (SVM) active learning for automated Glioblastoma segmentation. **2012**, | | 5 |
| 1843 | Stem cells in gliomas. **2012**, 104, 63-73 | | 9 |
| 1842 | Therapeutic targeting of VEGF in the treatment of glioblastoma. **2012**, 16, 973-84 | | 30 |
| 1841 | Nimotuzumab treatment of malignant gliomas. **2012**, 12, 1649-59 | | 44 |
| 1840 | . **2012**, | | |
| 1839 | A gene signature based method for identifying subtypes and subtype-specific drivers in cancer with an application to medulloblastoma. **2012**, | | 1 |
| 1838 | Identifying mutated core modules in glioblastoma by integrative network analysis. **2012**, | | |
| 1837 | enRoute: Dynamic path extraction from biological pathway maps for in-depth experimental data analysis. **2012**, | | 11 |
| 1836 | Multiscale integration of -omic, imaging, and clinical data in biomedical informatics. **2012**, 5, 74-87 | | 35 |
| 1835 | Consensus on the role of human cytomegalovirus in glioblastoma. **2012**, 14, 246-55 | | 205 |
| 1834 | Prognosis of patients with multifocal glioblastoma: a case-control study. **2012**, 117, 705-11 | | 77 |
| 1833 | Cortical and subventricular zone glioblastoma-derived stem-like cells display different molecular profiles and differential in vitro and in vivo properties. **2012**, 19 Suppl 3, S608-19 | | 24 |

| | | |
|---|---|---|
| 1832 | Alterations of metabolic genes and metabolites in cancer. **2012**, 23, 370-80 | 84 |
| 1831 | Hope and challenges for dendritic cell-based vaccine therapy for glioblastoma. **2012**, 77, 633-5 | 2 |
| 1830 | IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. **2012**, 18, 2490-501 | 108 |
| 1829 | Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy. **2012**, 5, 173-86 | 99 |
| 1828 | LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions. **2012**, 11, M111.013565 | 65 |
| 1827 | PDGF-B-mediated downregulation of miR-21: new insights into PDGF signaling in glioblastoma. **2012**, 21, 5118-30 | 22 |
| 1826 | Cadherin-11, a marker of the mesenchymal phenotype, regulates glioblastoma cell migration and survival in vivo. **2012**, 10, 293-304 | 50 |
| 1825 | Comprehensive literature review and statistical considerations for microarray meta-analysis. **2012**, 40, 3785-99 | 263 |
| 1824 | The quest for self-identity: not all cancer stem cells are the same. **2012**, 18, 3495-8 | 12 |
| 1823 | The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. **2012**, 180, 2108-19 | 157 |
| 1822 | Nature versus nurture in glioblastoma: microenvironment and genetics can both drive mesenchymal transcriptional signature. **2012**, 180, 1768-71 | 4 |
| 1821 | A novel adenoviral vector labeled with superparamagnetic iron oxide nanoparticles for real-time tracking of viral delivery. **2012**, 19, 875-80 | 30 |
| 1820 | Opposing roles of connexin43 in glioma progression. **2012**, 1818, 2058-67 | 82 |
| 1819 | Genetically engineered mouse models of diffuse gliomas. **2012**, 88, 72-9 | 18 |
| 1818 | Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. **2012**, 11, 133-44 | 56 |
| 1817 | GBM secretome induces transient transformation of human neural precursor cells. **2012**, 109, 457-66 | 14 |
| 1816 | Glioblastoma research 2006-2010: pattern of citation and systematic review of highly cited articles. **2012**, 114, 1207-10 | 12 |
| 1815 | MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. **2012**, 124, 547-60 | 213 |

| | | |
|---|---|---|
| 1814 | Correlation set analysis: detecting active regulators in disease populations using prior causal knowledge. **2012**, 13, 46 | 7 |
| 1813 | Matching of array CGH and gene expression microarray features for the purpose of integrative genomic analyses. **2012**, 13, 80 | 14 |
| 1812 | A REST derived gene signature stratifies glioblastomas into chemotherapy resistant and responsive disease. **2012**, 13, 686 | 13 |
| 1811 | Identification of a novel set of genes reflecting different in vivo invasive patterns of human GBM cells. **2012**, 12, 358 | 12 |
| 1810 | miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma. **2012**, 12, 378 | 36 |
| 1809 | Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall. **2012**, 12, 41 | 20 |
| 1808 | Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. **2012**, 11, 20 | 27 |
| 1807 | Immune genes are associated with human glioblastoma pathology and patient survival. **2012**, 5, 41 | 30 |
| 1806 | Genetics of adult glioma. **2012**, 205, 613-21 | 566 |
| 1805 | Dissecting the complex regulation of Mad4 in glioblastoma multiforme cells. **2012**, 13, 1339-48 | 6 |
| 1804 | The future of glioma treatment: stem cells, nanotechnology and personalized medicine. **2012**, 8, 1149-56 | 15 |
| 1803 | Epigenetic Alterations in Glioblastoma Multiforme. **2012**, 71-90 | 1 |
| 1802 | Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. **2012**, 14, 1153-62 | 56 |
| 1801 | Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). **2012**, 3, 9-14 | 60 |
| 1800 | Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. **2012** , 482, 226-31 | 1655 |
| 1799 | Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. **2012**, 7, e30313 | 171 |
| 1798 | GSVD comparison of patient-matched normal and tumor aCGH profiles reveals global copy-number alterations predicting glioblastoma multiforme survival. **2012**, 7, e30098 | 29 |
| 1797 | A simplified approach for the molecular classification of glioblastomas. **2012**, 7, e45475 | 47 |

| | | |
|---|---|---|
| 1796 | Overview of primary brain tumors: pathologic classification, epidemiology, molecular biology, and prognostic markers. **2012**, 26, 715-32 | 22 |
| 1795 | Clinical trials with immunotherapy for high-grade glioma. **2012**, 23, 459-70 | 15 |
| 1794 | Glioblastoma biomarkers from bench to bedside: advances and challenges. **2012**, 26, 189-94 | 17 |
| 1793 | Molecular subgroups of medulloblastoma. **2012**, 12, 871-84 | 103 |
| 1792 | A novel treatment for glioblastoma: integrin inhibition. **2012**, 12, 421-35 | 31 |
| 1791 | Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. **2012**, 483, 484-8 | 549 |
| 1790 | Clinical integration of next-generation sequencing technology. **2012**, 32, 585-99 | 49 |
| 1789 | MiR-410 regulates MET to influence the proliferation and invasion of glioma. **2012**, 44, 1711-7 | 84 |
| 1788 | Developmental origins of brain tumors. **2012**, 22, 844-9 | 29 |
| 1787 | Treatment of elderly patients with glioblastoma: from clinical evidence to molecular highlights. **2012**, 38, 988-95 | 20 |
| 1786 | MEF promotes stemness in the pathogenesis of gliomas. **2012**, 11, 836-44 | 27 |
| 1785 | Alternative transcription and alternative splicing in cancer. **2012**, 136, 283-94 | 91 |
| 1784 | [Guidelines for adult diffuse gliomas WHO grade II, III and IV: pathology and biology. Soci□ franc□aise de neuropathologie . R□eau de neuro-oncologie pathologique]. **2012**, 32, 318-27 | 7 |
| 1783 | The cancer stem cell subtype determines immune infiltration of glioblastoma. **2012**, 21, 2753-61 | 55 |
| 1782 | Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics. **2012**, 3, 40 | 106 |
| 1781 | Malignancies of the spinal cord. **2012**, 760, 101-13 | 7 |
| 1780 | The spectrum of vaccine therapies for patients with glioblastoma multiforme. **2012**, 13, 437-50 | 16 |
| 1779 | Biomarkers classification and therapeutic decision-making for malignant gliomas. **2012**, 13, 417-36 | 22 |

| | | |
|---|---|---|
| 1778 | Hypoxia Moderates (1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures. **2012**, 5, 200-7 | 26 |
| 1777 | Neural Development and Stem Cells. **2012**, | |
| 1776 | Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. **2012**, 31, 3039-50 | 59 |
| 1775 | Assessing Mechanisms of Glioblastoma Invasion. **2012**, 275-298 | 1 |
| 1774 | Neurofibromatosis Type 1. **2012**, | 16 |
| 1773 | Glioblastoma--a moving target. **2012**, 117, 251-6 | 37 |
| 1772 | Phosphoinositides I: Enzymes of Synthesis and Degradation. **2012**, | 6 |
| 1771 | Combing the hairball with BioFabric: a new approach for visualization of large networks. **2012**, 13, 275 | 25 |
| 1770 | Pediatric Cancer, Volume 2. **2012**, | 0 |
| 1769 | Clinical trials of small molecule inhibitors in high-grade glioma. **2012**, 23, 407-16 | 9 |
| 1768 | Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas. **2012**, 31, 85 | 22 |
| 1767 | Digital transcriptome profiling of normal and glioblastoma-derived neural stem cells identifies genes associated with patient survival. **2012**, 4, 76 | 39 |
| 1766 | Sample-level enrichment analysis unravels shared stress phenotypes among multiple cancer types. **2012**, 4, 28 | 34 |
| 1765 | Splitting random forest (SRF) for determining compact sets of genes that distinguish between cancer subtypes. **2012**, 2, 13 | 3 |
| 1764 | A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. **2012**, 8, e1002337 | 46 |
| 1763 | Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. **2012**, 7, e29653 | 88 |
| 1762 | miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. **2012**, 7, e33844 | 90 |
| 1761 | Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. **2012**, 7, e34546 | 94 |

| | | |
|---|---|---|
| 1760 | Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells. **2012**, 7, e40195 | 40 |
| 1759 | Cancer association study of aminoacyl-tRNA synthetase signaling network in glioblastoma. **2012**, 7, e40960 | 19 |
| 1758 | Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. **2012**, 7, e41036 | 128 |
| 1757 | A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. **2012**, 7, e41522 | 70 |
| 1756 | Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. **2012**, 7, e43339 | 106 |
| 1755 | Distinct and competitive regulatory patterns of tumor suppressor genes and oncogenes in ovarian cancer. **2012**, 7, e44175 | 24 |
| 1754 | Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. **2012**, 7, e46153 | 55 |
| 1753 | Multi-analyte network markers for tumor prognosis. **2012**, 7, e52973 | 18 |
| 1752 | MicroRNAs in Human Malignant Gliomas. **2012**, 2012, 732874 | 23 |
| 1751 | EGFR and Tumor Suppressor Function in Brain Cancer Development. **2012**, 217-225 | |
| 1750 | Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. **2012**, 50, 301-21 | 66 |
| 1749 | The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond. **2012**, 2012, 838916 | 34 |
| 1748 | Glioblastoma: biology, genetics, and behavior. **2012**, 102-7 | 8 |
| 1747 | Future directions in glioblastoma therapy. **2012**, 108-11 | 2 |
| 1746 | Subtyping of Gliomaby Combining Gene Expression and CNVs Data Based on a Compressive Sensing Approach. **2012**, 1, 101 | 3 |
| 1745 | Molecular biomarkers of glioblastoma: current targets and clinical implications. **2012**, 63 | 4 |
| 1744 | Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. **2012**, 3, 709-22 | 439 |
| 1743 | REST regulates oncogenic properties of glioblastoma stem cells. **2012**, 30, 405-14 | 56 |

| | | |
|---|---|---|
| 1742 | Reverse-engineering human regulatory networks. **2012**, 4, 311-25 | 42 |
| 1741 | Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. **2012**, 12, 1093-110 | 126 |
| 1740 | Rai is a new regulator of neural progenitor migration and glioblastoma invasion. **2012**, 30, 817-32 | 28 |
| 1739 | Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor. **2012**, 30, 845-53 | 61 |
| 1738 | Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and Skp1-Cullin-F-box ubiquitin ligase activity. **2012**, 30, 1313-26 | 44 |
| 1737 | Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. **2012**, 31, 1884-95 | 150 |
| 1736 | Translating cancer 'omics' to improved outcomes. **2012**, 22, 188-95 | 84 |
| 1735 | IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. **2012**, 483, 479-83 | 1373 |
| 1734 | The cellular origin for malignant glioma and prospects for clinical advancements. **2012**, 12, 383-94 | 113 |
| 1733 | Malignant glioma: lessons from genomics, mouse models, and stem cells. **2012**, 149, 36-47 | 416 |
| 1732 | Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. **2012**, 72, 1614-20 | 90 |
| 1731 | IDH mutation impairs histone demethylation and results in a block to cell differentiation. **2012**, 483, 474-8 | 1393 |
| 1730 | The MET oncogene is a functional marker of a glioblastoma stem cell subtype. **2012**, 72, 4537-50 | 104 |
| 1729 | Emerging insights into the molecular and cellular basis of glioblastoma. **2012**, 26, 756-84 | 388 |
| 1728 | Exploring the cancer stem cell phenotype with high-throughput screening applications. **2012**, 4, 1229-41 | 7 |
| 1727 | Stem Cell Pathways in Brain Tumors. **2012**, 329-349 | |
| 1726 | Antagonistic modulation of gliomagenesis by Pax6 and Olig2 in PDGF-induced oligodendroglioma. **2012**, 131, E1078-87 | 20 |
| 1725 | Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters. **2012**, 8, 549-58 | 16 |

| | | | |
|---|---|---|---|
| 1724 | Oligodendroglioma Models. **2012**, 57-82 | | |
| 1723 | DNA damage repair pathways in cancer stem cells. **2012**, 11, 1627-36 | | 113 |
| 1722 | DNA methylation profiling distinguishes three clusters of breast cancer cell lines. **2012**, 9, 848-56 | | 3 |
| 1721 | Glioblastoma Multiforme: Cryopreservation of Brain Tumor-Initiating Cells (Method). **2012**, 95-101 | | |
| 1720 | Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. **2012**, 14, 132-44 | | 165 |
| 1719 | Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. **2012**, 109, 8710-5 | | 64 |
| 1718 | Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. **2012**, 18, 1515-23 | | 37 |
| 1717 | Paediatric and adult malignant glioma: close relatives or distant cousins?. **2012**, 9, 400-13 | | 131 |
| 1716 | Glioma Stem Cells and their Therapy Resistance. **2012**, 01, | | 2 |
| 1715 | Recent advances in the molecular understanding of glioblastoma. **2012**, 108, 11-27 | | 269 |
| 1714 | Cancer-initiating enriched cell lines from human glioblastoma: preparing for drug discovery assays. **2012**, 8, 288-98 | | 9 |
| 1713 | Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. **2012**, 123, 841-52 | | 68 |
| 1712 | A prognostic gene expression signature in infratentorial ependymoma. **2012**, 123, 727-38 | | 131 |
| 1711 | A review of the role of stem cells in the development and treatment of glioma. **2012**, 154, 951-69; discussion 969 | | 11 |
| 1710 | Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents. **2012**, 64, 605-13 | | 76 |
| 1709 | Autophagy in brain tumors: a new target for therapeutic intervention. **2012**, 22, 89-98 | | 73 |
| 1708 | Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. *Cancer Cell*, **2012**, 21, 11-24 | 24.3 | 112 |
| 1707 | Spheres without influence: dissociating in vitro self-renewal from tumorigenic potential in glioma. *Cancer Cell*, **2012**, 21, 1-3 | 24.3 | 7 |

| | | | |
|---|---|---|---|
| 1706 | SnapShot: glioblastoma multiforme. *Cancer Cell*, **2012**, 21, 710-710.e1 | 24.3 | 27 |
| 1705 | VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. *Cancer Cell*, **2012**, 22, 21-35 | 24.3 | 423 |
| 1704 | Glioblastoma: therapeutic challenges, what lies ahead. **2012**, 1826, 338-49 | | 75 |
| 1703 | The sixth annual translational stem cell research conference of the New York Stem Cell Foundation. **2012**, 1255, 16-29 | | |
| 1702 | Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma. **2012**, 16, 545-54 | | 21 |
| 1701 | Bmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells. **2012**, 8, 141-53 | | 42 |
| 1700 | Simultaneous Multiple Response Regression and Inverse Covariance Matrix Estimation via Penalized Gaussian Maximum Likelihood. **2012**, 111, 241-255 | | 32 |
| 1699 | Glioma stem cells: their role in chemoresistance. **2012**, 77, 237-40 | | 22 |
| 1698 | Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib. **2012**, 318, 641-52 | | 7 |
| 1697 | Digital Pathology: Data-Intensive Frontier in Medical Imaging: Health-information sharing, specifically of digital pathology, is the subject of this paper which discusses how sharing the rich images in pathology can stretch the capabilities of all otherwise well-practiced disciplines. **2012**, 100, 991-1003 | | 26 |
| 1696 | Review: insights gained from modelling high-grade glioma in the mouse. **2012**, 38, 254-70 | | 15 |
| 1695 | Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. **2012**, 38, 271-91 | | 86 |
| 1694 | StratomeX: Visual Analysis of Large-Scale Heterogeneous Genomics Data for Cancer Subtype Characterization. **2012**, 31, 1175-1184 | | 59 |
| 1693 | Integration of global spectral karyotyping, CGH arrays, and expression arrays reveals important genes in the pathogenesis of glioblastoma multiforme. **2012**, 19, 2367-79 | | 7 |
| 1692 | The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation. **2012** , 51, 20-9 | | 12 |
| 1691 | A multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib. **2012**, 109, 213-24 | | 16 |
| 1690 | Platelet-derived growth factor receptor (PDGFR) expression in primary spinal cord gliomas. **2012**, 106, 235-42 | | 5 |
| 1689 | MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas. **2012**, 106, 217-24 | | 32 |

| | | |
|---|---|---|
| 1688 | Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma. **2012**, 106, 461-71 | 23 |
| 1687 | Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. **2012**, 107, 1-12 | 42 |
| 1686 | Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. **2012**, 107, 197-205 | 237 |
| 1685 | Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome. **2012**, 138, 35-47 | 30 |
| 1684 | Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting. **2012**, 123, 369-80 | 31 |
| 1683 | EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. **2013**, 32, 2670-81 | 83 |
| 1682 | BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas. **2013**, 11, 100 | 27 |
| 1681 | The Duality of Stem Cells: Double-Edged Sword in tumor Evolution and Treatment. **2013**, 391-433 | 3 |
| 1680 | Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma. **2013**, 28, 355-66 | 15 |
| 1679 | Murine cell line model of proneural glioma for evaluation of anti-tumor therapies. **2013**, 112, 375-82 | 29 |
| 1678 | Cancer heterogeneity--a multifaceted view. **2013**, 14, 686-95 | 160 |
| 1677 | Cilia and Nervous System Development and Function. **2013**, | 4 |
| 1676 | Invasion as target for therapy of glioblastoma multiforme. **2013**, 1836, 236-44 | 63 |
| 1675 | The integrated landscape of driver genomic alterations in glioblastoma. **2013**, 45, 1141-9 | 400 |
| 1674 | Animal Models of Brain Tumors. **2013**, | |
| 1673 | Progress on molecular biomarkers and classification of malignant gliomas. **2013**, 7, 150-6 | 17 |
| 1672 | DNA Repair of Cancer Stem Cells. **2013**, | 4 |
| 1671 | Tumor cohesion and glioblastoma cell dispersal. **2013**, 9, 1121-32 | 7 |

1670 Discovery and analysis of consistent active sub-networks in cancers. **2013**, 14 Suppl 2, S7 11

1669 GSVA: gene set variation analysis for microarray and RNA-seq data. **2013**, 14, 7 2930

1668 Learning contextual gene set interaction networks of cancer with condition specificity. **2013**, 14, 110 1

1667 Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. **2013**, 9, 977-90 19

1666 Computational Intelligence Methods for Bioinformatics and Biostatistics. **2013**,

1665 Impact of genetic targets on cancer therapy. Forward. **2013**, 779, v-vi 1

1664 A long non-coding RNA signature in glioblastoma multiforme predicts survival. **2013**, 58, 123-31 165

1663 The adolescent and young adult with cancer: state of the art--brain tumor. **2013**, 15, 308-16 7

1662 A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. **2013**, 260, 1469-80 21

1661 Upregulation of microRNA-224 confers a poor prognosis in glioma patients. **2013**, 15, 569-74 32

1660 DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome. **2013**, 19, 329-43 8

1659 Primary Tumors of the Nervous System. **2013**, 1-22

1658 LGR5 is a proneural factor and is regulated by OLIG2 in glioma stem-like cells. **2013**, 33, 851-65 15

1657 PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. **2013**, 23, 565-73 71

1656 Molecular neuro-oncology in clinical practice: a new horizon. **2013**, 14, e370-9 149

1655 Existence of glioma stroma mesenchymal stemlike cells in Korean glioma specimens. **2013**, 29, 549-63 22

1654 ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. **2013**, 126, 443-51 239

1653 Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. **2013**, 126, 277-89 36

| | | |
|---|---|---|
| 1652 | Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. **2013**, 16, 1373-82 | 306 |
| 1651 | Raman spectroscopy can discriminate distinct glioma subtypes as defined by RNA expression profiling. **2013**, 44, 1217-1221 | 5 |
| 1650 | Cancer stem cell contribution to glioblastoma invasiveness. **2013**, 4, 18 | 82 |
| 1649 | Molecular Surgical Pathology. **2013**, | 18 |
| 1648 | Integrating multi-platform genomic data using hierarchical Bayesian relevance vector machines. **2013**, 2013, 9 | 4 |
| 1647 | Subtyping glioblastoma by combining miRNA and mRNA expression data using compressed sensing-based approach. **2013**, 2013, 2 | 12 |
| 1646 | Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. **2013**, 3, 2127-41 | 51 |
| 1645 | Multifunctional protein APPL2 contributes to survival of human glioma cells. **2013**, 7, 67-84 | 13 |
| 1644 | An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. **2013**, 3, 1567-79 | 187 |
| 1643 | Age-Dependent Association between Protein Expression of the Embryonic Stem Cell Marker Cripto-1 and Survival of Glioblastoma Patients. **2013**, 6, 732-41 | 18 |
| 1642 | DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases. **2013**, 6, 133-42 | 8 |
| 1641 | Esami citologico, istologico, immunoistochimico e genetico dei tumori del sistema nervoso centrale. **2013**, 13, 1-26 | |
| 1640 | Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. **2013**, 19, 4392-403 | 131 |
| 1639 | The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. **2013**, 73, 3193-9 | 46 |
| 1638 | Tumorigenic potential of miR-18A* in glioma initiating cells requires NOTCH-1 signaling. **2013**, 31, 1252-65 | 31 |
| 1637 | Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. **2013**, 110, E1480-9 | 24 |
| 1636 | Cytogenetic and molecular genetic study on granular cell glioblastoma: a case report. **2013**, 44, 282-8 | 13 |
| 1635 | Inferring tumour purity and stromal and immune cell admixture from expression data. **2013**, 4, 2612 | 2572 |

| | | | |
|---|---|---|---|
| 1634 | Molecular pathways and potential therapeutic targets in glioblastoma multiforme. **2013**, 13, 1307-18 | | 2 |
| 1633 | Computational deconvolution: extracting cell type-specific information from heterogeneous samples. **2013**, 25, 571-8 | | 182 |
| 1632 | Glioblastoma and other malignant gliomas: a clinical review. **2013**, 310, 1842-50 | | 1313 |
| 1631 | Is glioblastoma an epigenetic malignancy?. **2013**, 5, 1120-39 | | 37 |
| 1630 | The somatic genomic landscape of glioblastoma. **2013**, 155, 462-77 | | 2900 |
| 1629 | A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. **2013**, 34, 725-38 | | 68 |
| 1628 | Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. **2013**, 15, 829-39 | | 74 |
| 1627 | Glypican 1 stimulates S phase entry and DNA replication in human glioma cells and normal astrocytes. **2013**, 33, 4408-21 | | 16 |
| 1626 | Network-based stratification of tumor mutations. **2013**, 10, 1108-15 | | 546 |
| 1625 | Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. **2013**, 31, 328-36 | | 80 |
| 1624 | Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions. **2013**, 15, 1469-78 | | 19 |
| 1623 | Update in the treatment of high-grade Gliomas. **2013**, 31, 847-67 | | 8 |
| 1622 | Experimental validation of 5 in-silico predicted glioma biomarkers. **2013**, 15, 1625-34 | | 24 |
| 1621 | IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. **2013**, 15, 1114-26 | | 85 |
| 1620 | Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data. **2013**, 7 Suppl 2, S4 | | 28 |
| 1619 | Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. *Cancer Cell*, **2013**, 24, 660-72 | 24.3 | 478 |
| 1618 | Gene markers in brain tumors: what the epileptologist should know. **2013**, 54 Suppl 9, 25-9 | | 14 |
| 1617 | Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome. **2013**, 319, 2230-43 | | 74 |

| | | | |
|---|---|---|---|
| 1616 | Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. **2013**, 19, 4951-60 | | 134 |
| 1615 | Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers. **2013**, 6, 35 | | 22 |
| 1614 | Bayesian methods for expression-based integration of various types of genomics data. **2013**, 2013, 13 | | 17 |
| 1613 | Pathprinting: An integrative approach to understand the functional basis of disease. **2013**, 5, 68 | | 8 |
| 1612 | Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. **2013**, 13, 402 | | 52 |
| 1611 | Characterization of aberrant pathways across human cancers. **2013**, 7 Suppl 1, S1 | | 8 |
| 1610 | Targeting the PDGF signaling pathway in tumor treatment. **2013**, 11, 97 | | 319 |
| 1609 | ASYMMETRIC CELL DIVISION: IMPLICATIONS FOR GLIOMA DEVELOPMENT AND TREATMENT. **2013**, 4, 484-503 | | 11 |
| 1608 | Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. **2013**, 12, 160 | | 10 |
| 1607 | Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data. **2013**, 14, 818 | | 56 |
| 1606 | A gene signature based method for identifying subtypes and subtype-specific drivers in cancer with an application to medulloblastoma. **2013**, 14 Suppl 18, S1 | | 66 |
| 1605 | Emerging patterns of somatic mutations in cancer. **2013**, 14, 703-18 | | 366 |
| 1604 | Mesenchymal differentiation mediated by NF-Ƀ promotes radiation resistance in glioblastoma. *Cancer Cell*, **2013**, 24, 331-46 | 24.3 | 610 |
| 1603 | Dissecting cancer heterogeneity--an unsupervised classification approach. **2013**, 45, 2574-9 | | 18 |
| 1602 | Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. **2013**, 2, 49-65 | | 95 |
| 1601 | Synergetic regulatory networks mediated by oncogene-driven microRNAs and transcription factors in serous ovarian cancer. **2013**, 9, 3187-98 | | 35 |
| 1600 | CSF-1R inhibition alters macrophage polarization and blocks glioma progression. **2013**, 19, 1264-72 | | 1294 |
| 1599 | Starvation favors glioma stem cells. **2013**, 16, 1359-61 | | 4 |

| | | |
|---|---|---|
| 1598 | Synaptic uSIRPation: the active neuron reigns over presynaptic partners. **2013**, 16, 1361-2 | |
| 1597 | IDH1 mutation analysis in low cellularity specimen: a limitation of diagnostic accuracy and a proposal for the diagnostic procedure. **2013**, 209, 284-90 | 7 |
| 1596 | Quantification of nanosized extracellular membrane vesicles with scanning ion occlusion sensing. **2013**, 8, 1443-58 | 88 |
| 1595 | Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. **2013**, 27, 852-60 | 134 |
| 1594 | Dissecting cancer heterogeneity with a probabilistic genotype-phenotype model. **2013**, 41, 8011-20 | 17 |
| 1593 | The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. **2013**, 5, 1196-212 | 262 |
| 1592 | Inhibition of tumor formation and redirected differentiation of glioblastoma cells in a xenotypic embryonic environment. **2013**, 242, 1078-93 | 11 |
| 1591 | Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms. **2013**, 17, 1218-35 | 42 |
| 1590 | Tumor subtype identification with weighted sparse non-negative matrix factorization for multiple heterogeneous data integration. **2013**, | 0 |
| 1589 | Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. **2013**, 5, 66 | 17 |
| 1588 | HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. **2013**, 15, 1595-603 | 178 |
| 1587 | Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. **2013**, 110, 4009-14 | 1107 |
| 1586 | High-Performance Computational Analysis of Glioblastoma Pathology Images with Database Support Identifies Molecular and Survival Correlates. **2013**, 229-236 | 4 |
| 1585 | DNA Repair Mechanisms in Glioblastoma Cancer Stem Cells. **2013**, 89-103 | |
| 1584 | MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma. **2013**, 22, 904-18 | 60 |
| 1583 | Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. **2013**, 10, 14-26 | 247 |
| 1582 | Receptor tyrosine kinases: principles and functions in glioma invasion. **2013**, 986, 143-70 | 27 |
| 1581 | The definition of primary and secondary glioblastoma. **2013**, 19, 764-72 | 640 |

| | | | |
|---|---|---|---|
| 1580 | Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. **2013**, 11, 10 | | 139 |
| 1579 | Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. **2013**, 17, 30-54 | | 226 |
| 1578 | Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. **2013**, 73, 1559-69 | | 105 |
| 1577 | Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. **2013**, 73, 496-501 | | 99 |
| 1576 | Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. **2013**, 3, 260-73 | | 152 |
| 1575 | Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. **2013**, 61, 25-41 | | 145 |
| 1574 | Developmental signaling pathways in cancer stem cells of solid tumors. **2013**, 1830, 2481-95 | | 133 |
| 1573 | Genetics and pharmacogenomics of diffuse gliomas. **2013**, 137, 78-88 | | 6 |
| 1572 | Glioblastoma: molecular analysis and clinical implications. **2013**, 64, 59-70 | | 75 |
| 1571 | Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. *Cancer Cell*, **2013**, 23, 186-99 | 24.3 | 305 |
| 1570 | Mitotic control of cancer stem cells. **2013**, 3, 141-4 | | 7 |
| 1569 | Cell death and neuronal differentiation of glioblastoma stem-like cells induced by neurogenic transcription factors. **2013**, 61, 225-39 | | 46 |
| 1568 | Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies. **2013**, 7, 79-90 | | 6 |
| 1567 | A mechanism for the upregulation of EGF receptor levels in glioblastomas. **2013**, 3, 2008-20 | | 37 |
| 1566 | Cytoplasmic TRADD confers a worse prognosis in glioblastoma. **2013**, 15, 888-97 | | 12 |
| 1565 | Regulation of HGF expression by EGFR-mediated c-Met activation in glioblastoma cells. **2013**, 15, 73-84 | | 27 |
| 1564 | Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas. **2013**, 11, 199-206 | | 6 |
| 1563 | Demystifying the molecular signature of glioblastoma multiforme arising in its rare morphologic variants--reply. **2013**, 44, 935 | | |

| | | |
|---|---|---|
| 1562 | S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages. **2013**, 19, 3764-75 | 61 |
| 1561 | The p53-microRNA-34a axis regulates cellular entry receptors for tumor-associated human herpes viruses. **2013**, 81, 62-7 | 6 |
| 1560 | Demystifying the molecular signature of glioblastoma multiforme arising in its rare morphological variants. **2013**, 44, 934-5 | 3 |
| 1559 | Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. **2013**, 19, 460-73 | 126 |
| 1558 | The miR-92b functions as a potential oncogene by targeting on Smad3 in glioblastomas. **2013**, 1529, 16-25 | 50 |
| 1557 | Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. **2013**, 145, 554-65 | 288 |
| 1556 | Incorporation of prognostic and predictive factors into glioma clinical trials. **2013**, 15, 56-63 | 30 |
| 1555 | On the pathway to success: defining subtypes of gliomas for better treatment selection and refining the meaning of success. **2013**, 15, 24-6 | 1 |
| 1554 | Tumor prognostic factors and the challenge of developing predictive factors. **2013**, 15, 33-46 | 1 |
| 1553 | Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma. **2013**, 30, 373 | 59 |
| 1552 | Telomere profiling: toward glioblastoma personalized medicine. **2013**, 47, 64-76 | 26 |
| 1551 | Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. **2013**, 45, 253-61 | 231 |
| 1550 | Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. **2013**, 331, 131-8 | 154 |
| 1549 | Proteoglycans and their roles in brain cancer. **2013**, 280, 2399-417 | 124 |
| 1548 | Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. **2013**, 23, 210-6 | 64 |
| 1547 | Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. **2013**, 21, 561-9 | 76 |
| 1546 | Surgical resection of malignant gliomas-role in optimizing patient outcome. **2013**, 9, 141-51 | 106 |
| 1545 | Impact of genetic targets on primary brain tumor therapy: what's ready for prime time?. **2013**, 779, 267-89 | 11 |

| | | |
|---|---|---|
| 1544 | Classification of Gliomas. **2013**, 3-20 | |
| 1543 | A distinct reactive oxygen species profile confers chemoresistance in glioma-propagating cells and associates with patient survival outcome. **2013**, 19, 2261-79 | 19 |
| 1542 | Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. **2013**, 73, 2418-27 | 211 |
| 1541 | The good, the bad and the ugly: epigenetic mechanisms in glioblastoma. **2013**, 34, 849-62 | 40 |
| 1540 | Targeting of TGF signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. **2013**, 19, 177-90 | 39 |
| 1539 | The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment. **2013**, 1830, 2496-508 | 117 |
| 1538 | Epigenetics and Brain Cancer. **2013**, 21-40 | |
| 1537 | Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme. **2013**, 32, 1539-48 | 44 |
| 1536 | Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. **2013**, 153, 139-52 | 572 |
| 1535 | The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. **2013**, 32, 699-712 | 191 |
| 1534 | Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours. **2013**, 13, 1595-607 | 22 |
| 1533 | A colorectal cancer classification system that associates cellular phenotype and responses to therapy. **2013**, 19, 619-25 | 670 |
| 1532 | IDH1 and IDH2 mutations in gliomas. **2013**, 13, 345 | 347 |
| 1531 | Characteristics of glioma stem cells. **2013**, 30, 209-14 | 38 |
| 1530 | Human Low-Grade Glioma Cultures. **2013**, 137-163 | 3 |
| 1529 | Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. **2013**, 19, 614-8 | 550 |
| 1528 | An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. **2013**, 340, 626-30 | 855 |
| 1527 | Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival. **2013**, 108, 2142-52 | 16 |

| | | | |
|---|---|---|---|
| 1526 | Molecular Pathology of the Central Nervous System. **2013**, 357-405 | | 3 |
| 1525 | Genome-wide associations of signaling pathways in glioblastoma multiforme. **2013**, 6, 11 | | 2 |
| 1524 | Growth factor receptors define cancer hierarchies. *Cancer Cell*, **2013**, 23, 135-7 | 24.3 | 6 |
| 1523 | Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. **2013**, 267, 212-20 | | 109 |
| 1522 | Colorectal Cancer and Its Molecular Subsystems: Construction, Interpretation, and Validation. **2013**, 107-132 | | 1 |
| 1521 | The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. **2013**, 153, 1064-79 | | 276 |
| 1520 | In vivo RNAi screen for BMI1 targets identifies TGF-/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis. *Cancer Cell*, **2013**, 23, 660-76 | 24.3 | 136 |
| 1519 | Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. *Cancer Cell*, **2013**, 23, 839-52 | 24.3 | 506 |
| 1518 | Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. **2013**, 126, 21-37 | | 13 |
| 1517 | Characterization of microglia/macrophages in gliomas developed in S-100B-v-erbB transgenic rats. **2013**, 33, 505-14 | | 7 |
| 1516 | EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. **2013**, 17, 1000-1008 | | 105 |
| 1515 | What underlies the diversity of brain tumors?. **2013**, 32, 5-24 | | 15 |
| 1514 | Molecular subtypes of glioma identified by genome-wide methylation profiling. **2013**, 52, 665-74 | | 21 |
| 1513 | BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. **2013**, 19, 901-908 | | 279 |
| 1512 | Exploitation of adaptive evolution in glioma treatment. **2013**, 2, 171-9 | | 4 |
| 1511 | Epidermal growth factor receptor as a therapeutic target in glioblastoma. **2013**, 15, 420-34 | | 31 |
| 1510 | Decoding the cancer stem cell hypothesis in glioblastoma. **2013**, 2, 319-30 | | 20 |
| 1509 | Glioblastoma cancer stem cells--from concept to clinical application. **2013**, 338, 32-40 | | 58 |

| | | | |
|---|---|---|---|
| 1508 | EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. *Cancer Cell*, **2013**, 23, 238-48 | 24.3 | 157 |
| 1507 | Whole-genome mRNA expression profiling identifies functional and prognostic signatures in patients with mesenchymal glioblastoma multiforme. **2013**, 19, 714-20 | | 17 |
| 1506 | The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. **2013**, 498, 246-50 | | 214 |
| 1505 | Update on bevacizumab and other angiogenesis inhibitors for brain cancer. **2013**, 18, 137-53 | | 23 |
| 1504 | Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation. **2013**, 328, 297-306 | | 18 |
| 1503 | Isobutylhydroxyamides from the pericarp of Nepalese Zanthoxylum armatum inhibit NF1-defective tumor cell line growth. **2013**, 76, 59-63 | | 38 |
| 1502 | Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. **2013**, 15, 189-97 | | 64 |
| 1501 | Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). **2013**, 1, 29 | | 3 |
| 1500 | Neuro-oncology: Novel molecular targets in treatment of glioblastoma. **2013**, 9, 612-3 | | 3 |
| 1499 | Multiclass Distance-Weighted Discrimination. **2013**, 22, 953-969 | | 11 |
| 1498 | Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. **2013**, 19, 4717-27 | | 54 |
| 1497 | Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. **2013**, 14, 178-92 | | 4783 |
| 1496 | Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis. **2013**, 15, 1317-29 | | 39 |
| 1495 | Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma. **2013**, 19, 6484-94 | | 98 |
| 1494 | Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. **2013**, 32, 3091-100 | | 277 |
| 1493 | Invariant delineation of nuclear architecture in glioblastoma multiforme for clinical and molecular association. **2013**, 32, 670-82 | | 70 |
| 1492 | Personalized Medicine for Glioblastoma: Current Challenges and Future Opportunities. **2013**, 13, 358-367 | | |
| 1491 | An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. **2013**, 12, 597-615 | | 49 |

1490 Stereotactic radiosurgery and atypical meningiomas. **2013**, 119, 472-4

1489 Non-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetime. **2013**, 50, 1-10 35

1488 ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. **2013**, 19, 3189-200 144

1487 Upregulation of DLX2 Confers a Poor Prognosis in Glioblastoma Patients by Inducing a Proliferative Phenotype. **2013**, 13, 438-445 1

1486 Relationship between cognitive function and prognosis in glioblastoma. **2013**, 2, 195-201 14

1485 Effect of disease and recovery on functional anatomy in brain tumor patients: insights from functional MRI and diffusion tensor imaging. **2013**, 5, 333-346 13

1484 iBAG: integrative Bayesian analysis of high-dimensional multiplatform genomics data. **2013**, 29, 149-59 91

1483 The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. **2013**, 26, 1425-32 81

1482 Brain neoplasms and coagulation. **2013**, 39, 881-95 27

1481 Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). **2013**, 15, 112-21 25

1480 TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells. **2013**, 15, 1353-65 43

1479 Republished: Non-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetime. **2013**, 89, 417-26 6

1478 Modeling Tumor-Associated Edema in Gliomas during Anti-Angiogenic Therapy and Its Impact on Imageable Tumor. **2013**, 3, 66 48

1477 Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression. **2013**, 3, 241 78

1476 Biomolecular events in cancer revealed by attractor metagenes. **2013**, 9, e1002920 78

1475 [Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification]. **2013**, 100, 715-26 10

1474 PLRS: a flexible tool for the joint analysis of DNA copy number and mRNA expression data. **2013**, 29, 1081-2 3

1473 Biological and clinical implications of cancer stem cells in primary brain tumors. **2013**, 3, 6 10

| | | |
|---|---|---|
| 1472 | Functional role of CLIC1 ion channel in glioblastoma-derived stem/progenitor cells. **2013**, 105, 1644-55 | 60 |
| 1471 | Modeling risk stratification in human cancer. **2013**, 29, 1149-57 | 39 |
| 1470 | Network signatures of survival in glioblastoma multiforme. **2013**, 9, e1003237 | 51 |
| 1469 | Ionizing radiation in glioblastoma initiating cells. **2013**, 3, 74 | 19 |
| 1468 | Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling. **2013**, 9, e1002887 | 42 |
| 1467 | Simultaneous identification of multiple driver pathways in cancer. **2013**, 9, e1003054 | 163 |
| 1466 | Brain Tumors and Gliomas. **2013**, 749-764 | |
| 1465 | Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules. **2013**, 15, 1684-95 | 39 |
| 1464 | Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma. **2013**, 15, 1048-57 | 31 |
| 1463 | CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia. **2013**, 15, 865-79 | 87 |
| 1462 | Imaging descriptors improve the predictive power of survival models for glioblastoma patients. **2013**, 15, 1389-94 | 76 |
| 1461 | An integrative characterization of recurrent molecular aberrations in glioblastoma genomes. **2013**, 41, 8803-21 | 33 |
| 1460 | A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma. **2013**, 2, e26852 | 11 |
| 1459 | The molecular landscape of diffuse glioma and prospects for biomarker development. **2013**, 7, 573-87 | 7 |
| 1458 | Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma. **2013**, 15, 279-89 | 38 |
| 1457 | Predictive biomarkers in adult gliomas: the present and the future. **2013**, 25, 689-94 | 30 |
| 1456 | Malignant astrocytoma in elderly patients: where do we stand?. **2013**, 26, 693-700 | 7 |
| 1455 | Molecular biomarkers in pediatric glial tumors: a needed wind of change. **2013**, 25, 665-73 | 11 |

| | | |
|---|---|---|
| 1454 | Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures. **2013**, 14, 625-37 | 31 |
| 1453 | β8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion. **2013**, 24, 474-82 | 53 |
| 1452 | Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. **2013**, 15, 626-34 | 78 |
| 1451 | High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance. **2013**, 15, 1264-75 | 29 |
| 1450 | A NOTCH3 transcriptional module induces cell motility in neuroblastoma. **2013**, 19, 3485-94 | 31 |
| 1449 | Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. **2013**, 73, 6219-29 | 148 |
| 1448 | Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. **2013**, 27, 654-69 | 103 |
| 1447 | Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. **2013**, 3, 198-211 | 63 |
| 1446 | Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. **2013**, 15, 670-81 | 74 |
| 1445 | TSGene: a web resource for tumor suppressor genes. **2013**, 41, D970-6 | 242 |
| 1444 | Evolutionary etiology of high-grade astrocytomas. **2013**, 110, 17933-8 | 29 |
| 1443 | A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. **2013**, 19, 900-8 | 85 |
| 1442 | Identifying dysfunctional miRNA-mRNA regulatory modules by inverse activation, cofunction, and high interconnection of target genes: a case study of glioblastoma. **2013**, 15, 818-28 | 22 |
| 1441 | TIARA genome database: update 2013. **2013**, 2013, bat003 | 5 |
| 1440 | Activation of the NF-Β pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells. **2013**, 11, 494-505 | 40 |
| 1439 | A tumorigenic MLL-homeobox network in human glioblastoma stem cells. **2013**, 73, 417-27 | 54 |
| 1438 | Oligodendrocyte/type-2 astrocyte progenitor cells and glial-restricted precursor cells generate different tumor phenotypes in response to the identical oncogenes. **2013**, 33, 16805-17 | 8 |
| 1437 | Molecular prognostic factors in glioblastoma: state of the art and future challenges. **2013**, 2, 495-510 | 9 |

| | | |
|---|---|---|
| 1436 | RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation. **2013**, 73, 5140-50 | 44 |
| 1435 | From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. **2013**, 34, E2 | 37 |
| 1434 | MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. **2013**, 267, 560-9 | 296 |
| 1433 | MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. **2013**, 8, e78115 | 206 |
| 1432 | Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. **2013**, 19, 5146-57 | 120 |
| 1431 | Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. **2013**, 110, 11982-7 | 398 |
| 1430 | Novel approaches to glioma drug design and drug screening. **2013**, 8, 1135-51 | 35 |
| 1429 | Prediction of response to chemotherapy in anaplastic glioma: how many markers does it take?. **2013**, 31, 297-8 | 5 |
| 1428 | Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. **2013**, 19, 4058-66 | 58 |
| 1427 | Glioblastoma resistance to anti-VEGF therapy: has the challenge been MET?. **2013**, 19, 1631-3 | 30 |
| 1426 | TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance. **2013**, 11, 865-74 | 37 |
| 1425 | Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. **2013**, 15, 972-8 | 31 |
| 1424 | The evolving landscape of glioblastoma stem cells. **2013**, 26, 701-7 | 61 |
| 1423 | Pathway-based personalized analysis of cancer. **2013**, 110, 6388-93 | 226 |
| 1422 | N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) promote growth and inhibit differentiation of glioma stem-like cells. **2013**, 288, 26188-26200 | 32 |
| 1421 | Clinical implications of microRNAs in human glioblastoma. **2013**, 3, 19 | 41 |
| 1420 | Molecular Characteristics in MRI-Classified Group 1 Glioblastoma Multiforme. **2013**, 3, 182 | 16 |
| 1419 | Inhibition of BET bromodomain targets genetically diverse glioblastoma. **2013**, 19, 1748-59 | 223 |

| | | |
|---|---|---|
| 1418 | MicroRNA in Human Glioma. **2013**, 5, 1306-31 | 38 |
| 1417 | Potential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastoma. **2013**, 34, 2271-7 | 34 |
| 1416 | Convection-enhanced delivery for targeted delivery of antiglioma agents: the translational experience. **2013**, 2013, 107573 | 21 |
| 1415 | Systematic use of computational methods allows stratification of treatment responders in glioblastoma multiforme. **2013**, 1, 130-136 | 1 |
| 1414 | Coagulation-related gene expression profile in glioblastoma is defined by molecular disease subtype. **2013**, 11, 1197-200 | 37 |
| 1413 | Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. **2013**, 15, 423-32 | 47 |
| 1412 | Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas. **2013**, 2, 457-67 | 23 |
| 1411 | Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux. **2013**, 2, 271-88 | 16 |
| 1410 | Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. **2013**, 110, 11751-6 | 181 |
| 1409 | Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. **2013**, 5, 1051-66 | 178 |
| 1408 | Gene expression signature-based prognostic risk score in patients with glioblastoma. **2013**, 104, 1205-10 | 42 |
| 1407 | New strategies in prostate cancer: translating genomics into the clinic. **2013**, 19, 517-23 | 47 |
| 1406 | Cell Type Specific Analysis of Human Brain Transcriptome Data to Predict Alterations in Cellular Composition. **2013**, 1, 151-160 | 11 |
| 1405 | Comparative expression analysis reveals lineage relationships between human and murine gliomas and a dominance of glial signatures during tumor propagation in vitro. **2013**, 73, 5834-44 | 20 |
| 1404 | Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation. **2013**, 20, 318-27 | 20 |
| 1403 | Deregulated expression of TANK in glioblastomas triggers pro-tumorigenic ERK1/2 and AKT signaling pathways. **2013**, 2, e79 | 7 |
| 1402 | BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. **2013**, 2, e109 | 230 |
| 1401 | Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. **2013**, 32, 872-82 | 56 |

| | | |
|---|---|---|
| 1400 | Three different brain tumours evolving from a common origin. **2013**, 2, e41 | 7 |
| 1399 | Epigenetic pathways and glioblastoma treatment. **2013**, 8, 785-95 | 44 |
| 1398 | Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells. **2013**, 73, 3062-74 | 19 |
| 1397 | Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. **2013**, 15, 242-50 | 71 |
| 1396 | Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. **2013**, 110, 8644-9 | 410 |
| 1395 | Tumor Dormancy, Quiescence, and Senescence, Volume 1. **2013**, | 3 |
| 1394 | Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. **2013**, 1, 112-22 | 146 |
| 1393 | A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. **2013**, 27, 1462-72 | 50 |
| 1392 | Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. **2013**, 3, 3544 | 42 |
| 1391 | Portraying the expression landscapes of cancer subtypes. **2013**, 1, 99-121 | 23 |
| 1390 | Expansive growth of two glioblastoma stem-like cell lines is mediated by bFGF and not by EGF. **2013**, 47, 330-7 | 24 |
| 1389 | Challenges in clinical trial design for recurrent glioblastoma. **2013**, 3, 835-848 | 1 |
| 1388 | Origins of Cancer Symposium Report. **2013**, 4, 457-459 | 2 |
| 1387 | Evolution of brain tumor-initiating cell research: in pursuit of a moving target. **2013**, 8, 1-3 | 1 |
| 1386 | PDGFRA gain in low-grade diffuse gliomas. **2013**, 72, 61-6 | 8 |
| 1385 | Surgical management of adult intrinsic brainstem tumors. **2013**, 60 Suppl 1, 131-8 | 10 |
| 1384 | Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma. **2013**, 60 Suppl 1, 57-63 | 12 |
| 1383 | Listening to the brain: new techniques in intraoperative brain mapping. **2013**, 60 Suppl 1, 64-9 | 5 |

| | | |
|---|---|---|
| 1382 | ELTD1, a potential new biomarker for gliomas. **2013**, 72, 77-90; discussion 91 | 62 |
| 1381 | Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection. **2013**, 35, e123-6 | 8 |
| 1380 | Imaging genomic mapping in glioblastoma. **2013**, 60 Suppl 1, 126-30 | 24 |
| 1379 | NF-B-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma. **2013**, 8, e78728 | 85 |
| 1378 | JOINT AND INDIVIDUAL VARIATION EXPLAINED (JIVE) FOR INTEGRATED ANALYSIS OF MULTIPLE DATA TYPES. **2013**, 7, 523-542 | 239 |
| 1377 | RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma. **2013**, 30, 2350-6 | 18 |
| 1376 | Anti-cancer Therapies in High Grade Gliomas. **2013**, 10, 246-260 | 24 |
| 1375 | How does genotype influence disease phenotype in inflammatory bowel disease?. **2013**, 19, 2021-30 | 12 |
| 1374 | Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights. **2013**, | |
| 1373 | IDH1-associated primary glioblastoma in young adults displays differential patterns of tumour and vascular morphology. **2013**, 8, e56328 | 23 |
| 1372 | Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. **2013**, 8, e62982 | 40 |
| 1371 | Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients. **2013**, 8, e65444 | 22 |
| 1370 | Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy. **2013**, 8, e70804 | 21 |
| 1369 | Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma. **2013**, 8, e71777 | 16 |
| 1368 | Transcriptional analysis of aggressiveness and heterogeneity across grades of astrocytomas. **2013**, 8, e76694 | 7 |
| 1367 | A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1. **2013**, 8, e77053 | 44 |
| 1366 | F11R is a novel monocyte prognostic biomarker for malignant glioma. **2013**, 8, e77571 | 32 |
| 1365 | Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker. **2013**, 8, e80056 | 17 |

| | | |
|---|---|---|
| 1364 | Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. **2013**, 8, e80397 | 45 |
| 1363 | The NF-Β RelB protein is an oncogenic driver of mesenchymal glioma. **2013**, 8, e57489 | 45 |
| 1362 | Machine-based morphologic analysis of glioblastoma using whole-slide pathology images uncovers clinically relevant molecular correlates. **2013**, 8, e81049 | 71 |
| 1361 | Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma. **2013**, 8, e81803 | 18 |
| 1360 | Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities. **2013**, 6, 931-42 | 15 |
| 1359 | Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy. **2013**, 3, 28 | 9 |
| 1358 | Alterations of 5-hydroxymethylcytosine in human cancers. **2013**, 5, 786-814 | 35 |
| 1357 | Glioblastoma-initiating cells: relationship with neural stem cells and the micro-environment. **2013**, 5, 1049-71 | 56 |
| 1356 | Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. **2013**, 6, 1363-72 | 100 |
| 1355 | Emerging biomarkers in glioblastoma. **2013**, 5, 1103-19 | 69 |
| 1354 | Platelet-derived growth factor. 135-143 | |
| 1353 | Bayesian Graphical Models for Integrating Multiplatform Genomics Data. 292-311 | |
| 1352 | Gliomas Biology: Angiogenesis and Invasion. **2013**, | 1 |
| 1351 | Gliomas. **2013**, 334-336 | |
| 1350 | Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. **2014**, 6, 149-70 | 112 |
| 1349 | Identification of molecular pathways facilitating glioma cell invasion in situ. **2014**, 9, e111783 | 38 |
| 1348 | Glioma cell proliferation controlled by ERK activity-dependent surface expression of PDGFRA. **2014**, 9, e87281 | 25 |
| 1347 | Rab27a was identified as a prognostic biomaker by mRNA profiling, correlated with malignant progression and subtype preference in gliomas. **2014**, 9, e89782 | 18 |

| | | |
|---|---|---|
| 1346 | Micro-environment causes reversible changes in DNA methylation and mRNA expression profiles in patient-derived glioma stem cells. **2014**, 9, e94045 | 30 |
| 1345 | AKT pathway genes define 5 prognostic subgroups in glioblastoma. **2014**, 9, e100827 | 9 |
| 1344 | Visualizing molecular profiles of glioblastoma with GBM-BioDP. **2014**, 9, e101239 | 37 |
| 1343 | Aberrant expression of interleukin-1 and inflammasome activation in human malignant gliomas. **2014**, 9, e103432 | 65 |
| 1342 | Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas. **2014**, 9, e106694 | 23 |
| 1341 | Surprisal analysis of Glioblastoma Multiform (GBM) microRNA dynamics unveils tumor specific phenotype. **2014**, 9, e108171 | 7 |
| 1340 | Response-predictive gene expression profiling of glioma progenitor cells in vitro. **2014**, 9, e108632 | 11 |
| 1339 | Molecular, histopathological, and genomic variants of glioblastoma. **2014**, 19, 1065-87 | 14 |
| 1338 | A Balanced Look at the Implications of Genomic (and Other "Omics") Testing for Disease Diagnosis and Clinical Care. **2014**, 5, 748-66 | 6 |
| 1337 | Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment. **2014**, 4, 47 | 30 |
| 1336 | The genetic landscape of anaplastic astrocytoma. **2014**, 5, 1452-7 | 59 |
| 1335 | The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells. **2014**, 7, 2013-9 | 13 |
| 1334 | The failure in the stabilization of glioblastoma-derived cell lines: spontaneous in vitro senescence as the main culprit. **2014**, 9, e87136 | 18 |
| 1333 | The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. **2014**, 6, 373-87 | 27 |
| 1332 | Complex role of HIF in cancer: the known, the unknown, and the unexpected. **2014**, 2, 59-70 | 9 |
| 1331 | Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response. **2014**, 3, 55-66 | 4 |
| 1330 | Nanoparticles containing allotropes of carbon have genotoxic effects on glioblastoma multiforme cells. **2014**, 9, 2409-17 | 36 |
| 1329 | Insights into the next generation of cancer stem cell research. **2014**, 19, 1015-27 | 6 |

| | | |
|---|---|---|
| 1328 | Brain stem cells as the cell of origin in glioma. **2014**, 6, 43-52 | 49 |
| 1327 | Alterations in TP53 gene Implications in Tumorigenesis Process and Prognosis in Central Nervous System Cancer. **2014**, | 1 |
| 1326 | . **2014**, | 2 |
| 1325 | . **2014**, | 4 |
| 1324 | A Comprehensive Approach to Patient-individual Glioblastoma Multiforme Model Establishment. **2014**, 06, | 1 |
| 1323 | Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas. **2014**, 16, 1220-8 | 8 |
| 1322 | A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. **2014**, 111, 3538-43 | 70 |
| 1321 | Para- and Autocrine Mediators in the Glioma Microenvironment. **2014**, 153-185 | |
| 1320 | Oncolytic adenoviruses: A thorny path to glioma cure. **2014**, 1, 214-226 | 10 |
| 1319 | Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status. **2014**, 7, 712-9 | 8 |
| 1318 | Ribosome profiling reveals a cell-type-specific translational landscape in brain tumors. **2014**, 34, 10924-36 | 79 |
| 1317 | A novel approach to the discovery of survival biomarkers in glioblastoma using a joint analysis of DNA methylation and gene expression. **2014**, 9, 873-83 | 22 |
| 1316 | Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature. **2014**, 15, 862-77 | 7 |
| 1315 | Glioblastoma Stem Cells Drive Tumor Recurrence and Patient Relapse. **2014**, 193-208 | 1 |
| 1314 | Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. **2014** , 14, 439-52 | 63 |
| 1313 | In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. **2014**, 71, 4007-26 | 35 |
| 1312 | A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. **2014**, 15, 473 | 52 |
| 1311 | Are patients open to elective re-sampling of their glioblastoma? A new way of assessing treatment innovations. **2014**, 156, 1855-62; discussion 1862-3 | 1 |

| | | |
|---|---|---|
| 1310 | Cancer stem cells as a target population for drug discovery. **2014**, 6, 1567-85 | 7 |
| 1309 | 1p/19q-driven prognostic molecular classification for high-grade oligodendroglial tumors. **2014**, 120, 607-14 | 6 |
| 1308 | Anatomical specificity of O6-methylguanine DNA methyltransferase protein expression in glioblastomas. **2014**, 120, 331-7 | 18 |
| 1307 | In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. **2014**, 111, 5248-53 | 113 |
| 1306 | Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients. **2014**, 14, 827 | 5 |
| 1305 | Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor. **2014**, 14, 115 | 31 |
| 1304 | Current role of anti-angiogenic strategies for glioblastoma. **2014**, 15, 551-66 | 22 |
| 1303 | Robust meta-analysis shows that glioma transcriptional subtyping complements traditional approaches. **2014**, 37, 317-29 | 3 |
| 1302 | E2F1 coregulates cell cycle genes and chromatin components during the transition of oligodendrocyte progenitors from proliferation to differentiation. **2014**, 34, 1481-93 | 47 |
| 1301 | Molecular characteristics of pediatric high-grade gliomas. **2014**, 3, 433-43 | 24 |
| 1300 | Heparan sulfate in the regulation of neural differentiation and glioma development. **2014**, 281, 4993-5008 | 42 |
| 1299 | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. **2014**, 33, 5626-36 | 24 |
| 1298 | Eph receptors as therapeutic targets in glioblastoma. **2014**, 111, 1255-61 | 50 |
| 1297 | TGF-□s an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. **2014**, 5, e1443 | 105 |
| 1296 | Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastoma. **2014**, 16, 960-70 | 29 |
| 1295 | Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. **2014**, 5, e1223 | 44 |
| 1294 | Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential. **2014**, 15, 216-24 | 21 |
| 1293 | A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. **2015**, 8, 45-56 | 23 |

| | | |
|---|---|---|
| 1292 | Structural pursuit over multiple undirected graphs. **2014**, 109, 1683-1696 | 40 |
| 1291 | Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. **2014**, 16 Suppl 8, viii7-13 | 71 |
| 1290 | Stem cell niches in glioblastoma: a neuropathological view. **2014**, 2014, 725921 | 30 |
| 1289 | Modeling mayhem: predicting invasion and proliferation kinetics in IDH1 mutant glioblastoma with mathematical models. **2014**, 16, 763-4 | 1 |
| 1288 | NCoR controls glioblastoma tumor cell characteristics. **2014**, 16, 241-9 | 12 |
| 1287 | Glioblastoma multiforme classified as mesenchymal subtype. **2014**, 56, 215-9 | 1 |
| 1286 | Brain Tumor Genomics. **2014**, 321-338 | |
| 1285 | Editorial commentary on "Analysis of IDH mutation, 1p19q deletion, and PTEN loss delineates prognosis in clinical low-grade gliomas". **2014**, 16, 891-2 | |
| 1284 | Emerging insights into barriers to effective brain tumor therapeutics. **2014**, 4, 126 | 108 |
| 1283 | Association of the miR-149 Rs2292832 polymorphism with papillary thyroid cancer risk and clinicopathologic characteristics in a Chinese population. **2014**, 15, 20968-81 | 29 |
| 1282 | Genetic basis of thrombosis in cancer. **2014**, 40, 284-95 | 15 |
| 1281 | Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma. **2014**, 121, 1434-45 | 21 |
| 1280 | Glioblastoma multiforme: State of the art and future therapeutics. **2014**, 5, 64 | 146 |
| 1279 | Case comparison and literature review of glioblastoma: A tale of two tumors. **2014**, 5, 121 | 2 |
| 1278 | Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice. **2014**, e51763 | 9 |
| 1277 | Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment. **2014**, 4, 142 | 42 |
| 1276 | BMPs as therapeutic targets and biomarkers in astrocytic glioma. **2014**, 2014, 549742 | 23 |
| 1275 | An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas. **2014**, 2014, 282815 | 6 |

| | | |
|---|---|---|
| 1274 | ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. **2014**, 4, 1198-213 | 43 |
| 1273 | The role of NF-Β in the pathogenesis of glioma. **2014**, 1, e963478 | 47 |
| 1272 | Domino: Extracting, Comparing, and Manipulating Subsets Across Multiple Tabular Datasets. **2014**, 20, 2023-32 | 34 |
| 1271 | Genomic landscape of glioblastoma and the potential clinical utility. **2014**, 3, 169-72 | |
| 1270 | Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma. **2014**, 16, 1210-9 | 21 |
| 1269 | Resolution of cystic enhancement to add-on tumor treating electric fields for recurrent glioblastoma after incomplete response to bevacizumab. **2014**, 6, 109-15 | 4 |
| 1268 | Highlights from the Literature. **2014**, 16, 1437-1440 | 78 |
| 1267 | EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. **2014**, 4, 956-71 | 199 |
| 1266 | Targeting endocannabinoid signaling in tumor-associated macrophages as treatment for glioblastoma multiforme. **2014**, 3, 39-51 | 2 |
| 1265 | Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. **2014**, 5, 5811 | 53 |
| 1264 | Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. **2014**, 75, 205-9 | 52 |
| 1263 | Molecular and cellular heterogeneity: the hallmark of glioblastoma. **2014**, 37, E11 | 110 |
| 1262 | The mathematician versus the malignancy. **2014**, 20, 460-3 | 7 |
| 1261 | Resistance to antiangiogenic therapies. **2014**, 10, 1417-25 | 9 |
| 1260 | Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. **2014**, 16, 1630-8 | 59 |
| 1259 | Characterization of metabolites in infiltrating gliomas using ex vivo □H high-resolution magic angle spinning spectroscopy. **2014**, 27, 578-93 | 42 |
| 1258 | C-glycoside mimetics inhibit glioma stem cell proliferation, migration, and invasion. **2014**, 57, 8293-306 | 26 |
| 1257 | Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. **2014**, 37, E13 | 36 |

| | | |
|---|---|---|
| 1256 | Versican isoform V1 regulates proliferation and migration in high-grade gliomas. **2014**, 120, 73-83 | 21 |
| 1255 | Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. **2014**, 128, 615-27 | 29 |
| 1254 | Advances in diagnostic and treatment modalities for intracranial tumors. **2014**, 28, 1165-85 | 53 |
| 1253 | Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma. **2014**, 3, 592-602 | 46 |
| 1252 | Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. **2014**, 64, 365-79 | 47 |
| 1251 | Molecularly targeted therapies for recurrent glioblastoma: current and future targets. **2014**, 37, E15 | 52 |
| 1250 | In vivo modeling of malignant glioma: the road to effective therapy. **2014**, 121, 261-330 | 19 |
| 1249 | Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk. **2014**, 12, 1838-49 | 23 |
| 1248 | Determination of molecular glioblastoma subclasses on the basis of analysis of gene expression. **2014**, 48, 383-391 | 2 |
| 1247 | PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas. **2014**, 20, 827-36 | 22 |
| 1246 | Statistical feature selection for enhanced detection of brain tumor. **2014**, | 4 |
| 1245 | Glioblastoma stem-like cells: approaches for isolation and characterization. **2014**, 1, 1 | 11 |
| 1244 | Primate-specific miR-663 functions as a tumor suppressor by targeting PIK3CD and predicts the prognosis of human glioblastoma. **2014**, 20, 1803-13 | 75 |
| 1243 | Beating the odds: extreme long-term survival with glioblastoma. **2014**, 16, 1159-60 | 38 |
| 1242 | Assessment and treatment relevance in elderly glioblastoma patients. **2014**, 16, 1459-68 | 26 |
| 1241 | Identifying radiographic specificity for phosphatase and tensin homolog and epidermal growth factor receptor changes: a quantitative analysis of glioblastomas. **2014**, 56, 1113-20 | 6 |
| 1240 | Computer-extracted MR imaging features are associated with survival in glioblastoma patients. **2014**, 120, 483-8 | 30 |
| 1239 | Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. **2014**, 2, 371-9 | 64 |

1238 The Cancer Genome Atlas expression profiles of low-grade gliomas. **2014**, 36, E23 10

1237 Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. **2014**, 14, 17 77

1236 Mutational profiling of kinases in glioblastoma. **2014**, 14, 718 39

1235 PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment. **2014**, 13, 247 30

1234 Response to imatinib as a function of target kinase expression in recurrent glioblastoma. **2014**, 3, 111 16

1233 Expression and prognostic significance of TCTN1 in human glioblastoma. **2014**, 12, 288 7

1232 Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. **2014**, 16, 1244-54 35

1231 DriverDB: an exome sequencing database for cancer driver gene identification. **2014**, 42, D1048-54 60

1230 Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier. **2014**, 74, 1011-21 39

1229 Molecular genetics of gliomas. **2014**, 20, 66-72 70

1228 Targeting a heterogeneous tumor: the promise of the interleukin-13 receptor ?2. **2014**, 75, N18-9 2

1227 A pilot study on EGFR-targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomas. **2014**, 39, e20-6 15

1226 Approaches to uncovering cancer diagnostic and prognostic molecular signatures. **2014**, 1, e957981 1

1225 Hematogenous dissemination of glioblastoma multiforme. **2014**, 6, 247ra101 193

1224 Platelet-derived growth factor in glioblastoma-driver or biomarker?. **2014**, 119, 298-305 26

1223 Let there be light and muscle contraction: optogenetic restoration of muscle function. **2014**, 75, N19-20

1222 Molecular Correlates of Morphometric Subtypes in Glioblastoma Multiforme. **2014**, 423-454

1221 IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. **2014**, 16, 81-91 290

| | | |
|---|---|---|
| 1220 | Isoform-level gene signature improves prognostic stratification and accurately classifies glioblastoma subtypes. **2014**, 42, e64 | 46 |
| 1219 | An integrated mRNA and microRNA expression signature for glioblastoma multiforme prognosis. **2014**, 9, e98419 | 23 |
| 1218 | PDGF receptors in tumor biology: prognostic and predictive potential. **2014**, 10, 1695-708 | 68 |
| 1217 | Advances in Oncolytic Virotherapy for Brain Tumors. **2014**, 137-151 | 1 |
| 1216 | A proposed quantitative index for assessing the potential contribution of reprogramming to cancer stem cell kinetics. **2014**, 2014, 249309 | 12 |
| 1215 | Immune Responses to Tumours in the CNS. **2014**, 363-384 | 2 |
| 1214 | IL-1 microenvironment promotes proliferation, migration, and invasion of human glioma cells. **2014**, 38, 1415-22 | 41 |
| 1213 | Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma. **2014**, 4, 90 | 15 |
| 1212 | Glioblastoma extracellular vesicles: reservoirs of potential biomarkers. **2014**, 7, 65-77 | 43 |
| 1211 | Spatial and temporal cancer evolution: causes and consequences of tumour diversity. **2014**, 14 Suppl 6, s33-7 | 14 |
| 1210 | Emerging therapies for glioblastoma. **2014**, 71, 1437-44 | 123 |
| 1209 | stepwiseCM: An R Package for Stepwise Classification of Cancer Samples Using Multiple Heterogeneous Data Sets. **2014**, 13, 1-11 | |
| 1208 | Brain neoplasms and coagulation-lessons from heterogeneity. **2014**, 5, e0030 | 8 |
| 1207 | Glioblastoma multiforme: a look inside its heterogeneous nature. **2014**, 6, 226-39 | 136 |
| 1206 | Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. **2014**, 33, 9 | 42 |
| 1205 | TopFed: TCGA tailored federated query processing and linking to LOD. **2014**, 5, 47 | 13 |
| 1204 | The regulatory network of proneural glioma in tumor progression. **2014**, 75, N15-6 | |
| 1203 | Contribution of tumor heterogeneity in a new animal model of CNS tumors. **2014**, 12, 742-53 | 19 |

| | | | |
|---|---|---|---|
| 1202 | Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. **2014**, 16, 662-70 | | 55 |
| 1201 | Micro-masters of glioblastoma biology and therapy: increasingly recognized roles for microRNAs. **2014**, 16, 622-7 | | 27 |
| 1200 | Immunohistochemical demonstration of isocitrate dehydrogenase 1 (IDH1) mutation in a small subset of prostatic carcinomas. **2014**, 22, 284-7 | | 11 |
| 1199 | Signals that regulate the oncogenic fate of neural stem cells and progenitors. **2014**, 260, 56-68 | | 13 |
| 1198 | Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner. **2014**, 33, 4433-41 | | 47 |
| 1197 | An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII. **2014**, 33, 4253-64 | | 33 |
| 1196 | A high Notch pathway activation predicts response to γ-secretase inhibitors in proneural subtype of glioma tumor-initiating cells. **2014**, 32, 301-12 | | 102 |
| 1195 | The cyclin-like protein Spy1 regulates growth and division characteristics of the CD133+ population in human glioma. *Cancer Cell*, **2014**, 25, 64-76 | 24.3 | 27 |
| 1194 | Indatraline inhibits Rho- and calcium-mediated glioblastoma cell motility and angiogenesis. **2014**, 443, 749-55 | | 9 |
| 1193 | Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines. **2014**, 111, 468-74 | | 33 |
| 1192 | Brain tumor stem cells: Molecular characteristics and their impact on therapy. **2014**, 39, 82-101 | | 120 |
| 1191 | PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations. **2014**, 33, 2568-76 | | 45 |
| 1190 | Glioblastoma: from molecular pathology to targeted treatment. **2014**, 9, 1-25 | | 346 |
| 1189 | Heterogeneous phenotype of human glioblastoma: in vitro study. **2014**, 32, 164-76 | | 10 |
| 1188 | Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. **2014**, 20, 2326-46 | | 31 |
| 1187 | Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. **2014**, 31, 33-45 | | 38 |
| 1186 | Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. **2014**, 127, 747-59 | | 21 |
| 1185 | Systematic review of protein biomarkers of invasive behavior in glioblastoma. **2014**, 49, 1212-44 | | 25 |

| | | |
|---|---|---|
| 1184 | Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas. **2014**, 342, 139-49 | 65 |
| 1183 | PRADA: pipeline for RNA sequencing data analysis. **2014**, 30, 2224-6 | 117 |
| 1182 | Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes. **2014**, 190, 925-32 | 34 |
| 1181 | Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study. **2014**, 67, 550-5 | 16 |
| 1180 | Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression. **2014**, 99, 152-168 | 40 |
| 1179 | Targeted therapy in gliomas. **2014**, 16, 379 | 30 |
| 1178 | Transcriptional diversity of long-term glioblastoma survivors. **2014**, 16, 1186-95 | 55 |
| 1177 | Thymosin 4 gene silencing decreases stemness and invasiveness in glioblastoma. **2014**, 137, 433-48 | 29 |
| 1176 | Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. **2014**, 74, 1238-49 | 93 |
| 1175 | Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era. **2014**, 117, 153-60 | 21 |
| 1174 | Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. **2014**, 117, 85-92 | 10 |
| 1173 | Mouse models of glioblastoma: lessons learned and questions to be answered. **2014**, 118, 1-8 | 18 |
| 1172 | A network-assisted co-clustering algorithm to discover cancer subtypes based on gene expression. **2014**, 15, 37 | 55 |
| 1171 | Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies. **2014**, 27, 86-95 | 19 |
| 1170 | Depletion of minichromosome maintenance protein 7 inhibits glioblastoma multiforme tumor growth in vivo. **2014**, 33, 4778-85 | 28 |
| 1169 | RETRACTED: Vulnerability of glioblastoma cells to catastrophic vacuolization and death induced by a small molecule. **2014**, 157, 313-328 | 85 |
| 1168 | Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling. **2014**, 20, 112-8 | 73 |
| 1167 | Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. **2014**, 135, 1822-31 | 89 |

| | | |
|---|---|---|
| 1166 | EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy. **2014**, 71, 3465-88 | 46 |
| 1165 | Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. **2014**, 35, 5911-20 | 80 |
| 1164 | c-Myc-dependent transcriptional regulation of cell cycle and nucleosomal histones during oligodendrocyte differentiation. **2014**, 276, 72-86 | 29 |
| 1163 | Deregulation of cell signaling in cancer. **2014**, 588, 2558-70 | 82 |
| 1162 | Using the molecular classification of glioblastoma to inform personalized treatment. **2014**, 232, 165-77 | 174 |
| 1161 | miRNA Expression and Functions in Glioma and Glioma Stem Cells. **2014**, 29-49 | |
| 1160 | Induced Differentiation of Brain Tumour Stem Cells. **2014**, 149-158 | |
| 1159 | Phage display discovery of novel molecular targets in glioblastoma-initiating cells. **2014**, 21, 1325-39 | 18 |
| 1158 | Using evolutional properties of gene networks in understanding survival prognosis of glioblastoma. **2014**, 18, 810-6 | 8 |
| 1157 | miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. **2014**, 111, 291-6 | 87 |
| 1156 | A mesenchymal glioma stem cell profile is related to clinical outcome. **2014**, 3, e91 | 47 |
| 1155 | Heat shock protein 47 regulated by miR-29a to enhance glioma tumor growth and invasion. **2014**, 118, 39-47 | 42 |
| 1154 | The epidemiology of glioma in adults: a "state of the science" review. **2014**, 16, 896-913 | 1044 |
| 1153 | Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma. **2014**, 32, 338-48 | 47 |
| 1152 | Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. **2014**, 157, 580-94 | 549 |
| 1151 | GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity. **2014**, 16, 1167-75 | 99 |
| 1150 | Pathology of gliomas and developments in molecular testing. **2014**, 26, 377-84 | 4 |
| 1149 | Current and investigational drug strategies for glioblastoma. **2014**, 26, 419-30 | 23 |

| | | |
|---|---|---|
| 1148 | A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1. **2014**, 16, 191-203 | 40 |
| 1147 | Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. **2014**, 127, 203-19 | 69 |
| 1146 | Neutrophils promote the malignant glioma phenotype through S100A4. **2014**, 20, 187-98 | 143 |
| 1145 | Oncoprotein stabilization in brain tumors. **2014**, 33, 4709-21 | 13 |
| 1144 | Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. **2014**, 14, 92-107 | 383 |
| 1143 | Therapeutic targeting of platelet-derived growth factor receptors in solid tumors. **2014**, 23, 211-26 | 30 |
| 1142 | Functional Brain Tumor Imaging. **2014**, | 1 |
| 1141 | A comparative survey of functional footprints of EGFR pathway mutations in human cancers. **2014**, 33, 5078-89 | 10 |
| 1140 | Long noncoding RNA profiles reveal three molecular subtypes in glioma. **2014**, 20, 339-43 | 55 |
| 1139 | Epigenetic Changes in Gliomas. **2014**, 23-45 | |
| 1138 | NF-Ƀ and STAT3 in glioblastoma: therapeutic targets coming of age. **2014**, 14, 1293-306 | 69 |
| 1137 | The evolving role of molecular markers in the diagnosis and management of diffuse glioma. **2014**, 20, 5601-11 | 44 |
| 1136 | Glioma Cell Biology. **2014**, | 2 |
| 1135 | Angiogenesis in Gliomas. **2014**, 187-219 | |
| 1134 | Cancer Stem Cells and Glioblastoma. **2014**, 3-22 | 2 |
| 1133 | Signaling Cascades Driving the Malignant Phenotype of Glioma Cells. **2014**, 47-75 | 1 |
| 1132 | Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation. **2014**, 16, 1607-17 | 25 |
| 1131 | The contribution of tumor and host tissue factor expression to oncogene-driven gliomagenesis. **2014**, 454, 262-8 | 16 |

| | | |
|---|---|---|
| 1130 | Pharmacologic therapies for malignant glioma: a guide for clinicians. **2014**, 28, 1127-37 | 9 |
| 1129 | A blustery wind of change. **2014**, 24, i-ii | 0 |
| 1128 | Bioinformatics for cancer immunotherapy target discovery. **2014**, 63, 1235-49 | 22 |
| 1127 | Advances in the management of paediatric high-grade glioma. **2014**, 16, 414 | 7 |
| 1126 | Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma. **2014**, 13, 4581-93 | 28 |
| 1125 | Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. **2014**, 16, 671-85 | 117 |
| 1124 | Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. **2014**, 20, 5023-31 | 70 |
| 1123 | Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle. **2014**, 1846, 560-75 | 31 |
| 1122 | IndividualizedPath: identifying genetic alterations contributing to the dysfunctional pathways in glioblastoma individuals. **2014**, 10, 2031-42 | 7 |
| 1121 | Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process. **2014**, 111, E4214-23 | 81 |
| 1120 | TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status. **2014**, 33, 217-26 | 18 |
| 1119 | Immunotherapy for brain cancer: recent progress and future promise. **2014**, 20, 3651-9 | 67 |
| 1118 | Targeting adaptive glioblastoma: an overview of proliferation and invasion. **2014**, 16, 1575-84 | 165 |
| 1117 | Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. **2014**, 111, 14217-22 | 74 |
| 1116 | Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. **2014**, 20, 878-89 | 84 |
| 1115 | Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients. **2014**, 35, 2756-62 | 25 |
| 1114 | Immunotherapy for primary brain tumors: no longer a matter of privilege. **2014**, 20, 5620-9 | 74 |
| 1113 | Facing the future of brain tumor clinical research. **2014**, 20, 5591-600 | 4 |

| | | |
|---|---|---|
| 1112 | Cancer genomics: one cell at a time. **2014**, 15, 452 | 202 |
| 1111 | Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. **2014**, 273, 168-74 | 220 |
| 1110 | G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues. **2014**, 278, 222-36 | 24 |
| 1109 | Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective. **2014**, 119, 481-90 | 17 |
| 1108 | Id2 mediates oligodendrocyte precursor cell maturation arrest and is tumorigenic in a PDGF-rich microenvironment. **2014**, 74, 1822-32 | 22 |
| 1107 | Medical management of high-grade astrocytoma: current and emerging therapies. **2014**, 41, 511-522 | 20 |
| 1106 | The genetic signatures of pediatric high-grade glioma: no longer a one-act play. **2014**, 24, 240-7 | 34 |
| 1105 | Supratentorial low-grade diffuse astrocytoma: medical management. **2014**, 41, 446-457 | 7 |
| 1104 | Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. **2014**, 16, 1304-12 | 93 |
| 1103 | Vaccine therapies for patients with glioblastoma. **2014**, 119, 531-46 | 24 |
| 1102 | Genetic markers in adult high-grade gliomas. **2014**, 24, 235-9 | 2 |
| 1101 | MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. **2014**, 111, 12550-5 | 166 |
| 1100 | Anatomical localization of p53 mutated tumors: A radiographic study of human glioblastomas. **2014**, 346, 94-8 | 8 |
| 1099 | The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. **2014**, 16, 1263-73 | 123 |
| 1098 | Guided visual exploration of genomic stratifications in cancer. **2014**, 11, 884-885 | 17 |
| 1097 | Molecular heterogeneity of glioblastoma and its clinical relevance. **2014**, 20, 777-87 | 54 |
| 1096 | Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma. **2014**, 74, 4536-48 | 68 |
| 1095 | Integrated chromosome 19 transcriptomic and proteomic data sets derived from glioma cancer stem-cell lines. **2014**, 13, 191-9 | 21 |

| | | | |
|---|---|---|---|
| 1094 | Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. **2014**, 90, 877-85 | | 42 |
| 1093 | Similarity network fusion for aggregating data types on a genomic scale. **2014**, 11, 333-7 | | 849 |
| 1092 | Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation. **2014**, 29, 341-50 | | 13 |
| 1091 | Recurrent epimutations activate gene body promoters in primary glioblastoma. **2014**, 24, 761-74 | | 35 |
| 1090 | Proteogenomic characterization of human colon and rectal cancer. **2014**, 513, 382-7 | | 900 |
| 1089 | Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. **2014**, 1, 75-86 | | 65 |
| 1088 | Therapeutic potential of targeting glucose metabolism in glioma stem cells. **2014**, 18, 1233-6 | | 19 |
| 1087 | Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner. **2014**, 8, 9755-66 | | 177 |
| 1086 | Isocitrate dehydrogenase 1 and 2 mutations in gliomas. **2014**, 92, 1611-20 | | 14 |
| 1085 | Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. **2014**, 131, 251-64 | | 29 |
| 1084 | Epidemiologic and molecular prognostic review of glioblastoma. **2014**, 23, 1985-96 | | 591 |
| 1083 | ECM stiffness regulates glial migration in Drosophila and mammalian glioma models. **2014**, 141, 3233-42 | | 53 |
| 1082 | Targeted biopharmaceuticals for cancer treatment. **2014**, 352, 145-51 | | 30 |
| 1081 | Proteomic analysis underlines the usefulness of both primary adherent and stem-like cell lines for studying proteins involved in human glioblastoma. **2014**, 110, 7-19 | | 1 |
| 1080 | RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. **2014**, 24, 1765-73 | | 237 |
| 1079 | Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. **2014**, 76, 98-115 | | 44 |
| 1078 | RESICstance is futile-but not in glioblastoma. *Cancer Cell*, **2014**, 26, 156-7 | 24.3 | |
| 1077 | Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. *Cancer Cell*, **2014**, 26, 288-300 | 24.3 | 261 |

| | | |
|---|---|---|
| 1076 | Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. **2014**, 74, 1429-39 | 53 |
| 1075 | Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. **2014**, 111, 8149-54 | 57 |
| 1074 | Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. **2014**, 272, 484-93 | 155 |
| 1073 | Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression. **2014**, 32, 1110-23 | 75 |
| 1072 | Mesenchymal stem cells from human fat engineered to secrete BMP4 are nononcogenic, suppress brain cancer, and prolong survival. **2014**, 20, 2375-87 | 57 |
| 1071 | Engineering strategies to mimic the glioblastoma microenvironment. **2014**, 79-80, 172-83 | 92 |
| 1070 | Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. **2014**, 20, 5290-301 | 400 |
| 1069 | Towards developing biomarkers for glioblastoma multiforme: a proteomics view. **2014**, 11, 621-39 | 27 |
| 1068 | Cannabinoids as seed compounds for the cancer treatment. **2014**, 32, 189-193 | 1 |
| 1067 | Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. **2014**, 15, 419 | 204 |
| 1066 | Differences among brain tumor stem cell types and fetal neural stem cells in focal regions of histone modifications and DNA methylation, broad regions of modifications, and bivalent promoters. **2014**, 15, 724 | 11 |
| 1065 | Proteogenomic convergence for understanding cancer pathways and networks. **2014**, 11, 22 | 28 |
| 1064 | Proneural-mesenchymal transformation of glioma stem cells: do therapies cause evolution of target in glioblastoma?. **2014**, 10, 1527-30 | 6 |
| 1063 | Predictive biomarkers investigated in glioblastoma. **2014**, 14, 883-93 | 13 |
| 1062 | Molecular neuro-oncology and the challenge of the blood-brain barrier. **2014**, 41, 438-445 | 11 |
| 1061 | Molecular and genetic pathways in gliomas: the future of personalized therapeutics. **2014**, 3, 123-36 | 18 |
| 1060 | Next-generation sequencing technologies: breaking the sound barrier of human genetics. **2014**, 29, 303-10 | 80 |
| 1059 | EDDY: a novel statistical gene set test method to detect differential genetic dependencies. **2014**, 42, e60 | 19 |

| | | |
|---|---|---|
| 1058 | Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. **2014**, 159, 402-14 | 126 |
| 1057 | CNS macrophages and peripheral myeloid cells in brain tumours. **2014**, 128, 347-62 | 104 |
| 1056 | Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab. **2014**, 261, 1559-64 | 16 |
| 1055 | Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas. **2014** , 37, 367-80; discussion 380 | 38 |
| 1054 | The role of neuropathology in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. **2014**, 118, 461-78 | 10 |
| 1053 | Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. **2014**, 118, 61-72 | 59 |
| 1052 | HIV-1-induced AIDS in monkeys. **2014**, 344, 1401-5 | 61 |
| 1051 | PDGF receptor signaling networks in normal and cancer cells. **2014**, 25, 273-83 | 159 |
| 1050 | Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. **2014**, 111, 3544-9 | 78 |
| 1049 | Chromosome-centric human proteome project: deciphering proteins associated with glioma and neurodegenerative disorders on chromosome 12. **2014**, 13, 3178-90 | 18 |
| 1048 | The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression. **2014**, 74, 1440-1451 | 37 |
| 1047 | A neurocentric perspective on glioma invasion. **2014**, 15, 455-65 | 446 |
| 1046 | Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets. **2014**, 53, 883-94 | 41 |
| 1045 | An epigenetic biomarker panel for glioblastoma multiforme personalized medicine through DNA methylation analysis of human embryonic stem cell-like signature. **2014**, 18, 310-23 | 18 |
| 1044 | Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. **2014**, 119, 429-35 | 25 |
| 1043 | The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. **2014**, 5, 3963 | 99 |
| 1042 | Medical therapy of gliomas. **2014**, 119, 503-12 | 12 |
| 1041 | Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. **2014**, 128, 561-71 | 148 |

| | | |
|---|---|---|
| 1040 | Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes. **2014**, 10, 55-61 | 4 |
| 1039 | MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme. **2014**, 16, 565-77 | 29 |
| 1038 | Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience. **2014**, 31, 985 | 69 |
| 1037 | MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme--a systematic overview. **2014**, 50, 896-913 | 42 |
| 1036 | Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. **2014**, 14, 151 | 50 |
| 1035 | Increased paired box transcription factor 8 has a survival function in glioma. **2014**, 14, 159 | 11 |
| 1034 | Postoperative hemorrhage in an elderly patient with a glioblastoma multiform and a calcified chronic subdural hematoma. **2014**, 12, 110 | 3 |
| 1033 | In silico modeling predicts drug sensitivity of patient-derived cancer cells. **2014**, 12, 128 | 21 |
| 1032 | Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. **2014**, 32, 783-90 | 280 |
| 1031 | Extracellular vesicles shed by glioma cells: pathogenic role and clinical value. **2014**, 35, 8425-38 | 56 |
| 1030 | Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice. **2014**, 33, 3451-62 | 88 |
| 1029 | Brain tumor cells in circulation are enriched for mesenchymal gene expression. **2014**, 4, 1299-309 | 159 |
| 1028 | Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. **2014**, 158, 1094-1109 | 146 |
| 1027 | Detoxification of oxidative stress in glioma stem cells: mechanism, clinical relevance, and therapeutic development. **2014**, 92, 1419-24 | 35 |
| 1026 | Brevican knockdown reduces late-stage glioma tumor aggressiveness. **2014**, 120, 63-72 | 31 |
| 1025 | Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. **2014**, 46, 726-30 | 116 |
| 1024 | Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. **2014**, 14, 357-69 | 321 |
| 1023 | ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. **2014**, 6, 313-24 | 77 |

| | | |
|---|---|---|
| 1022 | Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation. **2014**, 16, 193-206, 206.e19-25 | 96 |
| 1021 | Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics. **2014**, 45, 611-20 | 16 |
| 1020 | Microvesicles as mediators of intercellular communication in cancer. **2014**, 1165, 147-73 | 79 |
| 1019 | Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma model. **2014**, 16, 1048-56 | 37 |
| 1018 | Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. **2014**, 344, 1396-401 | 2401 |
| 1017 | Glial progenitors as targets for transformation in glioma. **2014**, 121, 1-65 | 26 |
| 1016 | Oncogenes and the coagulation system--forces that modulate dormant and aggressive states in cancer. **2014**, 133 Suppl 2, S1-9 | 44 |
| 1015 | Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways. **2014**, 4, 485-95 | 97 |
| 1014 | Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. **2014**, 156, 603-616 | 184 |
| 1013 | High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. **2014**, 6, 117-29 | 61 |
| 1012 | Proteogenomic database construction driven from large scale RNA-seq data. **2014**, 13, 21-8 | 90 |
| 1011 | PELO negatively regulates HER receptor signalling and metastasis. **2014**, 33, 1190-7 | 6 |
| 1010 | TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1.). **2014**, 33, 308-15 | 38 |
| 1009 | Epigenetics in human gliomas. **2014**, 342, 185-92 | 42 |
| 1008 | The association of subventricular zone involvement at recurrence with survival after repeat surgery in patients with recurrent glioblastoma. **2014**, 54, 302-9 | 23 |
| 1007 | Characterizing DNA methylation alterations from The Cancer Genome Atlas. **2014**, 124, 17-23 | 128 |
| 1006 | Glioblastoma heterogeneity and cancer cell plasticity. **2014**, 19, 327-36 | 120 |
| 1005 | Linking differential radiation responses to glioma heterogeneity. **2014**, 5, 1657-65 | 16 |

| | | |
|---|---|---|
| 1004 | DEAD-box helicase DP103 defines metastatic potential of human breast cancers. **2014**, 124, 3807-24 | 98 |
| 1003 | CSNK1A1 and Gli2 as Novel Targets Identified Through an Integrative Analysis of Gene Expression Data, Protein-Protein Interaction and Pathways Networks in Glioblastoma Tumors: Can These Two Be Antagonistic Proteins?. **2014**, 13, 93-108 | 7 |
| 1002 | The glioblastoma vasculature as a target for cancer therapy. **2014**, 42, 1647-52 | 30 |
| 1001 | Master regulators, regulatory networks, and pathways of glioblastoma subtypes. **2014**, 13, 33-44 | 3 |
| 1000 | The continuing evolution: biology and treatment of brain tumors. **2014**, 61 Suppl 1, 100-4 | 5 |
| 999 | Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas. **2014**, 7 Suppl 3, S2 | 11 |
| 998 | Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses. **2014**, 61 Suppl 1, 74-83 | 12 |
| 997 | YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line. **2014**, 32, 159-66 | 27 |
| 996 | Glioblastoma stem cells: new insights in therapeutic strategies. **2014**, 9, 639-653 | 3 |
| 995 | The adherens junction-associated protein 1 is a negative transcriptional regulator of MAGEA2, which potentiates temozolomide-induced apoptosis in GBM. **2014**, 44, 1243-51 | 11 |
| 994 | Glioblastoma: Defining Tumor Niches. **2015**, 1, 252-265 | 213 |
| 993 | Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis. **2015**, 136, 2047-54 | 10 |
| 992 | Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features. **2015**, 5, 16822 | 67 |
| 991 | Upregulation of miR-181s reverses mesenchymal transition by targeting KPNA4 in glioblastoma. **2015**, 5, 13072 | 51 |
| 990 | dbEMT: an epithelial-mesenchymal transition associated gene resource. **2015**, 5, 11459 | 85 |
| 989 | Ubiquitin-protein ligase E3C promotes glioma progression by mediating the ubiquitination and degrading of Annexin A7. **2015**, 5, 11066 | 21 |
| 988 | Targeted Therapy in Solid Tumors: Brain. **2015**, 177-189 | |
| 987 | Combining Targeted Therapies. **2015**, 14-26 | |

| | | |
|---|---|---|
| 986 | Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. **2015**, 5, 16066 | 38 |
| 985 | An evidence-based knowledgebase of metastasis suppressors to identify key pathways relevant to cancer metastasis. **2015**, 5, 15478 | 15 |
| 984 | Extracellular RNAs: development as biomarkers of human disease. **2015**, 4, 27495 | 54 |
| 983 | Isolation and Identification of Neural Cancer Stem/Progenitor Cells. **2015**, 145-167 | |
| 982 | Pathology and genetics of diffuse gliomas in adults. **2015**, 55, 28-37 | 10 |
| 981 | Epigenetic regulation by chromatin activation mark H3K4me3 in primate progenitor cells within adult neurogenic niche. **2014**, 4, 5371 | 21 |
| 980 | Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma. **2015**, 42, 6725-35 | 102 |
| 979 | Combined Mapping of Multiple clUsteriNg ALgorithms (COMMUNAL): A Robust Method for Selection of Cluster Number, K. **2015**, 5, 16971 | 13 |
| 978 | Bayesian Models for Flexible Integrative Analysis of Multi-Platform Genomics Data. 221-241 | 2 |
| 977 | Analyzing Combinations of Somatic Mutations in Cancer Genomes. 337-361 | |
| 976 | The proteomic landscape of glioma stem-like cells. **2015**, 8, 85-93 | 4 |
| 975 | HCsnip: An R Package for Semi-supervised Snipping of the Hierarchical Clustering Tree. **2015**, 14, 1-19 | 3 |
| 974 | Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. **2015**, 22, 200-5 | 8 |
| 973 | Quantitative assessment of short amplicons in FFPE-derived long-chain RNA. **2014**, 4, 7246 | 20 |
| 972 | Wnt5a, Ryk and Ror2 expression in glioblastoma subgroups. **2015**, 211, 963-72 | 16 |
| 971 | Leveraging global gene expression patterns to predict expression of unmeasured genes. **2015**, 16, 1065 | 2 |
| 970 | PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. **2015**, 3, 88 | 27 |
| 969 | The three glioma rat models C6, F98 and RG2 exhibit different metabolic profiles: in vivo 1H MRS and ex vivo 1H HRMAS combined with multivariate statistics. **2015**, 11, 1834-1847 | 7 |

| | | |
|---|---|---|
| 968 | Comparative transcriptomics reveals similarities and differences between astrocytoma grades. **2015**, 15, 952 | 26 |
| 967 | Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas. **2015**, 34, 127 | 15 |
| 966 | IDH2 mutation in gliomas including novel mutation. **2015**, 35, 236-44 | 16 |
| 965 | Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. **2015**, 13, 306 | 15 |
| 964 | CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. **2015**, 16, 160 | 132 |
| 963 | Genetic and epigenetic characterization of low-grade gliomas reveals frequent methylation of the MLH3 gene. **2015**, 54, 655-67 | 7 |
| 962 | Outcomes in Reoperated Low-Grade Gliomas. **2015**, 77, 175-84; discussion 184 | 38 |
| 961 | Intratumor heterogeneity and transcriptional profiling in glioblastoma: translational opportunities. **2015**, 10, 369-381 | |
| 960 | Imaging Genomics in Gliomas. **2015**, 21, 225-34 | 16 |
| 959 | Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells. **2015**, 137, 1630-42 | 117 |
| 958 | Imaging Markers of Isocitrate Dehydrogenase-1 Mutations in Gliomas. **2015**, 62 Suppl 1, 166-70 | 2 |
| 957 | Imaging Genomics of Glioblastoma: Biology, Biomarkers, and Breakthroughs. **2015**, 24, 155-63 | 12 |
| 956 | Pathology and Molecular Classification. **2015**, | |
| 955 | 34. Supratentorial Hemispheric Gliomas. **2015**, | |
| 954 | Comprehensive Genomic Profiling of Recurrent Classic Glioblastoma in a Patient Surviving Eleven Years Following Antineoplaston Therapy. **2015**, 4, 41 | 1 |
| 953 | Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation. **2015**, 9, 2063-2067 | 10 |
| 952 | Role of network biology and network medicine in early detection of cancer. 457-463 | |
| 951 | Targeting Glioma Stem Cells for Therapy: Perspectives and Challenges. **2015**, 06, | 0 |

| | | |
|---|---|---|
| 950 | Loss of tumor suppressive microRNA-31 enhances TRADD/NF-B signaling in glioblastoma. **2015**, 6, 17805-16 | 33 |
| 949 | Tumor Microenvironment Perivascular and Perinecrotic Niches. **2015**, | 2 |
| 948 | Recent Molecular Advances in Our Understanding of Glioma. **2015**, 7, e287 | 8 |
| 947 | Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas. **2015**, 6, 43653-66 | 11 |
| 946 | BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo. **2015**, 8, 689-97 | 10 |
| 945 | Autophagy in Human Brain Cancer. **2015**, 105-120 | 0 |
| 944 | CCAAT/enhancer binding protein induces motility and invasion of glioblastoma cells through transcriptional regulation of the calcium binding protein S100A4. **2015**, 6, 4369-84 | 19 |
| 943 | Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. **2015**, 6, 13579-90 | 17 |
| 942 | Prognostic significance of the markers IDH1 and YKL40 related to the subventricular zone. **2015**, 53, 52-9 | 19 |
| 941 | Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients. **2015**, 4, 1612-30 | 11 |
| 940 | Metabolomic Screening of Tumor Tissue and Serum in Glioma Patients Reveals Diagnostic and Prognostic Information. **2015**, 5, 502-20 | 42 |
| 939 | Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma. **2015**, 5, 147 | 67 |
| 938 | Targeting Aggressive Cancer Stem Cells in Glioblastoma. **2015**, 5, 159 | 95 |
| 937 | Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence. **2015**, 5, 251 | 68 |
| 936 | CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?. **2015**, 5, 259 | 20 |
| 935 | Combined epidermal growth factor receptor and Beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma. **2015**, 2015, 208076 | 15 |
| 934 | The role of Notch and Hedgehog signaling pathways in pituitary development and pathogenesis of pituitary adenomas. **2015**, 14, 5-18 | 22 |
| 933 | Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells. **2015**, 10, e0111532 | 15 |

| | | |
|---|---|---|
| 932 | Intermittent induction of HIF-1α produces lasting effects on malignant progression independent of its continued expression. **2015**, 10, e0125125 | 14 |
| 931 | Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations. **2015**, 10, e0125838 | 18 |
| 930 | The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells. **2015**, 10, e0127058 | 33 |
| 929 | Dexamethasone-Mediated Activation of Fibronectin Matrix Assembly Reduces Dispersal of Primary Human Glioblastoma Cells. **2015**, 10, e0135951 | 21 |
| 928 | An Eighteen Serum Cytokine Signature for Discriminating Glioma from Normal Healthy Individuals. **2015**, 10, e0137524 | 20 |
| 927 | Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-Resistance. **2015**, 10, e0140528 | 32 |
| 926 | ALDH1A3: A Marker of Mesenchymal Phenotype in Gliomas Associated with Cell Invasion. **2015**, 10, e0142856 | 22 |
| 925 | GO-PCA: An Unsupervised Method to Explore Gene Expression Data Using Prior Knowledge. **2015**, 10, e0143196 | 17 |
| 924 | EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study. **2015**, 14, 7290.2015.00008 | 17 |
| 923 | Desert Hedgehog/Patch2 Axis Contributes to Vascular Permeability and Angiogenesis in Glioblastoma. **2015**, 6, 281 | 12 |
| 922 | Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. **2015**, 9, 4479-99 | 249 |
| 921 | CXCR4 and Glioblastoma. **2016**, 16, 59-74 | 35 |
| 920 | Glioblastoma Circulating Cells: Reality, Trap or Illusion?. **2015**, 2015, 182985 | 21 |
| 919 | Automated Feature Extraction in Brain Tumor by Magnetic Resonance Imaging Using Gaussian Mixture Models. **2015**, 2015, 868031 | 37 |
| 918 | Analysis of gene profiles in glioma cells identifies potential genes, miRNAs, and target sites of migratory cells. **2015**, 101, 542-8 | 4 |
| 917 | EGFR Amplification and Glioblastoma Stem-Like Cells. **2015**, 2015, 427518 | 25 |
| 916 | A method for generating new datasets based on copy number for cancer analysis. **2015**, 2015, 467514 | 2 |
| 915 | Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma. **2015**, 2, 618-28 | 35 |

| | | |
|---|---|---|
| 914 | . **2015**, | 2 |
| 913 | Glioma. **2015**, | 0 |
| 912 | miR-146b-5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas. **2015**, 6, 29129-42 | 67 |
| 911 | Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells. **2015**, 6, 26192-215 | 68 |
| 910 | . **2015**, | 1 |
| 909 | The transcriptome and miRNome profiling of glioblastoma tissues and peritumoral regions highlights molecular pathways shared by tumors and surrounding areas and reveals differences between short-term and long-term survivors. **2015**, 6, 22526-52 | 23 |
| 908 | Immunology and Immunotherapy in Brain Tumors Immune Failure and Potential Counteractions. **2015**, | |
| 907 | An information theoretic method to identify combinations of genomic alterations that promote glioblastoma. **2015**, 7, 203-13 | 12 |
| 906 | Identifying core gene modules in glioblastoma based on multilayer factor-mediated dysfunctional regulatory networks through integrating multi-dimensional genomic data. **2015**, 43, 1997-2007 | 26 |
| 905 | EGFR promoter exhibits dynamic histone modifications and binding of ASH2L and P300 in human germinal matrix and gliomas. **2015**, 10, 496-507 | 12 |
| 904 | Brain Tumors. **2015**, 259-288 | 1 |
| 903 | The cancer cell map initiative: defining the hallmark networks of cancer. **2015**, 58, 690-8 | 89 |
| 902 | Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma. **2015**, 22, 1219-26 | 35 |
| 901 | Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. **2015**, 372, 2499-508 | 1181 |
| 900 | Glioblastoma: molecular pathways, stem cells and therapeutic targets. **2015**, 7, 538-55 | 83 |
| 899 | Malignant Glioma: Viewpoint hemotherapy. **2015**, 279-293 | |
| 898 | Genomic Applications in Brain Tumors. **2015**, 321-339 | |
| 897 | Molecular Pathology Techniques. **2015**, 35-44 | |

| | | |
|---|---|---|
| 896 | Clinicopathologic implications of NF1 gene alterations in diffuse gliomas. **2015**, 46, 1323-30 | 23 |
| 895 | Can lateral ventricle contact predict the ontogeny and prognosis of glioblastoma?. **2015**, 124, 45-55 | 19 |
| 894 | An integrative view on sex differences in brain tumors. **2015**, 72, 3323-42 | 101 |
| 893 | Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. **2015**, 130, 419-34 | 41 |
| 892 | Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. **2015**, 129, 789-808 | 39 |
| 891 | Glycosylation alterations in lung and brain cancer. **2015**, 126, 305-44 | 41 |
| 890 | [Elderly patients with glioblastoma: state of the art]. **2015**, 102, 277-86 | 9 |
| 889 | The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. **2015**, 15, 741-52 | 156 |
| 888 | Acute hypoxia induces upregulation of microRNA-210 expression in glioblastoma spheroids. **2015**, 4, 25-35 | 14 |
| 887 | Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma. **2015**, 122, 1144-50 | 47 |
| 886 | miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma. **2015**, 21, 4004-13 | 41 |
| 885 | Brain Tumor Stem Cells. **2015**, 23-34 | 1 |
| 884 | Extracellular vesicles, tissue factor, cancer and thrombosis - discussion themes of the ISEV 2014 Educational Day. **2015**, 4, 26901 | 57 |
| 883 | Biomarker-driven diagnosis of diffuse gliomas. **2015**, 45, 87-96 | 57 |
| 882 | Genomic Analysis of the BMP Family in Glioblastomas. **2015**, 7, 1-9 | 5 |
| 881 | Adult brainstem gliomas: Correlation of clinical and molecular features. **2015**, 353, 92-7 | 36 |
| 880 | Notching on Cancer's Door: Notch Signaling in Brain Tumors. **2014**, 4, 341 | 61 |
| 879 | MVDA: a multi-view genomic data integration methodology. **2015**, 16, 261 | 49 |

| | | | |
|---|---|---|---|
| 878 | Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. **2015**, 35, 15097-112 | | 41 |
| 877 | Investigating the Influence of HUVECs in the Formation of Glioblastoma Spheroids in High-Throughput Three-Dimensional Microwells. **2015**, 14, 790-6 | | 22 |
| 876 | A Tumor Suppressor Function for Notch Signaling in Forebrain Tumor Subtypes. *Cancer Cell*, **2015**, 28, 730-742 | 24.3 | 63 |
| 875 | Systematic pan-cancer analysis of tumour purity. **2015**, 6, 8971 | | 555 |
| 874 | Analyzing differential regulatory networks modulated by continuous-state genomic features in glioblastoma multiforme. **2015**, | | 1 |
| 873 | The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes. **2015**, 2, 1351-63 | | 160 |
| 872 | Advances in the treatment of newly diagnosed glioblastoma. **2015**, 13, 293 | | 31 |
| 871 | Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. **2015**, 4, 899-913 | | 42 |
| 870 | Integrating omics data for identifying disease subtypes: A multiplex network-based approach. **2015** , | | |
| 869 | Statistical Significance of Clustering using Soft Thresholding. **2015**, 24, 975-993 | | 29 |
| 868 | Efficient exploration of pan-cancer networks by generalized covariance selection and interactive web content. **2015**, 43, e98 | | 15 |
| 867 | The Molecular Signatures Database (MSigDB) hallmark gene set collection. **2015**, 1, 417-425 | | 3213 |
| 866 | Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. **2015**, 13, 2425-2439 | | 97 |
| 865 | Shedding light on glioblastoma cellular heterogeneity. **2015**, 17, 327-8 | | 2 |
| 864 | Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. **2015**, 12, 69-70 | | 69 |
| 863 | Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. **2015**, 112, 851-6 | | 251 |
| 862 | Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms. **2015**, 36, 1943-53 | | 25 |
| 861 | Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics. **2015**, 15, 506 | | 100 |

| | | |
|---|---|---|
| 860 | EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers. **2015**, 29, 23-29 | 25 |
| 859 | Secretory prostate apoptosis response (Par)-4 sensitizes multicellular spheroids (MCS) of glioblastoma multiforme cells to tamoxifen-induced cell death. **2015**, 5, 8-19 | 17 |
| 858 | Cellular and molecular portrait of eleven human glioblastoma cell lines under photon and carbon ion irradiation. **2015**, 360, 10-6 | 14 |
| 857 | A leak pathway for luminal protons in endosomes drives oncogenic signalling in glioblastoma. **2015**, 6, 6289 | 57 |
| 856 | EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. **2015**, 34, 5277-87 | 33 |
| 855 | EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner. **2015**, 4, 226-38 | 122 |
| 854 | Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression. **2015**, 10, 383-397 | 54 |
| 853 | Glioblastoma in England: 2007-2011. **2015**, 51, 533-542 | 108 |
| 852 | PTK7 regulates Id1 expression in CD44-high glioma cells. **2015**, 17, 505-15 | 22 |
| 851 | Cell of origin for malignant gliomas and its implication in therapeutic development. **2015**, 7, | 98 |
| 850 | Genomic discoveries in adult astrocytoma. **2015**, 30, 17-24 | 8 |
| 849 | Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells. **2015**, 290, 3814-24 | 86 |
| 848 | In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. **2015**, 17, 1086-94 | 26 |
| 847 | A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. **2015**, 17, 854-61 | 257 |
| 846 | Id4 suppresses MMP2-mediated invasion of glioblastoma-derived cells by direct inactivation of Twist1 function. **2015**, 34, 53-62 | 45 |
| 845 | Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. **2015**, 25, 316-27 | 240 |
| 844 | Survival and low-grade glioma: the emergence of genetic information. **2015**, 38, E6 | 212 |
| 843 | FGF2 as a potential prognostic biomarker for proneural glioma patients. **2015**, 54, 385-94 | 18 |

| | | |
|---|---|---|
| 842 | Clinical impact of molecular biomarkers in gliomas. **2015**, 22, 437-44 | 49 |
| 841 | Cancer Systems Biology: The Future. **2015**, 297-314.e3 | |
| 840 | The Biology of Primary Brain Tumors. **2015**, 573-580.e1 | |
| 839 | Novel genotype-phenotype associations in human cancers enabled by advanced molecular platforms and computational analysis of whole slide images. **2015**, 95, 366-76 | 39 |
| 838 | Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest. **2015**, 230, 1929-43 | 14 |
| 837 | Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. **2015**, 6, e1601 | 136 |
| 836 | Advances in anticancer immunotoxin therapy. **2015**, 20, 176-85 | 132 |
| 835 | Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1□ZEB1 axis. **2015**, 359, 107-16 | 192 |
| 834 | GLAD: a mixed-membership model for heterogeneous tumor subtype classification. **2015**, 31, 225-32 | 12 |
| 833 | Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy. **2015**, 149, 425-37 | 25 |
| 832 | The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells. **2015**, 22, 1517-25 | 31 |
| 831 | EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma. **2015**, 34, 129-134 | 36 |
| 830 | Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. **2015**, 17, 801-9 | 34 |
| 829 | A major role for microRNAs in glioblastoma cancer stem-like cells. **2015**, 38, 423-34 | 12 |
| 828 | Robustness of equations that define molecular subtypes of glioblastoma tumors based on five transcripts measured by RT-PCR. **2015**, 19, 41-51 | 2 |
| 827 | Romo1 is associated with ROS production and cellular growth in human gliomas. **2015**, 121, 73-81 | 11 |
| 826 | Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-□ receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. **2015**, 33, 357-70 | 75 |
| 825 | Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. **2015**, 16, 16 | 65 |

| | | |
|---|---|---|
| 824 | Extracellular vesicles in the biology of brain tumour stem cells--Implications for inter-cellular communication, therapy and biomarker development. **2015**, 40, 17-26 | 74 |
| 823 | Liquid biopsies in patients with diffuse glioma. **2015**, 129, 849-65 | 62 |
| 822 | Genetic variants in N-myc (and STAT) interactor and susceptibility to glioma in a Chinese Han population. **2015**, 36, 1579-88 | 4 |
| 821 | Incorporation of biomarkers in phase II studies of recurrent glioblastoma. **2015**, 36, 153-62 | 3 |
| 820 | Biomarkers for glioma immunotherapy: the next generation. **2015**, 123, 359-72 | 20 |
| 819 | Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. **2015**, 33, 1197-213 | 123 |
| 818 | Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins. **2015**, 13, 852-62 | 31 |
| 817 | EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide. **2015**, 107, | 31 |
| 816 | Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer. **2015**, 22, 38-46 | 22 |
| 815 | Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients. **2015**, 42, 212-21 | 80 |
| 814 | Epidermal growth factor-like module containing mucin-like hormone receptor 2 expression in gliomas. **2015**, 121, 53-61 | 7 |
| 813 | VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner. **2015**, 360, 60-7 | 32 |
| 812 | Joint estimation of sparse multivariate regression and conditional graphical models. **2015**, | 4 |
| 811 | A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells. **2015**, 11, 1809-21 | 61 |
| 810 | The future of high-grade glioma: Where we are and where are we going. **2015**, 6, S9-S44 | 22 |
| 809 | Personalized medicine for gliomas. **2015**, 6, S89-95 | 23 |
| 808 | (99m)Tc-ixolaris targets glioblastoma-associated tissue factor: in vitro and pre-clinical applications. **2015**, 136, 432-9 | 5 |
| 807 | Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs. **2015**, 88, 20150354 | 40 |

| | | |
|---|---|---|
| 806 | Molecularly based management of gliomas in clinical practice. **2015**, 36, 1551-7 | 4 |
| 805 | Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm. **2015**, 5, 11966 | 55 |
| 804 | RNA-Binding Protein Musashi1 Is a Central Regulator of Adhesion Pathways in Glioblastoma. **2015**, 35, 2965-78 | 33 |
| 803 | Oncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling. **2015**, 17, 225-37 | 28 |
| 802 | Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells. **2015**, 21, 5324-37 | 29 |
| 801 | DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. **2015**, 3, 34 | 47 |
| 800 | Progress in the application of molecular biomarkers in gliomas. **2015**, 465, 1-4 | 38 |
| 799 | Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells. **2015**, 5, 333-336 | 21 |
| 798 | Definition of a serum marker panel for glioblastoma discrimination and identification of Interleukin 1□n the microglial secretome as a novel mediator of endothelial cell survival induced by C-reactive protein. **2015**, 128, 251-61 | 19 |
| 797 | Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. **2015**, 33, 2735-44 | 205 |
| 796 | Targeting strategies on miRNA-21 and PDCD4 for glioblastoma. **2015**, 580, 64-74 | 38 |
| 795 | Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma. **2015**, 853, 111-38 | 36 |
| 794 | Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression. **2015**, 112, E4055-64 | 44 |
| 793 | DINGO: differential network analysis in genomics. **2015**, 31, 3413-20 | 68 |
| 792 | Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma. **2015**, 5, 5 | 154 |
| 791 | Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes. **2015**, 5, 1-9 | 51 |
| 790 | Cancer stem cells in glioblastoma. **2015**, 29, 1203-17 | 851 |
| 789 | CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. **2015**, 5, 11483 | 189 |

| | | |
|---|---|---|
| 788 | Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. **2015**, 124, 447-53 | 7 |
| 787 | An overview of new biomolecular pathways in pathogen-related cancers. **2015**, 11, 1625-39 | 11 |
| 786 | Insights from Chromosome-Centric Mapping of Disease-Associated Genes: Chromosome 12 Perspective. **2015**, 14, 3432-40 | 4 |
| 785 | Integrating different data types by regularized unsupervised multiple kernel learning with application to cancer subtype discovery. **2015**, 31, i268-75 | 94 |
| 784 | Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome. **2015**, 26, 880-887 | 26 |
| 783 | Applicable advances in the molecular pathology of glioblastoma. **2015**, 32, 153-62 | 11 |
| 782 | Gene Delivery and Therapy for Neurological Disorders. **2015**, | |
| 781 | Quest for Missing Proteins: Update 2015 on Chromosome-Centric Human Proteome Project. **2015**, 14, 3415-31 | 50 |
| 780 | Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. **2015**, 6, 7391 | 181 |
| 779 | Hierarchical control of coherent gene clusters defines the molecular mechanisms of glioblastoma. **2015**, 11, 1012-28 | |
| 778 | Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. **2015**, 372, 2481-98 | 1828 |
| 777 | Isocitrate Dehydrogenase (IDH) Mutation in Gliomas. **2015**, 441-458 | |
| 776 | Integrative multi-omics module network inference with Lemon-Tree. **2015**, 11, e1003983 | 58 |
| 775 | A computational approach to identifying gene-microRNA modules in cancer. **2015**, 11, e1004042 | 27 |
| 774 | Molecular profiling of gliomas: potential therapeutic implications. **2015**, 15, 955-62 | 15 |
| 773 | Molecular heterogeneity in glioblastoma: potential clinical implications. **2015**, 5, 55 | 125 |
| 772 | Toward precision medicine in glioblastoma: the promise and the challenges. **2015**, 17, 1051-63 | 142 |
| 771 | Iron metabolism: a double-edged sword in the resistance of glioblastoma to therapies. **2015**, 26, 322-31 | 31 |

| | | |
|---|---|---|
| 770 | Hurdles on the road to personalized medicine. **2015**, 9, 935-9 | 12 |
| 769 | A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel. **2015**, 98, 568-73 | 11 |
| 768 | A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: Analysis of 14,678 patients using systematic review and meta-analytical tools. **2015**, 22, 785-99 | 25 |
| 767 | Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status. **2015**, 297, 243-51 | 15 |
| 766 | Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. **2015**, 2, 152-163 | 124 |
| 765 | Adapting the drivers to the road: a new strategy for cancer evolution?. **2015**, 26, 827-829 | 3 |
| 764 | A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. **2015**, 15, 290-301 | 229 |
| 763 | [Molecular diagnostics in neuropathology]. **2015**, 36, 171-80 | 11 |
| 762 | □aminolevulinic acid-induced fluorescence unmasks biological intratumoral heterogeneity within histologically homogeneous areas of malignant gliomas. **2015**, 157, 617-9 | 8 |
| 761 | Role of Yes-associated protein 1 in gliomas: pathologic and therapeutic aspects. **2015**, 36, 2223-7 | 15 |
| 760 | Correlation of microRNA-10b upregulation and poor prognosis in human gliomas. **2015**, 36, 6249-54 | 18 |
| 759 | MicroRNA□mRNA interaction analysis to detect potential dysregulation in complex diseases. **2015**, 4, 1 | 7 |
| 758 | Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion. **2015**, 161, 803-16 | 314 |
| 757 | Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. **2015**, 15, 647-64 | 32 |
| 756 | Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-□B-inducing kinase (NIK) and noncanonical NF-□B signaling. **2015**, 14, 9 | 48 |
| 755 | Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma. **2015**, 13, 23 | 22 |
| 754 | A pseudogene-signature in glioma predicts survival. **2015**, 34, 23 | 14 |
| 753 | Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastoma. **2015**, 16, 5 | 101 |

| | | |
|---|---|---|
| 752 | Bayesian nonlinear model selection for gene regulatory networks. **2015**, 71, 585-95 | 15 |
| 751 | Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas. **2015**, 25, 2738-44 | 10 |
| 750 | Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma. **2015**, 13, 1227-37 | 20 |
| 749 | Stem Cell Biology in Neoplasms of the Central Nervous System. **2015**, | 2 |
| 748 | Molecular and Genomic Alterations in Glioblastoma Multiforme. **2015**, 185, 1820-33 | 101 |
| 747 | First-in-human dose study of the novel transforming growth factor-receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. **2015**, 21, 553-60 | 166 |
| 746 | Berberine induces senescence of human glioblastoma cells by downregulating the EGFR-MEK-ERK signaling pathway. **2015**, 14, 355-63 | 81 |
| 745 | Protein Kinase CK2 Cellular Function in Normal and Disease States. **2015**, | 3 |
| 744 | Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. **2015**, 129, 679-93 | 208 |
| 743 | Quantification of cell identity from single-cell gene expression profiles. **2015**, 16, 9 | 102 |
| 742 | Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones. **2015**, 36, 236-52 | 35 |
| 741 | Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone. **2015**, 75, 194-202 | 40 |
| 740 | Molecular targets in glioblastoma. **2015**, 11, 1407-20 | 27 |
| 739 | Glioblastoma: pathology, molecular mechanisms and markers. **2015**, 129, 829-48 | 360 |
| 738 | Flow-Cytometric Identification and Characterization of Neural Brain Tumor-Initiating Cells for Pathophysiological Study and Biomedical Applications. **2015**, 199-211 | |
| 737 | Glioblastoma multiforme: Pathogenesis and treatment. **2015**, 152, 63-82 | 370 |
| 736 | Next Generation Sequencing in Cancer Research, Volume 2. **2015**, | 4 |
| 735 | AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. **2015**, 14, 1614-24 | 60 |

| | | |
|---|---|---|
| 734 | Feedback circuitry between miR-218 repression and RTK activation in glioblastoma. **2015**, 8, ra42 | 11 |
| 733 | Transforming growth factor  and bone morphogenetic protein actions in brain tumors. **2015**, 589, 1588-97 | 29 |
| 732 | Genetic similarity between cancers and comorbid Mendelian diseases identifies candidate driver genes. **2015**, 6, 7033 | 22 |
| 731 | Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis. **2015**, 22, 50-8 | 62 |
| 730 | Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies. **2015**, 123, 373-83 | 11 |
| 729 | Comprehensive analysis of microRNA expression profile in malignant glioma tissues. **2015**, 9, 1324-40 | 56 |
| 728 | Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms. **2015**, 75, 2109-19 | 28 |
| 727 | Somatic mitochondrial DNA mutations in different grades of glioma. **2021**, | |
| 726 | Oncogene expression from extrachromosomal DNA is driven by copy number amplification and does not require spatial clustering. | 1 |
| 725 | Therapeutic Opportunities of Disrupting Genome Integrity in Adult Diffuse Glioma.. **2022**, 10, | |
| 724 | Pervasive conditional selection of driver mutations and modular epistasis networks in cancer. | 0 |
| 723 | Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients.. **2022**, 10, | 1 |
| 722 | The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis.. **2022**, 156, 257 | 1 |
| 721 | Single-cell RNA profiling identifies diverse cellular responses to EWSR1/FLI1 downregulation in Ewing sarcoma cells.. **2022**, 45, 19 | 3 |
| 720 | Exome sequencing of glioblastoma-derived cancer stem cells reveals rare clinically relevant frameshift deletion in MLLT1 gene.. **2022**, 22, 9 | |
| 719 | Inhibition of SHP2 as an approach to block RAS-driven cancers.. **2022**, 153, 205-236 | 0 |
| 718 | Patient-individual phenotypes of glioblastoma stem cells are conserved in culture and associate with radioresistance, brain infiltration and patient prognosis.. **2022**, | 1 |
| 717 | Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives.. **2022**, 14, | 5 |

| | | |
|---|---|---|
| 716 | Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors.. **2022**, 14, | 2 |
| 715 | An oncogenic splice variant of PDGFRin adult glioblastoma as a therapeutic target for selective CDK4/6 inhibitors.. **2022**, 12, 1275 | 1 |
| 714 | GNIFdb: a neoantigen intrinsic feature database for glioma.. **2022**, 2022, | 0 |
| 713 | High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?. **2022**, 20, 64 | 0 |
| 712 | In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.. **2022**, 52, E3 | 0 |
| 711 | HDAC6 involves in regulating the lncRNA-microRNA-mRNA network to promote the proliferation of glioblastoma cells.. **2022**, 41, 47 | 1 |
| 710 | Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.. **2022**, 13, 773264 | 1 |
| 709 | Diagnostic Evidence GAuge of Single cells (DEGAS): a flexible deep transfer learning framework for prioritizing cells in relation to disease.. **2022**, 14, 11 | 0 |
| 708 | EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma.. **2022**, 7, 33 | 3 |
| 707 | Improve consensus partitioning via a hierarchical procedure.. **2022**, | |
| 706 | Current Immunotherapeutic Approaches for Malignant Gliomas.. **2022**, 10, 1-11 | 1 |
| 705 | Regulation of Tumor Invasion by the Physical Microenvironment: Lessons from Breast and Brain Cancer.. **2022**, | 0 |
| 704 | Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target.. **2022**, 13, 767 | 3 |
| 703 | A Risk Score Signature Consisting of Six Immune Genes Predicts Overall Survival in Patients with Lower-Grade Gliomas.. **2022**, 2022, 2558548 | 1 |
| 702 | Sex disparities in DNA damage response pathways: Novel determinants in cancer formation and therapy.. **2022**, 25, 103875 | 1 |
| 701 | Glioblastoma stem cells express non-canonical proteins and exclusive mesenchymal-like or non-mesenchymal-like protein signatures. | |
| 700 | Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.. **2022**, 10, 19 | 2 |
| 699 | A Multielement Prognostic Nomogram Based on a Peripheral Blood Test, Conventional MRI and Clinical Factors for Glioblastoma.. **2022**, 13, 822735 | 0 |

| | | |
|---|---|---|
| 698 | Amphiphilic Triazine-Phosphorus Metallodendrons Possessing Anti-Cancer Stem Cell Activity.. **2022**, 14, | 3 |
| 697 | DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome - including in elderly patients. | |
| 696 | Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints.. **2022**, 23, | 5 |
| 695 | EZH2 Mediates Proliferation, Migration, and Invasion Promoted by Estradiol in Human Glioblastoma Cells.. **2022**, 13, 703733 | 1 |
| 694 | Canonical BMP2/4 signaling degrades SOX2 in glioblastoma propagating cells. | |
| 693 | Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas.. **2022**, 12, 1872 | |
| 692 | Upregulation of Cathepsin X in Glioblastoma: Interplay with Enolase and the Effects of Selective Cathepsin X Inhibitors.. **2022**, 23, | 1 |
| 691 | ASCL1 phosphorylation and ID2 upregulation are roadblocks to glioblastoma stem cell differentiation.. **2022**, 12, 2341 | 1 |
| 690 | XAF1 directs glioma response to temozolomide through apoptotic transition of autophagy by activation of ATM-AMPK signaling.. **2022**, 4, vdac013 | |
| 689 | DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis.. **2022**, 114, 110289 | 0 |
| 688 | Synthesis, in vitro cytotoxicity, molecular docking and ADME study of some indolin-2-one linked 1,2,3-triazole derivatives.. **2022**, 97, 107641 | 0 |
| 687 | MFmap: A semi-supervised generative model matching cell lines to tumours and cancer subtypes.. **2021**, 16, e0261183 | 0 |
| 686 | Clinical Characterization and Immunosuppressive Regulation of CD161 (KLRB1) in Glioma through 916 Samples. **2021**, | 4 |
| 685 | Deciphering functional tumor states at single-cell resolution.. **2021**, e109221 | 2 |
| 684 | Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?. **2021**, 13, | 1 |
| 683 | Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.. **2021**, 100854 | 0 |
| 682 | Targeting the Replication Stress of Glioblastoma. **2022**, 12, 42-51 | |
| 681 | Glioblastoma Microenvironment and Cellular Interactions.. **2022**, 14, | 1 |

| | | |
|---|---|---|
| 680 | Cell-based immunotherapy of glioblastoma multiforme.. **2022**, 23, 133 | 0 |
| 679 | Adapt to Persist: Glioblastoma Microenvironment and Epigenetic Regulation on Cell Plasticity.. **2022**, 11, | 1 |
| 678 | Innovating Strategies and Tailored Approaches in Neuro-Oncology.. **2022**, 14, | |
| 677 | Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?. **2022**, 10, 854352 | 1 |
| 676 | Defining the impact of adjuvant treatment on the prognosis of patients with inoperable glioblastoma undergoing biopsy only: does the survival benefit outweigh the treatment effort?. **2022**, | 1 |
| 675 | Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer.. **2022**, 13, 829451 | 2 |
| 674 | Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy.. **2022**, 14, | 2 |
| 673 | Scavenger receptor class F member 2 (SCARF2) as a novel therapeutic target in glioblastoma.. **2022**, 38, 249-256 | 0 |
| 672 | Cancer-associated venous thromboembolism.. **2022**, 8, 11 | 9 |
| 671 | Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma.. **2022**, 22, 233 | 0 |
| 670 | Production and Stabilization of Specific Upregulated Long Noncoding RNA HOXD-AS2 in Glioblastomas Are Mediated by TFE3 and miR-661, Respectively.. **2022**, 23, | |
| 669 | Extracellular Vesicles Secreted by Glioma Stem Cells Are Involved in Radiation Resistance and Glioma Progression.. **2022**, 23, | 3 |
| 668 | The Radiosensitivity Index (RSI) Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated with Susceptibility to Radiotherapy.. **2022**, | 0 |
| 667 | FOSL1 promotes proneural-to-mesenchymal transition of glioblastoma stem cells via UBC9/CYLD/NF-Ƀ axis.. **2022**, | 1 |
| 666 | On optimal temozolomide scheduling for slowly growing gliomas. | |
| 665 | DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.. **2022**, 10, 39 | 1 |
| 664 | TERT promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening in vivo.. **2022**, | 0 |
| 663 | A Deep Learning-Based Framework for Supporting Clinical Diagnosis of Glioblastoma Subtypes.. **2022**, 13, 855420 | 1 |

| | | |
|---|---|---|
| 662 | Subcellular progression of mesenchymal transition identified by two discrete synchronous cell lines derived from the same glioblastoma.. **2022**, 79, 181 | |
| 661 | LPPR5 Expression in Glioma Affects Growth, Vascular Architecture, and Sunitinib Resistance.. **2022**, 23, | 1 |
| 660 | Colony-stimulating factor 1 receptor signaling in the central nervous system and the potential of its pharmacological inhibitors to halt the progression of neurological disorders.. **2022**, 1 | 0 |
| 659 | Nucleolar localization of the ErbB3 receptor as a new target in glioblastoma.. **2022**, 23, 13 | 0 |
| 658 | Network-based cancer heterogeneity analysis incorporating multi-view of prior information.. **2022**, | 0 |
| 657 | Glioblastoma states are defined by cohabitating cellular populations with progression-, imaging- and sex-distinct patterns. | 0 |
| 656 | Spatial patterning and immunosuppression of glioblastoma immune contexture in hypoxic niches. | 0 |
| 655 | CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas.. **2022**, 12, 4295 | 0 |
| 654 | Algorithmic reconstruction of glioblastoma network complexity.. **2022**, 25, 104179 | 1 |
| 653 | Polyunsaturated Fatty Acid-Enriched Lipid Fingerprint of Glioblastoma Proliferative Regions Is Differentially Regulated According to Glioblastoma Molecular Subtype.. **2022**, 23, | 1 |
| 652 | BIDIMENSIONAL LINKED MATRIX FACTORIZATION FOR PAN-OMICS PAN-CANCER ANALYSIS.. **2022**, 16, 193-215 | 0 |
| 651 | NOX4 regulates TGF□nduced proliferation and self-renewal in glioblastoma stem cells.. **2022**, | 0 |
| 650 | Delivering Glioblastoma a Kick-DGK□nhibition as a Promising Therapeutic Strategy for GBM.. **2022**, 14, | |
| 649 | Proteomic analysis reveals microvesicles containing NAMPT as mediators of radiation resistance in glioma. | |
| 648 | Assessing Nordihydroguaiaretic Acid Therapeutic Effect for Glioblastoma Multiforme.. **2022**, 22, | |
| 647 | The Role of Micro RNAs in Regulating PI3K/AKT Signaling Pathways in Glioblastoma.. **2022**, 17, 122-136 | 2 |
| 646 | Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.. **2022**, | 0 |
| 645 | Radiogenomic Predictors of Recurrence in Glioblastoma-A Systematic Review.. **2022**, 12, | |

| | | |
|---|---|---|
| 644 | Up-regulated YB-1 protein promotes glioblastoma growth through an YB-1/CCT4/mLST8/mTOR pathway.. **2022**, | 0 |
| 643 | Histone Deacetylase Inhibitors Impair Glioblastoma Cell Motility and Proliferation.. **2022**, 14, | 1 |
| 642 | In-depth matrisome and glycoproteomic analysis of human brain glioblastoma versus control tissue.. **2022**, 100216 | 2 |
| 641 | A Toolkit for Profiling the Immune Landscape of Pediatric Central Nervous System Malignancies.. **2022**, 13, 864423 | 0 |
| 640 | RNA Editing in Glioma as a Sexually Dimorphic Prognostic Factor That Affects mRNA Abundance in Fatty Acid Metabolism and Inflammation Pathways.. **2022**, 11, | |
| 639 | Platelet-derived growth factor signalling in neurovascular function and disease.. **2022**, 106187 | 0 |
| 638 | Alterations in 3D chromatin organization contribute to tumorigenesis of -amplified glioblastoma.. **2022**, 20, 1967-1978 | 0 |
| 637 | Divergent MEK/ERK and AMPK signaling dictate lipogenic plasticity and dependence on fatty acid synthesis in Glioblastoma. | |
| 636 | Advances in Nanoparticle mediated Targeting of RNA Binding Protein for Cancer.. **2022**, 114257 | 1 |
| 635 | Expression Profiles of HOXC6 Predict the Survival of Glioblastoma Patients and Correlate with Cell Cycle.. **2022**, 2022, 8656865 | |
| 634 | PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38 signalling.. **2022**, | 0 |
| 633 | Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.. **2022**, 13, 849592 | 3 |
| 632 | Patient-Derived Xenotransplant of CNS Neoplasms in Zebrafish: A Systematic Review.. **2022**, 11, | |
| 631 | Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis.. **2022**, 39, 110595 | 2 |
| 630 | Diversified physiological sensory input connectivity questions the existence of distinct classes of spinal interneurons.. **2022**, 25, 104083 | 1 |
| 629 | Glioma-derived exosomes hijack the blood-brain barrier to facilitate nanocapsule delivery via LCN2.. **2022**, 345, 537-548 | 0 |
| 628 | Synthesis and in vitro evaluation of a novel thienopyrimidine with phototoxicity towards rat glioma F98 cells. **2022**, 10, 100114 | |
| 627 | PIMREG expression level predicts glioblastoma patient survival and affects temozolomide resistance and DNA damage response.. **2022**, 166382 | 0 |

| | | |
|---|---|---|
| 626 | A Nanoparticle-Conjugated Anti-TBK1 siRNA Induces Autophagy-Related Apoptosis and Enhances cGAS-STING Pathway in GBM Cells.. **2021**, 2021, 6521953 | 2 |
| 625 | Graph-guided Bayesian SVM with Adaptive Structured Shrinkage Prior for High-dimensional Data.. **2021**, 2021, 4472-4479 | |
| 624 | A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines.. **2022**, 4, vdab192 | |
| 623 | Outcome-guided sparse K-means for disease subtype discovery via integrating phenotypic data with high-dimensional transcriptomic data. **2022**, 71, 352-375 | |
| 622 | Transcriptional Regulation of Amino Acid Transport in Glioblastoma Multiforme.. **2021**, 13, | 0 |
| 621 | Hypoxia Contributes to Poor Prognosis in Primary IDH-wt GBM by Inducing Tumor Cells MES-Like Transformation Trend and Inhibiting Immune Cells Activity.. **2021**, 11, 782043 | 0 |
| 620 | Gene Alterations Define Specific Features of a Subset of Glioblastomas.. **2021**, 23, | 1 |
| 619 | Noncanonical structural requirements of neurofibromin SUMOylation reveal a folding-deficiency of several pathogenic mutants. | 0 |
| 618 | FOXO3 regulates a common genomic program in aging and glioblastoma stem cells. **2021**, 2, 137-159 | 0 |
| 617 | Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI.. **2021**, | 1 |
| 616 | LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response. **2021**, 13, eabf7036 | 2 |
| 615 | Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma.. **2021**, 14, | 2 |
| 614 | Microglia and astrocyte involvement in neurodegeneration and brain cancer.. **2021**, 18, 298 | 2 |
| 613 | ALDH1A3 Segregated Expression and Nucleus-Associated Proteasomal Degradation Are Common Traits of Glioblastoma Stem Cells.. **2021**, 10, | 1 |
| 612 | RNA sequencing of glioblastoma tissue slice cultures reveals the effects of treatment at the transcriptional level.. **2021**, | |
| 611 | Heterogeneity and excitability of BRAF ᵛ600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss. **2021**, | 1 |
| 610 | Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography.. **2021**, 14, | 0 |
| 609 | Unveiling a Ghost Proteome in the Glioblastoma Non-Coding RNAs.. **2021**, 9, 703583 | 1 |

| | | |
|---|---|---|
| 608 | Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy.. **2021**, | 2 |
| 607 | Hippo Pathway in Regulating Drug Resistance of Glioblastoma.. **2021**, 22, | 3 |
| 606 | The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia.. **2021**, 22, | 0 |
| 605 | Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment.. **2021**, 10, | 4 |
| 604 | Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds. **2021**, | 4 |
| 603 | PTEN inhibits AMPK to control collective migration. | |
| 602 | Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.. **2021**, | 4 |
| 601 | Systems Biology Approaches to Decipher the Underlying Molecular Mechanisms of Glioblastoma Multiforme.. **2021**, 22, | 0 |
| 600 | Growth factor independence underpins a paroxysmal, aggressive Wnt5a/EphA2 phenotype in glioblastoma stem cells, conducive to experimental combinatorial therapy.. **2022**, 41, 139 | 1 |
| 599 | Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma.. **2022**, 22, 151 | 2 |
| 598 | Comprehensive analysis of epigenetics regulation, prognostic and the correlation with immune infiltrates of GPX7 in adult gliomas.. **2022**, 12, 6442 | 0 |
| 597 | Galvanotactic Migration of Glioblastoma and Brain Metastases Cells.. **2022**, 12, | 0 |
| 596 | NSG-70, a new glioblastoma cell line with mixed proneural-mesenchymal features, associates NOTCH1-WNT5A signaling with stem cell maintenance and angiogenesis.. **2022**, 157, 575 | |
| 595 | Functional Contribution of Cancer-Associated Fibroblasts in Glioblastoma. | |
| 594 | Emerging therapies for glioblastoma: current state and future directions.. **2022**, 41, 142 | 7 |
| 593 | RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an mA-YTHDF2-dependent manner.. **2022**, | 1 |
| 592 | GBP2 facilitates the progression of glioma via regulation of KIF22/EGFR signaling.. **2022**, 8, 208 | 1 |
| 591 | Nuclear respiratory factor 1 transcriptomic signatures as prognostic indicators of recurring aggressive mesenchymal glioblastoma and resistance to therapy in White American females.. **2022**, 1 | |

| | | |
|---|---|---|
| 590 | Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma.. **2022**, 1 | 0 |
| 589 | The Profiles of Tet-Mediated DNA Hydroxymethylation in Human Gliomas.. **2022**, 12, 621460 | |
| 588 | Identification of a key glioblastoma candidate gene, FUBP3, based on weighted gene co-expression network analysis.. **2022**, 22, 139 | 1 |
| 587 | Immune Landscape in PTEN-Related Glioma Microenvironment: A Bioinformatic Analysis.. **2022**, 12, | 1 |
| 586 | High SOX9 Maintains Glioma Stem Cell Activity through a Regulatory Loop Involving STAT3 and PML.. **2022**, 23, | |
| 585 | GALNT12 is associated with the malignancy of glioma and promotes glioblastoma multiforme in´vitro by activating Akt signaling.. **2022**, 610, 99-106 | 1 |
| 584 | The central nervous system. 3185-3317 | |
| 583 | Cancer pharmacogenomics: challenges, promises, and its application to cancer drug discovery. 499-517 | |
| 582 | Data_Sheet_1.pdf. **2019**, | |
| 581 | Data_Sheet_2.ZIP. **2019**, | |
| 580 | Data_Sheet_1.pdf. **2020**, | |
| 579 | Table_1.DOCX. **2020**, | |
| 578 | Table_2.DOCX. **2020**, | |
| 577 | Table_1.DOCX. **2019**, | |
| 576 | Image_1.TIF. **2019**, | |
| 575 | Image_2.TIF. **2019**, | |
| 574 | Image_3.TIF. **2019**, | |
| 573 | Image_4.TIF. **2019**, | |

572 Table_1.XLSX. **2019**,

571 Data_Sheet_1.PDF. **2019**,

570 Data_Sheet_2.PDF. **2019**,

569 Table_1.XLSX. **2019**,

568 Table_2.XLSX. **2019**,

567 Table_3.XLSX. **2019**,

566 Table_4.XLSX. **2019**,

565 Table_5.xlsx. **2019**,

564 Table_6.XLSX. **2019**,

563 Table_7.XLSX. **2019**,

562 Table_8.xlsx. **2019**,

561 Data_Sheet_1.docx. **2020**,

560 Table_1.docx. **2020**,

559 Data_Sheet_1.ZIP. **2020**,

558 Table_1.DOCX. **2020**,

557 DataSheet_1.xlsx. **2020**,

556 Presentation_1.pdf. **2020**,

555 Image_1.tiff. **2020**,

554 Table_1.docx. **2020**,

553 Table_2.docx. **2020**,

552 Table_3.docx. **2020**,

551 Table_4.xlsx. **2020**,

550 Table_5.xlsx. **2020**,

549 Image_1.tif. **2020**,

548 Image_2.tif. **2020**,

547 Image_3.tif. **2020**,

546 Image_4.tif. **2020**,

545 Image_5.tif. **2020**,

544 Image_6.tif. **2020**,

543 Image_7.tif. **2020**,

542 Table_1.XLSX. **2020**,

541 DataSheet_1.pdf. **2019**,

540 Table_1.doc. **2019**,

539 Image_1.tif. **2020**,

538 Image_2.tif. **2020**,

537 Table_1.docx. **2020**,

536 Table_1.docx. **2019**,

535 Presentation_1.pdf. **2019**,

534 Image_1.tif. **2019**,

533 Table_1.XLSX. **2020**,

532 Data_Sheet_1.docx. **2019**,

531 Data_Sheet_1.PDF. **2020**,

530 Image1.PDF. **2018**,

529 Image2.PDF. **2018**,

528 Image3.PDF. **2018**,

527 Image4.PDF. **2018**,

526 Presentation1.pdf. **2018**,

525 Table1.PDF. **2018**,

524 Table2.PDF. **2018**,

523 Table3.PDF. **2018**,

522 Image_1.TIF. **2020**,

521 Image_2.TIF. **2020**,

520 Table_1.DOCX. **2020**,

519 Table_2.DOCX. **2020**,

518 Data_Sheet_1.docx. **2020**,

517 Table_1.DOCX. **2020**,

516 Table_2.DOCX. **2020**,

515 Table_3.XLSX. **2020**,

514 Table_4.XLSX. **2020**,

513 Table_5.XLSX. **2020**,

512 Image_1.tif. **2020**,

511 Image_2.tif. **2020**,

510 Image_3.tif. **2020**,

509 Table_1.DOCX. **2020**,

508 Image_1.jpeg. **2020**,

507 Table_1.xlsx. **2020**,

506 Data_Sheet_1.PDF. **2019**,

505 Table_1.xlsx. **2019**,

504 Table_1.XLS. **2020**,

503 Data_Sheet_1.PDF. **2019**,

502 Data_Sheet_1.CSV. **2020**,

501 Data_Sheet_2.PDF. **2020**,

500 Image_1.TIFF. **2020**,

499 Image_2.TIFF. **2020**,

498 Data_Sheet_1.csv. **2019**,

497 Data_Sheet_2.csv. **2019**,

496 Data_Sheet_3.csv. **2019**,

495 Data_Sheet_4.docx. **2019**,

494 Data_Sheet_5.docx. **2019**,

493 Image_1.TIF. **2020**,

492 Image_2.TIF. **2020**,

491 Image_3.TIF. **2020**,

490 Image_4.TIF. **2020**,

489 Image_5.TIF. **2020**,

488 Image_6.TIF. **2020**,

487 Data_Sheet_1.DOCX. **2020**,

486 Data_Sheet_2.docx. **2020**,

485 DataSheet_1.pdf. **2020**,

484 Table_1.doc. **2020**,

483 Table_2.doc. **2020**,

482 Table_1.DOCX. **2020**,

481 Image_1.JPEG. **2019**,

480 Image_2.JPEG. **2019**,

479 Image_3.JPEG. **2019**,

478 Image_4.JPEG. **2019**,

477 Image_5.JPEG. **2019**,

476 Image_6.JPEG. **2019**,

475 Table_1.XLSX. **2019**,

474 Table_2.XLSX. **2019**,

473 Image_1.TIF. **2020**,

472 Image_2.TIF. **2020**,

471 Image_3.TIF. **2020**,

470 Image_4.TIF. **2020**,

469 Image_5.TIF. **2020**,

468 Image_6.TIF. **2020**,

467 Table_1.docx. **2020**,

466 Table_2.docx. **2020**,

465 Data_Sheet_1.PDF. **2020**,

| | | |
|---|---|---|
| 464 | Image_1.TIF. **2019**, | |
| 463 | Table_1.XLS. **2019**, | |
| 462 | Data_Sheet_1.docx. **2019**, | |
| 461 | Image_1.TIFF. **2018**, | |
| 460 | Image_2.TIFF. **2018**, | |
| 459 | Table_1.DOCX. **2018**, | |
| 458 | Table_1.XLSX. **2019**, | |
| 457 | Chemerin enhances mesenchymal features of glioblastoma by establishing autocrine and paracrine networks in a CMKLR1-dependent manner.. **2022**, | 0 |
| 456 | CBX3 accelerates the malignant progression of glioblastoma multiforme by stabilizing EGFR expression.. **2022**, | 2 |
| 455 | Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival.. **2022**, 13, 2236 | 0 |
| 454 | Resistance to PI3□nhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.. **2022**, | 0 |
| 453 | A2B5 Expression in Central Nervous System and Gliomas.. **2022**, 23, | 0 |
| 452 | EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a non-canonical regulatory axis between EGFR and wild-type p53 in glioblastoma.. **2022**, | |
| 451 | A Weakly Supervised Clustering Method for Cancer Subgroup Identification. **2022**, 10, 178-186 | |
| 450 | Integrated regulation of chondrogenic differentiation in mesenchymal stem cells and differentiation of cancer cells.. **2022**, 22, 169 | 1 |
| 449 | Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates.. **2022**, 13, 832742 | |
| 448 | A Novel Risk Score Model Based on Eleven Extracellular Matrix-Related Genes for Predicting Overall Survival of Glioma Patients.. **2022**, 2022, 4966820 | 0 |
| 447 | Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.. **2022**, 15, 437-468 | 1 |

| | | |
|---|---|---|
| 446 | lncRNA PRADX is a Mesenchymal Glioblastoma Biomarker for Cellular Metabolism Targeted Therapy.. **2022**, 12, 888922 | 0 |
| 445 | DNA methylation as a diagnostic tool.. **2022**, 10, 71 | 1 |
| 444 | MEOX2 Regulates the Growth and Survival of Glioblastoma Stem Cells by Modulating Genes of the Glycolytic Pathway and Response to Hypoxia.. **2022**, 14, | 0 |
| 443 | Molecular Tumor Board Case Report: IDH-mutant Astrocytoma with EGFR Amplification Genomic Profiling in Four Cases and Review of Literature. | |
| 442 | Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study.. **2022**, | 3 |
| 441 | Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.. **2022**, | 0 |
| 440 | Rho family GTPase 1 (RND1), a novel regulator of p53, enhances ferroptosis in glioblastoma.. **2022**, 12, 53 | 1 |
| 439 | Leveraging the neurosurgical operating room for therapeutic development in NeuroOncology.. **2022**, 186, 114337 | 0 |
| 438 | ASC proneural factors are necessary for chromatin remodeling during neuroectodermal to neuroblast fate transition to ensure the timely initiation of the neural stem cell program.. **2022**, 20, 107 | |
| 437 | Multi-Omics Analysis of Glioblastoma and Glioblastoma Cell Line: Molecular Insights Into the Functional Role of GPR56 and TG2 in Mesenchymal Transition. **2022**, 12, | |
| 436 | Nuclear medicine and radiotherapy in the clinical management of glioblastoma patients. 1 | 0 |
| 435 | Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.. **2022**, 20, 146 | 1 |
| 434 | Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?. **2022**, 13, | 3 |
| 433 | Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma.. **2022**, 30, 100801 | 1 |
| 432 | Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.. **2022**, | 1 |
| 431 | Therapy-induced shaping of the glioblastoma microenvironment: Macrophages at play.. **2022**, | 1 |
| 430 | CD133-Functionalized Gold Nanoparticles as a Carrier Platform for Telaglenastat (CB-839) against Tumor Stem Cells. **2022**, 23, 5479 | 4 |
| 429 | Brain and Spinal Cord Tumors. **2022**, 133-149 | |

| | | |
|---|---|---|
| 428 | Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?. **2022**, 14, 2416 | 4 |
| 427 | Chromatin structure predicts survival in glioma patients.. **2022**, 12, 8221 | |
| 426 | Intra-tumoral angiogenesis correlates with immune features and prognosis in glioma.. **2022**, 14, | |
| 425 | Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma. | 0 |
| 424 | Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma. **2022**, 12, | |
| 423 | Investigating the Interactions of Glioma Stem Cells in the Perivascular Niche at Single-Cell Resolution using a Microfluidic Tumor Microenvironment Model. 2201436 | 0 |
| 422 | Glioblastoma Cell invasiveness and epithelial-to-mesenchymal Transitioning are modulated by kinin receptors. **2022**, 100045 | |
| 421 | Updates in IDH-Wildtype Glioblastoma. | 1 |
| 420 | Modeling Brain Tumors: A Perspective Overview of in vivo and Organoid Models. **2022**, 15, | 1 |
| 419 | Glioma progression is shaped by genetic evolution and microenvironment interactions. **2022**, | 4 |
| 418 | Mapping the tumor-infiltrating immune cells during glioblastoma progression. | 0 |
| 417 | Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidenephthalide in a Recurrent GBM. **2022**, 2022, 1-14 | 0 |
| 416 | Single-Cell Transcriptomics Revealed Subtype-Specific Tumor Immune Microenvironments in Human Glioblastomas. **2022**, 13, | 0 |
| 415 | A novel DNA damage and repair-related gene signature to improve predictive capacity of overall survival for patients with gliomas. | 0 |
| 414 | Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma. **2022**, 12, | 0 |
| 413 | Multiomics Data Analysis and Identification of Immune-Related Prognostic Signatures With Potential Implications in Prognosis and Immune Checkpoint Blockade Therapy of Glioblastoma. **2022**, 13, | 0 |
| 412 | Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. **2022**, | 0 |
| 411 | Integrated Multi-Omics Maps of Lower-Grade Gliomas. **2022**, 14, 2797 | 1 |

| | | | |
|---|---|---|---|
| 410 | The sex-dependent role of the androgen receptor in glioblastoma: results of molecular analyses. | | 0 |
| 409 | PDGF signaling inhibits mitophagy in glioblastoma stem cells through N-methyladenosine. **2022**, | | 2 |
| 408 | Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. | | 0 |
| 407 | Construction of m6A-Related lncRNA Prognostic Signature Model and Immunomodulatory Effect in Glioblastoma Multiforme. 12, | | 0 |
| 406 | LAT1, a novel pharmacological target for the treatment of glioblastoma. **2022**, 201, 115103 | | 0 |
| 405 | Functions of long non-coding RNA ROR in patient-derived glioblastoma cells. **2022**, 200, 131-139 | | 1 |
| 404 | Editorial. Supramaximal resection of eloquent glioblastoma: a continued paradigm shift in neurosurgical oncology. **2022**, 1-3 | | |
| 403 | NADPH oxidase promotes glioblastoma radiation resistance in a PTEN-dependent manner. | | |
| 402 | Leveraging the CSF proteome toward minimally-invasive diagnostics and biological characterization of brain malignancies. | | |
| 401 | Spatial heterogeneity in DNA methylation and chromosomal alterations in diffuse gliomas and meningiomas. | | 0 |
| 400 | Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. *Cancer Cell*, **2022**, 40, 639-655.e13 | 24.3 | 4 |
| 399 | Targeting Acid Ceramidase Inhibits Glioblastoma Cell Migration through Decreased AKT Signaling. **2022**, 11, 1873 | | 1 |
| 398 | Ferroptosis-Associated Molecular Features to Aid Patient Clinical Prognosis and Therapy Across Human Cancers. 13, | | |
| 397 | Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression. **2022**, 13, | | 0 |
| 396 | Altered cytoskeletal status in the transition from proneural to mesenchymal glioblastoma subtypes. **2022**, 12, | | 1 |
| 395 | Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity. | | 1 |
| 394 | Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma. | | |
| 393 | Characterization of gene cluster heterogeneity in single-cell transcriptomic data within and across cancer types. **2022**, 11, | | 0 |

| | | |
|---|---|---|
| 392 | KDELR1 Is an Independent Prognostic Predictor and Correlates With Immunity in Glioma. 12, | 0 |
| 391 | Pharmacological targets for the induction of ferroptosis: Focus on Neuroblastoma and Glioblastoma. 12, | 0 |
| 390 | A hierarchical spike-and-slab model for pan-cancer survival using pan-omic data. **2022**, 23, | |
| 389 | Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils. 13, | 0 |
| 388 | Iron commensalism of mesenchymal glioblastoma promotes ferroptosis susceptibility upon dopamine treatment. **2022**, 5, | 0 |
| 387 | Prognostic Value and Biological Function of Galectins in Malignant Glioma. 12, | 0 |
| 386 | Immune landscape of a genetically engineered murine model of glioma compared with human glioma. **2022**, 7, | 0 |
| 385 | Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib. | 1 |
| 384 | Metabolomic profiles of human glioma inform patient survival. | |
| 383 | Integrative multi-omics approach to targeted therapy for glioblastoma. **2022**, 182, 106308 | 2 |
| 382 | TumorHost Interactions in Malignant Gliomas. **2022**, 509-518 | |
| 381 | Genomic Landscape and Immunological Profile of Glioblastoma in East Asians. | |
| 380 | Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis. **2022**, 21, 153303382211096 | 0 |
| 379 | i-Modern: Integrated multi-omics network model identifies potential therapeutic targets in glioma by deep learning with interpretability. **2022**, 20, 3511-3521 | 2 |
| 378 | A Comprehensive Clinical Review of Adult-Type Diffuse Glioma Incorporating the 2021 World Health Organization Classification. **2022**, 12, 43-70 | |
| 377 | Biclustering reveals potential knee OA phenotypes in exploratory analyses: Data from the Osteoarthritis Initiative. **2022**, 17, e0266964 | 0 |
| 376 | Glioblastoma, from disease understanding towards optimal cell-based in vitro models. | 1 |
| 375 | Next-Generation Grade and Survival Expression Biomarkers of Human Gliomas Based on Algorithmically Reconstructed Molecular Pathways. **2022**, 23, 7330 | 1 |

| | | |
|---|---|---|
| 374 | A Targeted Next-Generation Sequencing Panel to Genotype Gliomas. **2022**, 12, 956 | 1 |
| 373 | S100A10 Is a New Prognostic Biomarker Related to the Malignant Molecular Features and Immunosuppression Process of Adult Gliomas. **2022**, | |
| 372 | Differential migration mechanics and immune responses of glioblastoma subtypes. | |
| 371 | Prostate Apoptosis Response-4 (Par-4): A Novel Target in Pyronaridine-Induced Apoptosis in Glioblastoma (GBM) Cells. **2022**, 14, 3198 | 0 |
| 370 | Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. **2022**, 15, | 2 |
| 369 | Quinolinate Promotes Immune Tolerance through Macrophage Polarization in Glioblastoma. | |
| 368 | Multiomics technologies: role in disease biomarker discoveries and therapeutics. | |
| 367 | Interrogating glioma-M2 macrophage interactions identifies Gal-9/Tim-3 as a viable target against PTEN -null glioblastoma. **2022**, 8, | 0 |
| 366 | Ribosomes and Ribosomal Proteins Promote Plasticity and Stemness Induction in Glioma Cells via Reprogramming. **2022**, 11, 2142 | |
| 365 | Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions. | 0 |
| 364 | The Interaction between DNMT1 and High-Mannose CD133 Maintains the Slow-Cycling State and Tumorigenic Potential of Glioma Stem Cell. 2202216 | 0 |
| 363 | Interferon-□resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells. **2022**, | 0 |
| 362 | Identification of growth hormone receptor as a relevant target for precision medicine in low-EGFR expressing glioblastoma. **2022**, 12, | 0 |
| 361 | Immune surveillance in glioblastoma: Role of the NKG2D system and novel cell-based therapeutic approaches. | 0 |
| 360 | Optimization of synthetic molecular reporters for a mesenchymal glioblastoma transcriptional program by integer programming. | 0 |
| 359 | Applications of single-cell multi-omics sequencing in deep understanding of brain diseases. **2022**, 2, | |
| 358 | Targeting Glioblastoma through Nano- and Micro-particle-Mediated Immune Modulation. **2022**, 116913 | 1 |
| 357 | PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBP□degradation to facilitate proneural-to-mesenchymal transition. **2022**, 41, | 2 |

| | | |
|---|---|---|
| 356 | JUN activation modulates chromatin accessibility to drive TNF□induced mesenchymal transition in glioblastoma. | |
| 355 | Identification of a Five-mRNA Signature as a Novel Potential Prognostic Biomarker for Glioblastoma by Integrative Analysis. 13, | |
| 354 | Using AI-Based Evolutionary Algorithms to Elucidate Adult Brain Tumor (Glioma) Etiology Associated with IDH1 for Therapeutic Target Identification. **2022**, 44, 2982-3000 | 1 |
| 353 | P-Rex1 Signaling Hub in Lower Grade Glioma Patients, Found by In Silico Data Mining, Correlates With Reduced Survival and Augmented Immune Tumor Microenvironment. 12, | 0 |
| 352 | Pro-inflammatory cytokines mediate the epithelial-to-mesenchymal-like transition of pediatric posterior fossa ependymoma. **2022**, 13, | 0 |
| 351 | Metabolic Rewiring in Glioblastoma Cancer: EGFR, IDH and Beyond. 12, | 1 |
| 350 | Low expression and Hypermethylation of ATP2B1 in Intrahepatic Cholangiocarcinoma Correlated With Cold Tumor Microenvironment. 12, | 1 |
| 349 | Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47□combination therapy against glioblastoma. **2022**, | 7 |
| 348 | Pyruvate carboxylation identifies Glioblastoma Stem-like Cells opening new metabolic strategy to prevent tumor recurrence. | |
| 347 | Antitumor Effects of Ral-GTPases Downregulation in Glioblastoma. **2022**, 23, 8199 | 0 |
| 346 | Consensus clustering for Bayesian mixture models. **2022**, 23, | 1 |
| 345 | A brain precursor atlas reveals the acquisition of developmental-like states in adult cerebral tumours. **2022**, 13, | 0 |
| 344 | An in vivo model of glioblastoma radiation resistance identifies long non-coding RNAs and targetable kinases. | 1 |
| 343 | Identification of Prognostic Genes in Gliomas Based on Increased Microenvironment Stiffness. **2022**, 14, 3659 | 1 |
| 342 | Genes of the Ubiquitin Proteasome System Qualify as Differential Markers in Malignant Glioma of Astrocytic and Oligodendroglial Origin. | 0 |
| 341 | Coagulation Proteases and Neurotransmitters in Pathogenicity of Glioblastoma multiforme. 1-17 | |
| 340 | Sprouty 1 is associated with stemness and cancer progression in glioblastoma. **2022**, 13, 120-126 | |
| 339 | Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy. **2022**, 14, 3743 | 1 |

| | | |
|---|---|---|
| 338 | Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma. **2022**, 14, 3705 | 2 |
| 337 | Pan-cancer integrative analysis of whole-genome De novo somatic point mutations reveals 17 cancer types. **2022**, 23, | |
| 336 | ELF4 is a critical component of a miRNA-transcription factor network and is a bridge regulator of glioblastoma receptor signaling and lipid dynamics. | |
| 335 | A Quantitative Digital Analysis of Tissue Immune Components Reveals an Immunosuppressive and Anergic Immune Response with Relevant Prognostic Significance in Glioblastoma. **2022**, 10, 1753 | 0 |
| 334 | CDH6 as a prognostic indicator and marker for chemotherapy in gliomas. 13, | |
| 333 | The novel compensatory reciprocal interplay between neutrophils and monocytes drives cancer progression. | |
| 332 | Looking Beyond the Glioblastoma Mask: Is Genomics the Right Path?. 12, | 0 |
| 331 | Basic premises: searching for new targets and strategies in diffuse gliomas. | 0 |
| 330 | Comprehensive analysis of the transcription factor REST regulatory networks in IDH-mutant and IDH-wild type glioma. | |
| 329 | Molecular mechanisms of drug resistance of glial tumor of brain. Part 2: Proliferation, angiogenesis, metastasis and recurrency. **2022**, 22, 89-117 | |
| 328 | GPCR genes as a predictor of glioma severity and clinical outcome. **2022**, 50, 030006052211139 | 0 |
| 327 | Pathogenesis and Therapeutic Targets of Focal Cortical Dysplasia Based on Bioinformatics Analysis. | |
| 326 | Reduced Graphene Oxide Modulates the FAK-Dependent Signaling Pathway in Glioblastoma Multiforme Cells In Vitro. **2022**, 15, 5843 | |
| 325 | HepaCAM Suppresses Glioblastoma Stem Cell Invasion in the Brain. | |
| 324 | Supervised pretraining through contrastive categorical positive samplings to improve COVID-19 mortality prediction. **2022**, | 1 |
| 323 | IGFBPs were associated with stemness, inflammation, extracellular matrix remodeling and poor prognosis of low-grade glioma. 13, | 0 |
| 322 | Integrating cell cycle score for precise risk stratification in ovarian cancer. 13, | |
| 321 | Chromobox 7/8 serve as independent indicators for glioblastoma via promoting proliferation and invasion of glioma cells. 13, | 1 |

| | | |
|---|---|---|
| 320 | Anti-Migratory Effect of Dipotassium Glycyrrhizinate on Glioblastoma Cell Lines: Microarray Data for the Identification of Key MicroRNA Signatures. 12, | |
| 319 | Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?. **2022**, 23, 8637 | 1 |
| 318 | SUPREME: A cancer subtype prediction methodology integrating multiomics data using Graph Convolutional Neural Network. | 0 |
| 317 | Improvements in Quality Control and Library Preparation for Targeted Sequencing Allowed Detection of Potentially Pathogenic Alterations in Circulating Cell-Free DNA Derived from Plasma of Brain Tumor Patients. **2022**, 14, 3902 | |
| 316 | PLVAP is associated with glioma-associated malignant processes and immunosuppressive cell infiltration as a promising marker for prognosis. **2022**, 8, e10298 | 0 |
| 315 | Immune Microenvironment and Lineage Tracing Help to Decipher Rosette-Forming Glioneuronal Tumors. **2022**, Publish Ahead of Print, | |
| 314 | Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies. 13, | 1 |
| 313 | In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. **2022**, 12, | |
| 312 | Simplex cerebral cavernous malformations with MAP3K3 mutation have distinct clinical characteristics. 13, | 0 |
| 311 | Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. 1-24 | 1 |
| 310 | EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation. **2022**, 24, 1291-1305 | 0 |
| 309 | Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma. **2022**, 11, 2530 | 0 |
| 308 | P2Y12 receptor antagonism inhibits proliferation, migration and leads to autophagy of glioblastoma cells. | |
| 307 | Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment : integrated computational analysis and in vitro study. **2022**, 12, | |
| 306 | USP21 promotes self-renewal and tumorigenicity of mesenchymal glioblastoma stem cells by deubiquitinating and stabilizing FOXD1. **2022**, 13, | |
| 305 | CD93 is Associated with Glioma-related Malignant Processes and Immunosuppressive Cell Infiltration as an Inspiring Biomarker of Survivance. | 1 |
| 304 | The multifaceted mechanisms of malignant glioblastoma progression and clinical implications. | 0 |
| 303 | Characterization and comparison of human glioblastoma models. **2022**, 22, | 0 |

| | | |
|---|---|---|
| 302 | A SOX2-engineered epigenetic silencer factor represses the glioblastoma genetic program and restrains tumor development. **2022**, 8, | 1 |
| 301 | Identification of a Hypoxia-Angiogenesis lncRNA Signature Participating in Immunosuppression in Gastric Cancer. **2022**, 2022, 1-24 | |
| 300 | Studies on Biological and Molecular Effects of Small-Molecule Kinase Inhibitors on Human Glioblastoma Cells and Organotypic Brain Slices. **2022**, 12, 1258 | 0 |
| 299 | Emerging immune-based technologies for high-grade gliomas. 1-24 | |
| 298 | Image-based deep learning identifies glioblastoma risk groups with genomic and transcriptomic heterogeneity: a multi-center study. | |
| 297 | PTEN inhibits AMPK to control collective migration. **2022**, 13, | 0 |
| 296 | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | 0 |
| 295 | Complex heatmap visualization. **2022**, 1, | 5 |
| 294 | Translational Significance of CDKN2A/B Homozygous Deletion in IDH-Mutant Astrocytoma. | |
| 293 | Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review. | 0 |
| 292 | Non-negative matrix factorization model-based construction for molecular clustering and prognostic assessment of head and neck squamous carcinoma. **2022**, 8, e10100 | |
| 291 | SLFN11 negatively regulates non-canonical NF-kB signaling to promote glioblastoma progression. | |
| 290 | FMRP modulates the Wnt signalling pathway in glioblastoma. **2022**, 13, | 2 |
| 289 | Characterization of aging cancer-associated fibroblasts draws implications in prognosis and immunotherapy response in low-grade gliomas. 13, | 0 |
| 288 | A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma. | 1 |
| 287 | Pathway-based approach reveals differential sensitivity to E2F1 inhibition in glioblastoma. | |
| 286 | Pervasive conditional selection of driver mutations and modular epistasis networks in cancer. **2022**, 40, 111272 | 0 |
| 285 | Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma. 12, | 1 |

| | | |
|---|---|---|
| 284 | PDPN marks a subset of aggressive and radiation-resistant glioblastoma cells. 12, | |
| 283 | Diallyl trisulfide sensitizes radiation therapy on glioblastoma through directly targeting thioredoxin 1. **2022**, 189, 157-168 | |
| 282 | A Cuproptosis Activation Scoring model predicts neoplasm-immunity interactions and personalized treatments in glioma. **2022**, 148, 105924 | 2 |
| 281 | Natural coevolution of tumor and immunoenvironment in glioblastoma. | 1 |
| 280 | Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM. **2022**, 83, 104239 | 0 |
| 279 | Epigenetic Suppression of the IL-7 Pathway in Progressive Glioblastoma. **2022**, 10, 2174 | 0 |
| 278 | Gene interaction perturbation network deciphers a high-resolution taxonomy in colorectal cancer. | 0 |
| 277 | Exploring glioblastoma stem cell heterogeneity: Immune microenvironment modulation and therapeutic opportunities. 12, | 1 |
| 276 | Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy. **2022**, 7, 100566 | 0 |
| 275 | The role of mixed lineage kinase 3 (MLK3) in cancers. **2022**, 238, 108269 | 0 |
| 274 | Inhibition of the pseudokinase MLKL alters extracellular vesicle release and reduces tumor growth in glioblastoma. **2022**, 25, 105118 | 0 |
| 273 | Integration of differential expression and network structure for □mics data analysis. **2022**, 150, 106133 | 0 |
| 272 | MCluster-VAEs: An end-to-end variational deep learning-based clustering method for subtype discovery using multi-omics data. **2022**, 150, 106085 | 1 |
| 271 | Aberrant Protein Glycosylation in Brain Cancers, with Emphasis on Glioblastoma. **2022**, 39-70 | 0 |
| 270 | Horizontal Integration: Disease □Cancer Systems Biology. **2022**, | 0 |
| 269 | Survival analysis for the identified cancer gene subtype from the co-clustering algorithm. **2022**, | 0 |
| 268 | Modeling nervous system tumors with human stem cells and organoids. | 0 |
| 267 | Exploring the multidimensional heterogeneities of glioblastoma multiforme based on sample-specific edge perturbation in gene interaction network. 13, | 0 |

| | | |
|---|---|---|
| 266 | Regulation of Signaling from the Epidermal Growth Factor Family. | 0 |
| 265 | The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma. 13, | 3 |
| 264 | Advances in nano-based materials for glioblastoma multiforme diagnosis: A mini-review. 4, | 0 |
| 263 | Co-amplified with PDGFRA , IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma. | 0 |
| 262 | Regulation of Signaling from the Epidermal Growth Factor Family. **2022**, 126, 7475-7485 | 0 |
| 261 | Elucidating the diversity of malignant mesenchymal states in glioblastoma by integrative analysis. **2022**, 14, | 0 |
| 260 | Identification of immune and stromal cell infiltration-related gene signature for prognosis prediction in acute lymphoblastic leukemia. **2022**, 14, 7470-7504 | 0 |
| 259 | Angiocrine extracellular vesicles impose mesenchymal reprogramming upon proneural glioma stem cells. **2022**, 13, | 1 |
| 258 | ZEB1 loss increases glioma stem cell tumorigenicity and resistance to chemoradiation. **2022**, 1-12 | 0 |
| 257 | Exploring the role of Nrf2 signaling in glioblastoma multiforme. **2022**, 13, | 1 |
| 256 | Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF- signaling in recurrent tumors. | 0 |
| 255 | GBM tumors are heterogeneous in their fatty acid metabolism and modulating fatty acid metabolism sensitizes cancer cells derived from recurring GBM tumors to temozolomide. 12, | 0 |
| 254 | Curcumin-based-fluorescent probes targeting ALDH1A3 as a promising tool for glioblastoma precision surgery and early diagnosis. **2022**, 5, | 0 |
| 253 | Integrated genomic, transcriptomic, and epigenetic analyses identify a leukotriene synthesis-related M2 macrophage gene signature that predicts prognosis and treatment vulnerability in gliomas. 13, | 0 |
| 252 | Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers. **2022**, 2022, 1-16 | 0 |
| 251 | Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma. | 2 |
| 250 | Mechanosensitive expression of the mesenchymal subtype marker connective tissue growth factor in glioblastoma. **2022**, 12, | 0 |
| 249 | The impediments of cancer stem cells and an exploration into the nanomedical solutions for glioblastoma. **2022**, 22, | 0 |

| | | |
|---|---|---|
| 248 | Genetic alterations shaping tumor response to anti-EGFR therapies. **2022**, 64, 100863 | 0 |
| 247 | Patient derived glioma stem cell spheroid reporter assays for live cell high content analysis. **2022**, | 0 |
| 246 | Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. **2022**, 10, 1448 | 0 |
| 245 | EGFR, the Lazarus target for precision oncology in glioblastoma. | 1 |
| 244 | Neuropilin-1 modulates the 3D invasive properties of glioblastoma stem-like cells. 10, | 0 |
| 243 | An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment. | 1 |
| 242 | Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation. | 0 |
| 241 | Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma. 13, | 0 |
| 240 | Microglia cell conversations in brain cancer progression. **2022**, | 0 |
| 239 | Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy. 16, | 0 |
| 238 | Modeling tissue-specific breakpoint proximity of structural variations from whole-genomes to identify cancer drivers. **2022**, 13, | 0 |
| 237 | Polymer Nanocarriers for Targeted Local Delivery of Agents in Treating Brain Tumors. | 0 |
| 236 | On optimal temozolomide scheduling for slowly growing glioblastomas. | 0 |
| 235 | Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges. | 1 |
| 234 | Injury programs shape glioblastoma. **2022**, | 0 |
| 233 | Rewired Metabolism of Amino Acids and Its Roles in Glioma Pathology. **2022**, 12, 918 | 1 |
| 232 | Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods. | 0 |
| 231 | Integrative genomic analysis facilitates precision strategies for glioblastoma treatment. **2022**, 105276 | 0 |

| | | |
|---|---|---|
| 230 | WNT signaling at the intersection between neurogenesis and brain tumorigenesis. 15, | 0 |
| 229 | Differential role of Pax6 and its interaction with Shh□Gli1□DH2 axis in regulation of glioma growth and chemoresistance. | 0 |
| 228 | Leveraging the CSF proteome toward minimally-invasive diagnostics surveillance of brain malignancies. | 0 |
| 227 | Curcumin Enhanced Ionizing Radiation-Induced Immunogenic Cell Death in Glioma Cells through Endoplasmic Reticulum Stress Signaling Pathways. **2022**, 2022, 1-17 | 0 |
| 226 | Fast and interpretable consensus clustering via minipatch learning. **2022**, 18, e1010577 | 0 |
| 225 | Niche deconvolution of the glioblastoma proteome reveals a distinct infiltrative phenotype within the proneural transcriptomic subgroup. **2022**, 9, | 0 |
| 224 | H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes. **2022**, 11, 3376 | 0 |
| 223 | Integration of single-cell RNA sequencing and spatial transcriptomics to reveal the glioblastoma heterogeneity. 11, 1180 | 0 |
| 222 | Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. | 0 |
| 221 | CXCR4 expression is associated with proneural-to-mesenchymal transition in glioblastoma. | 0 |
| 220 | Pre-operative MRI radiomics model non-invasively predicts key genomic markers and survival in glioblastoma patients. **2022**, 160, 253-263 | 0 |
| 219 | MicroRNA and mRNA Expression Changes in Glioblastoma Cells Cultivated under Conditions of Neurosphere Formation. **2022**, 44, 5294-5311 | 0 |
| 218 | Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma. **2022**, 12, 1426 | 0 |
| 217 | Heterogeneity of glioblastoma stem cells in the context of the immune microenvironment and geospatial organization. 12, | 0 |
| 216 | Emerging trends and research foci of epithelial□mesenchymal transition in gliomas: A scientometric analysis and review. 12, | 0 |
| 215 | New insights into the Immune TME of adult-type diffuse gliomas. Publish Ahead of Print, | 0 |
| 214 | P300 promotes tumor recurrence by regulating radiation-induced conversion of glioma stem cells to vascular-like cells. **2022**, 13, | 0 |
| 213 | Roles of Chromatin Remodelling and Molecular Heterogeneity in Therapy Resistance in Glioblastoma. **2022**, 14, 4942 | 0 |

| | | |
|---|---|---|
| 212 | Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy. **2022**, 11, 5961 | 0 |
| 211 | A novel brain penetrant PDGFR□nhibitor HY-008 is effective against glioblastoma. | 0 |
| 210 | Identification of potential driver mutations in glioblastoma using machine learning. | 0 |
| 209 | The translatome of Glioblastoma multiforme. | 0 |
| 208 | Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma. | 0 |
| 207 | Mass spectrometry imaging discriminates glioblastoma tumor cell subpopulations and different microvascular formations based on their lipid profiles. **2022**, 12, | 0 |
| 206 | Preservation of the Hypoxic Transcriptome in Glioblastoma Patient-Derived Cell Lines Maintained at Lowered Oxygen Tension. **2022**, 14, 4852 | 0 |
| 205 | Exploiting Radiation Immunostimulatory Effects To Improve Glioblastoma Outcome. | 0 |
| 204 | Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors. **2022**, 14, 5108 | 3 |
| 203 | A molecular interactome of the glioblastoma perivascular niche reveals integrin binding sialoprotein as a mediator of tumor cell migration. **2022**, 41, 111511 | 0 |
| 202 | Metabolic Heterogeneity of Brain Tumor Cells of Proneural and Mesenchymal Origin. **2022**, 23, 11629 | 1 |
| 201 | Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas. 13, | 0 |
| 200 | Childhood Obesity: A Potential Key Factor in the Development of Glioblastoma Multiforme. **2022**, 12, 1673 | 3 |
| 199 | The Significance of MGMT Promoter Methylation Status in Diffuse Glioma. **2022**, 23, 13034 | 1 |
| 198 | Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma. | 0 |
| 197 | A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance. | 0 |
| 196 | Medical Device Advances in the Treatment of Glioblastoma. **2022**, 14, 5341 | 1 |
| 195 | Feedforward loop between IMP1 and YAP / TAZ promotes tumorigenesis and malignant progression in glioblastoma. | 0 |

| | | |
|---|---|---|
| 194 | The peritumoral brain zone in glioblastoma: where we are and where we are going. | 1 |
| 193 | Transcriptome Analysis Identifies Accumulation of Natural Killer Cells with Enhanced Lymphotoxin-Expression during Glioblastoma Progression. **2022**, 14, 4915 | 0 |
| 192 | Dual EGFR- and TfR-targeted Gene Transfer Improves Efficacy of Sodium Iodide Symporter (NIS) Gene Therapy of Glioblastoma. **2022**, | 0 |
| 191 | Genetic Inactivation of Notch1 Synergizes with Loss of Trp53 to Induce Tumor Formation in the Adult Mouse Forebrain. **2022**, 14, 5409 | 0 |
| 190 | Functional analysis of the short splicing variant encoded by CHI3L1/YKL-40 in glioblastoma. 12, | 0 |
| 189 | Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma. **2022**, 14, 5386 | 0 |
| 188 | Bioinformatic Analysis of Kynurenine Pathway Enzymes and Their Relationship with Glioma Hallmarks. **2022**, 12, 1054 | 1 |
| 187 | Ablation efficacy of 5-aminolevulinic acid-mediated photodynamic therapy on human glioma stem cells. **2022**, 103119 | 0 |
| 186 | Multi-regional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos. | 0 |
| 185 | AI in Translational Bioinformatics and Precision Medicine. **2022**, 391-429 | 0 |
| 184 | Influence of measurement mode on the results of glioblastoma multiforme analysis with the FTIR microspectroscopy. **2022**, 122086 | 0 |
| 183 | Repurposing clemastine to target glioblastoma cell stemness. | 0 |
| 182 | Two independent variants of epidermal growth factor receptor associated with risk of glioma in a Korean population. **2022**, 12, | 0 |
| 181 | A large-scale targeted proteomics of plasma extracellular vesicles shows utility for prognosis prediction subtyping in colorectal cancer. | 0 |
| 180 | Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation. **2022**, 10, | 1 |
| 179 | Logical design of synthetic cis-regulatory DNA for genetic tracing of cell identities and state changes. | 0 |
| 178 | ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells. **2022**, 41, | 0 |
| 177 | LncRNA as potential biomarker and therapeutic target in glioma. | 0 |

| | | |
|---|---|---|
| 176 | Hybrid Gorilla Troops Optimizer-Based NMF Algorithm for Integrative Data Analysis. **2023**, 433-443 | 0 |
| 175 | Flap-enabled next-generation capture (FENGC): precision targeted single-molecule profiling of epigenetic heterogeneity, chromatin dynamics, and genetic variation. | 0 |
| 174 | Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival. **2022**, 13, | 2 |
| 173 | circSMARCA5 Is an Upstream Regulator of the Expression of miR-126-3p, miR-515-5p, and Their mRNA Targets, Insulin-like Growth Factor Binding Protein 2 (IGFBP2) and NRAS Proto-Oncogene, GTPase (NRAS) in Glioblastoma. **2022**, 23, 13676 | 0 |
| 172 | Dual inhibition of CPT1A and G6PD suppresses glioblastoma tumorspheres. | 0 |
| 171 | Image-localized Biopsy Mapping of Brain Tumor Heterogeneity: A Single-Center Study Protocol. | 0 |
| 170 | RAGE Ablation Attenuates Glioma Progression and Enhances Tumor Immune Responses by Suppressing Galectin-3 Expression. | 0 |
| 169 | Rewiring of the promoter-enhancer interactome and regulatory landscape in glioblastoma orchestrates gene expression underlying neurogliomal synaptic communication. | 0 |
| 168 | Glioma Stem Cells: Novel Data Obtained by Single-Cell Sequencing. **2022**, 23, 14224 | 0 |
| 167 | Immunotherapeutic Strategies for Glioma Treatment. **2022**, | 0 |
| 166 | Cancer immune profiling unveils biomarkers, immunological pathways, and cell type score associated with glioblastoma patients survival. **2022**, 14, 175883592211276 | 0 |
| 165 | Enhanced Factor Based Whale Optimization Algorithm with Improved Weight Based Long Short-Term Memory for Cancer Subtypes Diagnosis. **2022**, | 0 |
| 164 | Irigenin inhibits glioblastoma progression through suppressing YAP/ catenin signaling. 13, | 1 |
| 163 | ONX-0914 Induces Apoptosis and Autophagy with p53 Regulation in Human Glioblastoma Cells. **2022**, 14, 5712 | 0 |
| 162 | Multi-view spectral clustering with latent representation learning for applications on multi-omics cancer subtyping. | 1 |
| 161 | Neuronal and tumourigenic boundaries of glioblastoma plasticity. **2022**, | 1 |
| 160 | ZBTB18 inhibits SREBP-dependent lipid synthesis by halting CTBPs and LSD1 activity in glioblastoma. **2023**, 6, e202201400 | 1 |
| 159 | Cost Matrix of Molecular Pathology in Glioma owards AI-Driven Rational Molecular Testing and Precision Care for the Future. **2022**, 10, 3029 | 0 |

| | | |
|---|---|---|
| 158 | Epithelioid glioblastoma exhibits a heterogeneous molecular feature: A targeted next-generation sequencing study. 12, | 0 |
| 157 | Methylation Profiling in Diffuse Gliomas: Diagnostic Value and Considerations. **2022**, 14, 5679 | 0 |
| 156 | ToMExO: A probabilistic tree-structured model for cancer progression. **2022**, 18, e1010732 | 0 |
| 155 | Caspase-8 as a novel mediator linking Src kinase signaling to enhanced glioblastoma malignancy. | 0 |
| 154 | Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology. **2022**, 10, 3205 | 1 |
| 153 | Differential response of patient-derived primary glioblastoma cells to metabolic and adhesion inhibitors. | 0 |
| 152 | The Radiogenomic and Spatiogenomic Landscapes of Glioblastoma, and their Relationship to Oncogenic Drivers. | 0 |
| 151 | The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. **2022**, 54, 1881-1894 | 0 |
| 150 | Molecular targeted therapy: A new avenue in glioblastoma treatment (Review). **2022**, 25, | 0 |
| 149 | PLK4 initiates crosstalk between cell cycle, cell proliferation and macrophages infiltration in gliomas. 12, | 0 |
| 148 | ET1 Peptide Sensitizes Glioma Cells to Temozolomide in a Glioblastoma Organoid Platform. | 0 |
| 147 | Stromal protein CCN family contributes to the poor prognosis in lower-grade gioma by modulating immunity, matrix, stemness, and metabolism. 9, | 0 |
| 146 | Immune landscape-based machine-learning-assisted subclassification, prognosis, and immunotherapy prediction for glioblastoma. 13, | 0 |
| 145 | Learning cell identity in immunology, neuroscience, and cancer. | 0 |
| 144 | Roadmap toward subtype-specific vulnerabilities in adult glioma. **2022**, 1, | 0 |
| 143 | Glioblastoma stem cells express non-canonical proteins and exclusive mesenchymal-like or non-mesenchymal-like protein signatures. | 0 |
| 142 | Reclassification of TCGA Diffuse Glioma Profiles Linked to Transcriptomic, Epigenetic, Genomic and Clinical Data, According to the 2021 WHO CNS Tumor Classification. **2023**, 24, 157 | 0 |
| 141 | Oncogene expression from extrachromosomal DNA is driven by copy number amplification and does not require spatial clustering in glioblastoma stem cells. 11, | 0 |

| | | |
|---|---|---|
| 140 | Glioblastoma Molecular Classification Tool Based on mRNA Analysis: From Wet-Lab to Subtype. **2022**, 23, 15875 | 0 |
| 139 | Federated learning enables big data for rare cancer boundary detection. **2022**, 13, | 1 |
| 138 | Modulation of Genes and MicroRNAs in the Neurospheres of Glioblastoma Cell Lines U343 and T98G Induced by Ionizing Radiation and Temozolomide Therapy. **2022**, | 0 |
| 137 | BI-907828, a novel potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. | 0 |
| 136 | Lipid droplets and ferroptosis as new players in brain cancer glioblastoma progression and therapeutic resistance. 12, | 0 |
| 135 | Microglia and Brain Macrophages as Drivers of Glioma Progression. **2022**, 23, 15612 | 0 |
| 134 | A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. **2022**, 3, 1534-1552 | 1 |
| 133 | Association of Graph-based Spatial Features with Overall Survival Status of Glioblastoma Patients. | 0 |
| 132 | BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network. | 0 |
| 131 | Decellularized Brain Extracellular Matrix Slice Glioblastoma Culture Model Recapitulates the Interaction Between Cells and the Extracellular Matrix Without a Nutrient-Oxygen Gradient Interference. **2022**, | 0 |
| 130 | PD-L1-related LncRNAs are Associated with Immune Microenvironment and Prognosis in Glioma. | 0 |
| 129 | Extracellular vesicles in the glioblastoma microenvironment: A diagnostic and therapeutic perspective. **2022**, 101167 | 0 |
| 128 | Mesenchymal Stem Cell-mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice. | 0 |
| 127 | The translatome of Glioblastoma multiforme. | 0 |
| 126 | Temporal and spatial stability of the EM/PM molecular subtypes in adult diffuse glioma. | 0 |
| 125 | The Role of Neuro-Inflammation and Innate Immunity in Pathophysiology of Brain and Spinal Cord Tumors. **2023**, 41-49 | 0 |
| 124 | Proteome-based insights for IDH-mutant glioma classification. **2023**, 4, 100909 | 0 |
| 123 | Signaling pathways in brain tumors and therapeutic interventions. **2023**, 8, | 0 |

| | | |
|---|---|---|
| 122 | Melanoma and Glioblastoma: Not a Serendipitous Association. Publish Ahead of Print, | 0 |
| 121 | Targeting fatty acid metabolism in glioblastoma. **2023**, 133, | 1 |
| 120 | Monocyte-neutrophil entanglement in glioblastoma. **2023**, 133, | 1 |
| 119 | SADLN: Self-attention based deep learning network of integrating multi-omics data for cancer subtype recognition. 13, | 0 |
| 118 | Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling. **2023**, 15, 460 | 0 |
| 117 | Olig1/2-expressing intermediate lineage progenitors are predisposed to PTEN/p53-loss-induced gliomagenesis and harbor specific therapeutic vulnerabilities. | 1 |
| 116 | Genetic evolution and cellular interactions within the tumour microenvironment determine glioblastoma progression. 12, 52 | 0 |
| 115 | Highly Multiplexed Spatially Resolved Proteomic and Transcriptional Profiling of the Glioblastoma Microenvironment Using Archived Formalin-Fixed Paraffin-Embedded Specimens. **2023**, 36, 100034 | 0 |
| 114 | Correlation between ITGB2 expression and clinical characterization of glioma and the prognostic significance of its methylation in low-grade glioma(LGG). 13, | 1 |
| 113 | CDC42: promising target of glioma treatment related to Treg cell proliferation. | 0 |
| 112 | Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. 12, | 0 |
| 111 | TREM2 is associated with tumor immunity and implies poor prognosis in glioma. 13, | 0 |
| 110 | Biomaterial-based in vitro 3D modeling of glioblastoma multiforme. **2023**, | 0 |
| 109 | A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance. **2023**, 208, 115410 | 0 |
| 108 | Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma. **2023**, 36, 100872 | 0 |
| 107 | Photodynamic therapy for glioblastoma: A light at the end of the tunnel. **2023**, 13, 100161 | 0 |
| 106 | Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma. **2022**, 100946 | 0 |
| 105 | ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449. | 0 |

| | | |
|---|---|---|
| 104 | Cerebellar High-Grade Glioma: A Translationally Oriented Review of the Literature. **2023**, 15, 174 | 0 |
| 103 | Non-Association of Driver Alterations in PTEN with Differential Gene Expression and Gene Methylation in IDH1 Wildtype Glioblastomas. **2023**, 13, 186 | 0 |
| 102 | Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects. Volume 16, 71-86 | 0 |
| 101 | Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal Adenocarcinoma. **2023**, 30, 1648-1662 | 0 |
| 100 | Studies on the therapeutic and prognostic biomarkers of glioma using a novel Cuproptosis-related LncRNA signature and validation in glioma. **2023**, | 0 |
| 99 | Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma. **2023**, 14, | 0 |
| 98 | Anti-Vimentin Nanobody Decreases Glioblastoma Cell Invasion In Vitro and In Vivo. **2023**, 15, 573 | 0 |
| 97 | EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status. **2023**, 15, 670 | 0 |
| 96 | Comprehensive analysis of pyroptosis-related gene signatures for glioblastoma immune microenvironment and target therapy. | 0 |
| 95 | Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. **2023**, 14, | 0 |
| 94 | GBM Cells Exhibit Susceptibility to Metformin Treatment According to TLR4 Pathway Activation and Metabolic and Antioxidant Status. **2023**, 15, 587 | 0 |
| 93 | A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for low grade glioma. 12, | 0 |
| 92 | Natural killer cells in the treatment of glioblastoma: Diverse antitumor functions and potential clinical applications. **2023**, 335-367 | 0 |
| 91 | The STEMRI trial: magnetic resonance spectroscopy imaging can define tumor areas enriched in glioblastoma-initiating cells. | 0 |
| 90 | TRIM8: a double-edged sword in glioblastoma with the power to heal or hurt. **2023**, 28, | 0 |
| 89 | Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction. **2023**, 19, e1010815 | 0 |
| 88 | Cellular and molecular features related to exceptional therapy response and extreme long-term survival in glioblastoma. | 0 |
| 87 | Metabolomic profiles of human glioma inform patient survival. | 0 |

| | | |
|---|---|---|
| 86 | Differential Transcriptome Responses in Human THP-1 Macrophages Following Exposure to T98G and LN-18 Human Glioblastoma Secretions: A Simplified Bioinformatics Approach to Understanding Patient-Glioma-Specific Effects on Tumor-Associated Macrophages. **2023**, 24, 5115 | 0 |
| 85 | Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma. **2023**, 14, | 0 |
| 84 | Long non-coding RNA in glioblastoma invasion: Angiogenesis and mesenchymal transition via PI3K and Wnt signalling. 36-52 | 0 |
| 83 | Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5. **2023**, 39, 100894 | 0 |
| 82 | Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor. **2023**, 106, 110641 | 0 |
| 81 | Standardizing analysis of intra-tumoral heterogeneity with computational pathology. | 0 |
| 80 | Glioblastoma Spheroid Invasion through Soft, Brain-Like Matrices Depends on Hyaluronic Acid□CD44 Interactions. 2203143 | 0 |
| 79 | A robust and lightweight deep attention multiple instance learning algorithm for predicting genetic alterations. **2023**, 105, 102189 | 0 |
| 78 | Endocannabinoids are potential inhibitors of glioblastoma multiforme proliferation. **2023**, 21, 120-129 | 0 |
| 77 | Insights into the Peritumoural Brain Zone of Glioblastoma: CDK4 and EXT2 May Be Potential Drivers of Malignancy. **2023**, 24, 2835 | 0 |
| 76 | Heterogeneity of Amino Acid Profiles of Proneural and Mesenchymal Brain-Tumor Initiating Cells. **2023**, 24, 3199 | 0 |
| 75 | Glioblastoma and cerebral organoids: development and analysis of an in vitro model for glioblastoma migration. **2023**, 17, 647-663 | 0 |
| 74 | Pharmacological Inhibition of Membrane Signaling Mechanisms Reduces the Invasiveness of U87-MG and U251-MG Glioblastoma Cells In Vitro. **2023**, 15, 1027 | 0 |
| 73 | Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment. **2023**, 12, 547 | 0 |
| 72 | Prognostic Prediction Model for Glioblastoma: A Ferroptosis-Related Gene Prediction Model and Independent External Validation. **2023**, 12, 1341 | 0 |
| 71 | Rise of Deep Learning Clinical Applications and Challenges in Omics Data: A Systematic Review. **2023**, 13, 664 | 0 |
| 70 | Scalable co-sequencing of RNA and DNA from individual nuclei. | 0 |
| 69 | Identification of TSGA10 and GGNBP2 splicing variants in 5? untranslated region with distinct expression profiles in brain tumor samples. 13, | 0 |

| | | |
|---|---|---|
| 68 | Lessons learned from evolving frameworks in adult glioblastoma. **2023**, 131-140 | 0 |
| 67 | Modeling glioblastoma complexity with organoids for personalized treatments. **2023**, 29, 282-296 | 0 |
| 66 | Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. **2023**, 15, 664 | 0 |
| 65 | The Prognostic Impact of Gender, Therapeutic Strategies, Molecular Background, and Tumor-Infiltrating Lymphocytes in Glioblastoma: A Still Unsolved Jigsaw. **2023**, 14, 501 | 0 |
| 64 | Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies. **2023**, 15, 547 | 0 |
| 63 | Brain network mapping and glioma pathophysiology. **2023**, 5, | 0 |
| 62 | The Superoncogene Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme. **2023**, 24, 4217 | 0 |
| 61 | A Novel Molecular Classification Method for Glioblastoma Based on Tumor Cell Differentiation Trajectories. **2023**, 2023, 1-27 | 0 |
| 60 | Histone H3K9 methyltransferase SETDB1 overexpression correlates with pediatric high-grade gliomas progression and prognosis. **2023**, 101, 387-401 | 0 |
| 59 | Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance. | 0 |
| 58 | Peritumoral ADC Values Correlate with the MGMT Methylation Status in Patients with Glioblastoma. **2023**, 15, 1384 | 0 |
| 57 | Epigenomic perturbation of novelEGFRenhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide. | 0 |
| 56 | Integrative analysis of a Novel six methylated pseudogene Prognostic signature in patients with glioma. | 0 |
| 55 | Spatial transcriptomics reveals niche-specific enrichment and vulnerabilities of radial glial stem-like cells in malignant gliomas. **2023**, 14, | 0 |
| 54 | Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. **2023**, 29, 615-622 | 0 |
| 53 | Injury primes mutation-bearing astrocytes for dedifferentiation in later life. **2023**, 33, 1082-1098.e8 | 0 |
| 52 | Cell migration simulator-based biomarkers for glioblastoma. | 0 |
| 51 | Molecular Markers: Indispensable Tools for Diagnosing Central Nervous System Tumors. **2023**, 1-17 | 0 |

| | | |
|---|---|---|
| 50 | Single-cell RNA sequencing and spatial transcriptomics reveal cancer-associated fibroblasts in glioblastoma with protumoral effects. **2023**, 133, | 1 |
| 49 | Systems Medicine for Precise Targeting of Glioblastoma. | 0 |
| 48 | The paracaspase MALT1 controls cholesterol homeostasis in glioblastoma stem-like cells through lysosome proteome shaping. | 0 |
| 47 | Modeling nervous system tumors with human stem cells and organoids. **2023**, 12, | 0 |
| 46 | Exploring Novel Therapeutic Opportunities for Glioblastoma Using Patient-Derived Cell Cultures. **2023**, 15, 1562 | 0 |
| 45 | EGFRvIII Promotes the Proneural–Mesenchymal Transition of Glioblastoma Multiforme and Reduces Its Sensitivity to Temozolomide by Regulating the NF-κB/ALDH1A3 Axis. **2023**, 14, 651 | 0 |
| 44 | The Role of Long Noncoding RNAs in Glioblastoma: What the Neurosurgeon Should Know. **2023**, Publish Ahead of Print, | 0 |
| 43 | SOX11 regulates SWI/SNF complex components as member of the adrenergic neuroblastoma core regulatory circuitry. **2023**, 14, | 0 |
| 42 | Cancer-associated fibroblasts suppressed ferroptosis in glioblastoma via upregulating lncRNA DLEU1. **2023**, 324, C1039-C1052 | 0 |
| 41 | Identification of Genetic Alterations in Rapid Progressive Glioblastoma by Use of Whole Exome Sequencing. **2023**, 13, 1017 | 0 |
| 40 | Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. **2023**, 12, 843 | 0 |
| 39 | The dark side of mRNA translation and the translation machinery in glioblastoma. 11, | 0 |
| 38 | Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma. **2023**, 42, 112235 | 0 |
| 37 | Dihydroartemisinin inhibits EMT of glioma via gene BASP1 in extrachromosomal DNA. | 0 |
| 36 | Advanced Bioinformatics Analysis and Genetic Technologies for Targeting Autophagy in Glioblastoma Multiforme. **2023**, 12, 897 | 0 |
| 35 | Mechanisms of cancer-associated thrombosis. **2023**, 7, 100123 | 0 |
| 34 | Statistical Methods for Integrative Clustering of Multi-omics Data. **2023**, 73-93 | 0 |
| 33 | Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPARγ signaling axis. **2023**, 14, | 0 |

| | | |
|---|---|---|
| 32 | Glioblastoma-Derived Small Extracellular Vesicles: Nanoparticles for Glioma Treatment. **2023**, 24, 5910 | 0 |
| 31 | IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis. **2023**, 14, | 0 |
| 30 | USP10 deubiquitinates RUNX1 and promotes proneural-to-mesenchymal transition in glioblastoma. **2023**, 14, | 0 |
| 29 | Astrocytic neoplasms. **2013**, 705-728 | 0 |
| 28 | Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data. **2023**, 18, | 0 |
| 27 | Integrative Analysis of the Predictive Value of Perilipin Family on Clinical Significance, Prognosis and Immunotherapy of Glioma. **2023**, 11, 1009 | 0 |
| 26 | A novel method to accurately estimate pathway activity in single cells for clustering and differential analysis. | 0 |
| 25 | OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM). **2023**, 78, 100120 | 0 |
| 24 | Neural Stem Cells as Potential Glioblastoma Cells of Origin. **2023**, 13, 905 | 0 |
| 23 | Untargeted Metabolomic Characterization of Glioblastoma Intra-Tumor Heterogeneity Using OrbiSIMS. **2023**, 95, 5994-6001 | 0 |
| 22 | Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies. | 0 |
| 21 | The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma. **2023**, 15, 1134 | 0 |
| 20 | SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair. | 0 |
| 19 | Patient-derived glioblastoma neurosphere cultures differentially express nicotinic acetylcholine receptors depending on ambient choline. | 0 |
| 18 | The tumour ecology of quiescence: niches across scales of complexity. **2023**, | 0 |
| 17 | Pan-cancer analysis of the ion permeome reveals functional regulators of glioblastoma aggression. | 0 |
| 16 | IL17RB and IL17REL Expression Are Associated with Improved Prognosis in HPV-Infected Head and Neck Squamous Cell Carcinomas. **2023**, 12, 572 | 0 |
| 15 | Proteomic analysis reveals microvesicles containing NAMPT as mediators of radioresistance in glioma. **2023**, 6, e202201680 | 0 |

| | | |
|---|---|---|
| 14 | The prognostic value of tumor-associated macrophages in glioma patients. | 0 |
| 13 | Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures. 13, | 0 |
| 12 | Tumor-secreted lactate contributes to an immunosuppressive microenvironment and affects CD8 T-cell infiltration in glioblastoma. 14, | 0 |
| 11 | Stalled oligodendrocyte differentiation in IDH-mutant gliomas. **2023**, 15, | 0 |
| 10 | CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway. **2023**, 14, | 0 |
| 9 | Role of Molecular Targeted Therapeutic Drugs in Treatment of Glioblastoma: A Review Article. **2023**, 10, 042-047 | 0 |
| 8 | Low-coverage and cost-effective whole-genome sequencing assay for glioma risk stratification. | 0 |
| 7 | Biomarkers of Tumor Heterogeneity in Glioblastoma Multiforme Cohort of TCGA. **2023**, 15, 2387 | 0 |
| 6 | Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review. | 0 |
| 5 | Knockdown of circ_CLIP2 regulates the proliferation, metastasis and apoptosis of glioma cells through miR-641/EPHA3/STAT3 axis. 1-10 | 0 |
| 4 | BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression. | 0 |
| 3 | The clinical value of proneural, classical and mesenchymal protein signatures in WHO 2021 adult-type diffuse lower-grade gliomas. **2023**, 18, e0285732 | 0 |
| 2 | Metabolomics Approach Reveals Important Glioblastoma Plasma Biomarkers for Tumor Biology. **2023**, 24, 8813 | 0 |
| 1 | A Novel and Highly Selective Epidermal Growth Factor Receptor Inhibitor, SMUZ106, for the Treatment of Glioblastoma. **2023**, 15, 1501 | 0 |